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Abstract 
Non-ribosomal peptide synthetases (NRPSs) synthesise small highly diverse peptides with a 
wide range of activities, such as antibiotics, anticancer drugs, and immunosuppressants. 
NRPS synthesis often resembles an assembly line, in which each module acts in a linear 
order to add one monomer to the growing peptide chain. In the basic mechanism of 
synthesis, an adenylation (A) domain within each module activates a specific monomer. 
Once activated, the monomer is attached to an immediately downstream thiolation (T) 
domain via a prosthetic phosphopantheine group, which acts as a flexible arm to pass the 
substrate between catalytic domains. A condensation (C) domain, upstream to the 
A-T domains, catalyses peptide bond formation between an acceptor substrate attached to 
the T domain and a donor substrate attached to the T domain of the upstream module. The 
peptide remains attached to the T domain of the acceptor substrate, and then acts as the 
donor substrate for the next C domain. When peptide synthesis reaches the final module, the 
peptide is released by a thioesterase (TE) domain.  
The linear mode of synthesis and discrete functional domains within each module gives the 
potential to generate new products by substituting domains or entire modules with ones that 
activate alternative substrates. Attempts to create new products using domain and module 
substitution often result in a loss of activity. The work in this thesis focuses on identifying 
barriers to effective domain substitution. The NRPS enzyme pvdD, which adds the final 
residue to the eleven residue non-ribosomal peptide pyoverdine, was developed as a model 
for domain substitution. The primary benefit for using this model is that pyoverdine creates 
easily detectible fluorescent products. 
The first set of experiments focused on testing the limitations of A domain and C-A domain 
substitutions to alter pyoverdine. Nine A domain and nine C-A domain substitution pvdD 
variants were constructed and used to complement a P. aeruginosa PAO1 pvdD deletion 
strain. The A domain substitutions that specified the wild type substrate were highly 
functional, whereas A domains that specified other substrates resulted in low levels of 
wild type pyoverdine production. This suggests the acceptor site substrate specificity of the 
C domain limited the success of A domain substitutions, rather than disruption of the C/A 
domain junction. In contrast, although C-A domain substitutions in pvdD in some cases 
synthesised novel pyoverdines, the majority lost function for unknown reasons. The high 
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success rate A domain substitutions (when not limited by the acceptor site specificity of the 
C domain) suggested the addition of new C domains was a likely cause for loss of function. 
The second set of experiments investigated whether disrupting the protein interface between 
C domains and their upstream T domains may cause a loss in function of C-A domain 
substitutions. However, domain substitutions of T domains were found to have a high rate of 
success. Therefore, the results thus far confirmed that disrupting interactions of the 
C domain with A domains or T domains does not have a large affect on enzyme activity.  
An alternative explanation for the loss in function with C-A domain substitutions is that 
C domains translocated to a new enzyme are unable to process the new incoming donor 
peptide chain because of substrate specificity or steric constraints. To develop methods to 
circumvent limitations caused by the C domain, the final part of this thesis examined 
acceptor substrate specificity of C domains. Acceptor site substrate specificity was chosen 
over donor site specificity as it acts on only an amino acid rather than peptide chain. The 
substrate specificity was narrowed down to a small subsection of the C domain. This was an 
initial study of C domain substrate specificity, which may guide future development of 
relaxed specificity C domains.  
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Chapter 1: Introduction 
1.1 General overview 
Non-ribosomal peptides are a class of natural products synthesised mainly by bacteria and 
fungi. They are generally very small peptide or mixed-peptide products; the largest 
non-ribosomal peptide to have been identified to date contains 49 residues, with all others 
known containing under 23 residues, and more commonly under ten residues (Caboche et 
al., 2010). Despite their small size, they are highly diverse in terms of the monomers that 
can be incorporated. As of 2010, over 500 unique monomers have been detected in 
non-ribosomal peptides (Caboche et al., 2010), including both proteinogenic and 
non-proteinogenic D- and L- amino acids, carboxylic acids and amines (Marahiel et al., 
1997; Sieber and Marahiel, 2005). In addition to substrate diversity, non-ribosomal 
peptides exhibit high structural diversity with only 27 % being linear; the remainder 
having cyclic, branched or other complex primary structures (Caboche et al., 2010). 
Figure 1-1 highlights this diversity by showing a number of peptides relevant to this 
introduction. 
The diversity of non-ribosomal peptides imparts on them many useful bioactivities, and 
peptides have been identified with antibiotic, anticancer, anti-inflammatory, 
immunosuppressant and antiviral activities (Felnagle et al., 2008; Marahiel et al., 1997; 
Sieber and Marahiel, 2005). Often natural products need to be modified to improve 
clinical properties and/or bypass resistance mechanisms (Bush, 2012; O’Connell et al., 
2013). Due to difficulty in their synthesis, most clinical natural product derivatives are 
created by means of semisynthesis; a process whereby the natural product is chemically 
modified after isolation from fermentation or biological sources (Kirschning and Hahn, 
2012; O’Connell et al., 2013; Walsh, 2003). An alternative that would open up a range of 
structural diversity is protein engineering to create combinatorial libraries of existing 
natural products. For non-ribosomal peptides, their modular mode of synthesis, which 
will be discussed below, makes them potentially amenable to rational manipulation at the 
genetic level. However, modifications often greatly impair activity, thereby limiting the 
ability to create new non-ribosomal peptides using protein engineering. The work in this 
thesis focuses on identifying barriers to effective domain recombination for the creation 
of novel non-ribosomal peptides. 
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Figure 1-1. Examples of non-ribosomal peptides. Non-proteinogenic amino acids are highlighted 
in red, D-isomers in green, and an atypical peptide bond formed via a side-chain shown in purple. 
Orn, ornithine; 3mGlu, 3-methylglutamic acid; Kyn, kynurenine; standard three letter 
abbreviations are used for proteinogenic amino acids. Structures generated based on diagrams 
from Doekel et al. (2008) and Marahiel et al. (1997). 
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1.2 Multiple template model of non-ribosomal peptide synthesis 
The accepted mode of non-ribosomal peptide synthesis is referred to as the multiple 
template model and was proposed by Stein et al. (Stein et al., 1994, 1996). A main 
characteristic of this model is that peptides are synthesised in a modular assembly 
line-like manner by non-ribosomal peptide synthetase (NRPS) enzymes. An NRPS 
pathway may be on one or multiple enzymes, and modules are classified as initiation, 
elongation and termination modules depending on their location. Modules are defined by 
their ability to recognise, activate and incorporate one monomer into the final peptide 
product (von Döhren et al., 1997; Marahiel et al., 1997). 
In synthesis, an initiation module activates the first monomer and passes it to the 
immediately downstream elongation module. The elongation module activates a second 
monomer, condenses it with the monomer received from the upstream module and passes 
the resulting dipeptide to the next module downstream. In this way, each additional 
elongation module adds one additional residue. The final module is referred to as a 
termination module, and condenses one further monomer onto the peptide before 
releasing the final product (Hur et al., 2012; Sieber and Marahiel, 2005). In the modular 
system just described the modules are colinear with the peptide product, such that the 
module location dictates the position of the monomer in the final peptide (Marahiel et al., 
1997). These co-linear NRPS pathways are referred to as Type A NRPS enzymes. 
Alternatively, iterative Type B pathways are similar, but differ in that the pathway is 
iterated and two to three independently-assembled smaller peptides are joined together to 
yield the final product. In contrast, non-linear Type C pathways are different as the order 
of modules in the NRPS complex does not represent the final product (Mootz et al., 
2002). 
Within each module of the NRPS assembly lines, discrete adenylation (A), thiolation (T) 
and condensation (C) domains function in the steps of substrate activation, transfer and 
condensation. These domains and their structural and functional independence from each 
other are central to this study, and are described in Figure 1-2 and the following sections. 
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Figure 1-2. The domain architecture and mechanism of synthesis for a hypothetical NRPS. (A) 
The arrangement of domains within a hypothetical three module NRPS containing an initiation 
(blue), an elongation (green) and a termination (orange) module. (B) Activation of each module 
by post-translational attachment of a 4′-phosphopantetheine (4′-pp) cofactor to the T domain 
(sometimes referred to as a peptidyl carrier protein (PCP) domain). (C) The first domain to act 
within a module is an A domain that activates and tethers a specific monomer to the 4′-pp 
prosthetic group of the immediately downstream T domain. (D) The monomer attached to the 
T domain can then be passed between C domains. C domains are located upstream to the 
A domain, and C-A-T domains represent a basic elongation module. The C domain catalyses 
peptide bond formation between the carboxyl group of the donor substrate attached to the 
T domain of the upstream module and the amino group of the acceptor substrate of the 
downstream T domain. (E) Peptide bond formation breaks the upstream thioester bond, resulting 
in the peptide being attached to the downstream T domain, and this peptide serves as the donor 
substrate for the C domain of the next module. (F) After addition of the final monomer by the 
termination module, the peptide product is released by a thioesterase (TE) domain. After peptide 
release, the NRPS is returned to step (C) and peptide synthesis can repeat. NRPS domains are 
covered by several reviews (Felnagle et al., 2008; Hur et al., 2012; Marahiel et al., 1997; Sieber 
and Marahiel, 2005). 
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1.2.1 Adenylation domains 
NRPS A domains function to adenylate a specific monomer and attach it to a T domain. 
Based on sequence similarity, they are part of a superfamily of adenylate-forming 
enzymes including acyl-CoA synthases and luciferases (Turgay et al., 1992). A domains 
catalyse an ATP-dependent two-step reaction. First an aminoacyl-adenylate is formed 
with concomitant release of pyrophosphate (PPi), followed by attachment of the 
aminoacyl intermediate to the 4′-pp thiol group of that module's T domain and the 
concomitant release of AMP (Figure 1-3) (Gevers et al., 1968, 1969; Stachelhaus and 
Marahiel, 1995; Stein et al., 1994). Although typically functioning as part of a 
multimodular enzyme, A domains are semi-autonomous and deletion experiments have 
shown the adenylation reaction (Figure 1-3A) can occur when A domains are expressed 
in isolation (Dieckmann et al., 1995; Haese et al., 1994; Stachelhaus and Marahiel, 1995). 
However, the thiolation step (Figure 1-3B) requires the presence of a T domain 
(Stachelhaus and Marahiel, 1995). 
 
Figure 1-3. Two step adenylation domain reaction. (A) The A domain adenylates the amino acid 
substrate using ATP as a substrate. (B) The aminoacyl adenylate is then attacked by the terminal 
thiol of a 4′-pp group of the immediately downstream T domain to form a thioester. Image 
modified from Felnagle et al. (2008). 
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1.2.1.1 A domain structure and specificity 
The first NRPS A domain structure to be determined was the X-ray crystal structure of 
PheA, the A domain from the NRPS GrsA (Conti et al., 1997). GrsA is the first NRPS 
involved in gramicidin S synthesis. It is a single module NRPS that activates Phe, 
epimerises it and passes it to the downstream enzyme GrsB. Together GrsA and GrsB 
synthesise a pentapeptide and two of these pentapeptides are connected head-to-tail to 
form the decapeptide gramicidin S. GrsA contains a single module consisting of an A, T 
and epimerisation (E) domain (The E domain epimerises L-Phe to a D-isomer following 
attachment to the T domain; Section 1.2.6). In this thesis, multiple domains of the same 
enzyme will be separated by hyphens, i.e. the GrsA domains will be referred to as 
A-T-E domains.  
The X-ray crystal structure of PheA was solved to 1.9 Å and consisted of a large 
N-terminal domain (~450 amino acids) and a smaller C-terminal domain (~100 amino 
acids) connected by a small linker region (Conti et al., 1997). Despite sharing only 16 % 
amino acid sequence identity, PheA had high structural homology to the previously 
solved crystal structure of firefly luciferase (Conti et al., 1996, 1997). Sequence 
alignments demonstrate A domains have ten conserved motifs named A1 to A10. These 
are predicted to be involved in ATP binding, hydrolysis and adenylation of the substrate  
(Marahiel et al., 1997; Turgay et al., 1992). Consistent with their proposed catalytic roles 
these motifs are all located around the active site with the exception of motifs A1 and A2 
(Marahiel et al., 1997).  
An important feature of the PheA structure was that it was obtained in complex with Phe 
and AMP. The presence of Phe in the binding pocket of PheA allowed ten residues lining 
the amino acid binding pocket to be identified (Conti et al., 1997). Due to the large 
structural homology between PheA and firefly luciferase, and greater sequence similarity 
among A domains, it was assumed the structure of all A domains would be highly similar 
(Marahiel et al., 1997). Subsequently it was shown the substrate binding pocket residues 
can be identified by alignment of A domain peptide sequences, and these residues can be 
used to predict the substrate activated by A domains (Challis et al., 2000; Stachelhaus et 
al., 1999). Based on the binding pocket residues, online servers have been developed to 
provide substrate specificity predictions (Bachmann and Ravel, 2009). More recent 
algorithms have also been developed to take into account all residues within 8 Å of the 
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substrate (a distance that includes the substrate binding pocket residues) (Rausch et al., 
2005; Rottig et al., 2011). These algorithms that take into account additional residues 
were found to have improved prediction ability (Rausch et al., 2005), suggesting residues 
close to the binding pocket also influence the substrate specificity. 
Later A domain structures had an overall similar topography, but differed in the relative 
orientation of the two subdomains (May et al., 2002; Tanovic et al., 2008; Yonus et al., 
2008). These changes in orientation were proposed to be essential for catalysis, and a 
mechanism of catalysis involving catalytic cycling of A domain structure was proposed 
(Yonus et al., 2008). In this model, an open conformation of the A domain allows ATP 
and the amino acid substrate to enter their respective binding pockets. Electrostatic 
interactions between ATP and the A domain cause a conformational shift of the small 
subdomain, creating a closed conformation that promotes formation of the aminoacyl 
adenylate. The formation of the aminoacyl adenylate and loss of pyrophosphate then 
causes further changes to the A domain structure, which push the 4′-pp prosthetic group 
of the T domain into the A domain binding pocket. This allows the formation of the 
aminoacyl thioester linkage to the 4′-pp prosthetic group with the concurrent release of 
AMP. 
1.2.2 Thiolation domains 
Located downstream to A domains are T domains, 80-100 residue domains to which 
activated amino acids and the growing peptide chain are attached (Sieber and Marahiel, 
2005). The T domain is functionally and structurally related to other carrier proteins 
involved in polyketide and fatty acid synthesis (Mercer and Burkart, 2007). Following 
translation, T domains are modified by attachment of a 4′-pp prosthetic group derived 
from Coenzyme A (CoA). The attachment site is a conserved Ser residue within an 
[I/L]GG[D/H]SL motif (Schlumbohm et al., 1991; Stein et al., 1994), and attachment is 
mediated by phosphopantetheine transferases (PPTase) (Lambalot et al., 1996; Mootz et 
al., 2001). Three classes of PPTase exist; Sfp-type PPTases act on NRPS T domains and 
are named due to Sfp from surfactin biosynthesis being the archetype of this class (Beld 
et al., 2013; Hur et al., 2012).  
The 4′-pp group attached to the T domain has a reach of about 18 Å and is thought to act 
as a swinging arm that transfers substrates between catalytic centres (von Döhren et al., 
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1997; Hur et al., 2012). Although not catalysing any reactions itself, expression of the 
T domain from the first module of tyrocidine A synthesis as an isolated domain found it 
retains its ability to be activated by phosphopantetheine transferases and receive 
monomers in trans from A domains (Stachelhaus et al., 1996).  
1.2.2.1 T domain structure 
An NMR solution structure of the T domain from the seventh module of tyrocidine A 
synthesis was the first T domain structure solved (Weber et al., 2000). Tyrocidine A is 
synthesised by three NRPS enzymes, TycA, TycB and TycC, which contain one, three 
and six modules respectively. Here, modules from tyrocidine synthetases are referred to 
by the enzyme they are located in (TycA, TycB or TycC) followed by a subscript of the 
module number within that enzyme, i.e. the seventh tyrocidine synthetase module is 
referred to as TycC3. The structure of the T domain from TycC3 was shown to contain a 
bundle of four antiparallel helices named helix I-IV, with the 4′-pp attachment site located 
in a large loop between helices I and II; a similar topography to acyl carrier proteins 
(Weber et al., 2000). The TycC3 T domain was further analysed by NMR spectroscopy 
and found to have three states: apo (A), holo (H) and A/H (Koglin et al., 2006). Prior to 
attachment of the 4′-pp cofactor, the T domain was found to slowly change between the A 
and A/H states; after attachment, the equilibrium was shifted to between the A/H and H 
states (Koglin et al., 2006). Mutation of the 4′-pp attachment Ser residue to an Ala locked 
the structure in the A state. The A-state contains helices I, II and IV, with the residues of 
helix III being stretched as a loop and embedded within the protein core. Within the A/H 
state, helix III reforms and is located outside the core of the protein. The H-state differs in 
that helix III is again unravelled. This unravelling of the helix III shifts the 
4′-phosphopantetheine by 16 Å. Titration with other domains found the PPTase Sfp only 
interacted with the A-state, whereas SrfTEII (a type II thioesterase (TEII) functioning in 
the removal of aberrant CoA; see Section 1.2.5) interacted specifically with the H-state. 
This shows the conformational changes are important for the interactions with catalytic 
partners (Koglin et al., 2006). Additionally, it was suggested that the conformational 
shifting between states may also be involved in the movement of substrates between A 
and C domains (Koglin et al., 2006).  
Substrates attached to T domains need to reach multiple catalytic partners. For example, 
in the context of an elongation module, a T domain needs to have a monomer attached to 
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it by an upstream A domain, and the tethered monomer then needs to cycle between both 
the upstream and downstream C domains. The role of conformational switching being 
important for activity was supported by later NMR and crystal structures of T domains 
solved in the presence of other NRPS domains (Frueh et al., 2008; Samel et al., 2007; 
Tanovic et al., 2008). These structures showed T domain conformational changes were 
necessary for the attached substrate to reach all catalytic partners, however, the precise 
conformational changes are unknown (Strieker et al., 2010; Weissman and Müller, 2008).  
1.2.3 Condensation domains 
The ~450 residue C domain is located upstream to the A-T domains and mediates peptide 
bond formation between substrates attached to the T domains of adjacent modules (Figure 
1-4). C domains share significant amino acid identity with E domains, but do not appear 
to be closely related to any other protein. However, sequence alignments of C domains 
identified a conserved catalytic HHxxxDG motif, which is also found in chloramphenicol 
acetyltransferases (CAT) and dihydrolipoyl transacetylases (E2p) (De Crécy-Lagard et 
al., 1995). The second His residue of the HHxxxDG motif was confirmed to be essential 
for condensation by mutagenesis studies (Bergendahl et al., 2002; Roche and Walsh, 
2003; Stachelhaus et al., 1998) and it was suggested this His, in a similar manner to that 
present in CAT and E2p, functions as a general base to deprotonate the acceptor substrate 
amine, enabling nucleophilic attack of the carbonyl group of the donor substrate 
(Bergendahl et al., 2002).  
 
Figure 1-4. Peptide bond formation catalysed by the C domain reaction. Image modified from 
Felnagle et al. (2008). 
 
 
 
10 
 
1.2.3.1 C domain structure 
The first structure of a C domain was of VibH solved at 2.55 Å by X-ray crystallography 
(Keating et al., 2002). VibH is an unusual C domain as it is a standalone domain (rather 
than part of a multi domain module), which catalyses condensation of 
2,3-dihydroxybenzoic acid (DHB), tethered to the standalone T domain VibB, directly 
onto norspermidine. Nevertheless it was argued that the structure of VibH would 
resemble both C and E domains because of a high degree of primary sequence similarity 
(Keating et al., 2002). The structure of VibH contained two subdomains with the putative 
catalytic His placed in a V-shaped solvent channel running between the subdomains. 
There was an extended flexible loop spanning over the solvent channel from one 
subdomain to the other. The channel provided access by the donor and acceptor substrates 
from adjacent ends of the channel. Mutation of the catalytic His to either Ala or Glu did 
not hinder activity, suggesting that this residue does not act as a base for VibH (Keating 
et al., 2002). The His not acting as a base was hypothesised to be due to VibH binding 
norspermidine directly and not requiring a base for catalysis, or that VibH may function 
to align the residues close to one another and the reaction occurs spontaneously due to 
amide bonds being thermodynamically favoured over thioesters (Keating et al., 2002). 
The second C domain crystal structure to be solved was of the T-C domains from the 
ninth and tenth modules of tyrocidine synthesis at a resolution of 1.8 Å (Samel et al., 
2007). The C domain contained a similar V-shape solvent channel to VibH with a loop 
spanning the channel. The authors made an analogy of the loop spanning the channel to 
the flexible lid regions of NRPS TE domains. Comparing the structure to VibH found the 
subdomains were highly similar but the orientation of the subdomains to each other was 
rotated by 12°. Calculating the pK values of the putative catalytic His residue suggested 
the His residue is protonated under physiological conditions and may not act as a catalytic 
base as previously suggested (Bergendahl et al., 2002). Instead the His residue may 
function to electrostatically stabilise a tetrahedral reaction intermediate (Samel et al., 
2007). Another feature of the tyrocidine synthetase T-C domain structure was the 
T domain facing away from the catalytic centre of the C domain at a distance of over 
47 Å to the His residue. In this state the 4′-pp attachment site was at a distance too great 
for the T domain to pass its substrate to the C domain catalytic centre (~20 Å in length) 
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and may represent a state compatible for interactions with the upstream A or C domain 
(Samel et al., 2007). 
A third C domain structure was part of a crystal structure solved at 2.6 Å of SrfA-C, the 
entire termination module from surfactin biosynthesis (Tanovic et al., 2008). SrfA-C 
contains C-A-T-TE domains and adds the final residue to surfactin prior to release by the 
TE domain. To obtain uniform crystals, it was necessary to mutate the Ser attachment site 
of the T domain to Ala (Strieker et al., 2010). The domains had similar folds to structures 
of individual domains solved in other studies. In the structure, there was a large surface of 
interactions at the C/A domain interface (~1621 Å
2
) and the linker region between these 
domains appeared inflexible as it was well defined and closely associated with the C and 
A domains (Tanovic et al., 2008). The interactions at the C/A interface suggest these 
domains form an invariant “workbench” and do not shift from one another during 
catalysis. Importantly, it was hypothesised this invariant workbench may limit the ability 
to fuse NRPS enzymes at the C/A domain junction (Tanovic et al., 2008). The active sites 
of the C and A domain were separated by greater than 63 Å – a distance not coverable by 
the 4′-pp cofactor of the T domain – supporting the assumption that large changes in 
T domain conformation would be needed during catalysis (Tanovic et al., 2008).  
1.2.3.2 C domain substrate specificity 
Although A domains govern the initial selection of monomers, C domains have also been 
shown to exhibit specificity. The specificity of C domains was first tested by loading 
aminoacyl-CoA directly onto the T domains of a two module NRPS system. The first 
module incorporates Phe and contains A-T-E domains, the second incorporates Pro and 
contains C-A-T domains (Belshaw et al., 1999). These two modules, referred to as 
PheATE and ProCAT, were previously shown to non-enzymatically release the dipeptide 
as a diketopiperazine (DKP) product following condensation (Figure 1-5) (Stachelhaus et 
al., 1998). Artificial loading of the T domain from PheATE with five different amino 
acids (L-Ala, D-Ala, L-Leu, L-Phe and D-Phe) and the T domain from ProCAT with Pro 
led to a DKP being formed in all cases. As the T domain of PheATE passes its substrate 
to the C domain donor site of ProCAT, it was concluded C domains have no stereo or 
side-chain specificity towards the monomer received. Next, the same five substrates were 
loaded onto the T domain of ProCAT whilst Phe was loaded onto PheATE. As Pro is 
needed for DKP formation, condensation in this case was measured by attachment of a 
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dipeptide to ProCAT. Out of the five monomers loaded onto ProCAT, only L-Ala 
allowed product formation. Based on only one amino acid acting as an acceptor substrate, 
it was concluded that the acceptor sites of C domains have high side-chain and stereo 
specificity (Belshaw et al., 1999). 
 
 
Figure 1-5. Formation of a DKP product using PheATE and ProCAT. Artificially loading an 
amino acid onto PheATE and Pro onto ProCAT leads to spontaneous release of a DKP product 
following condensation. R refers to the side-chain of amino acid loaded onto PheATE. Image 
modified from Belshaw et al. (1999). 
 
A second substrate specificity study used aminoacyl-N-acetylcysteamine thioesters 
(aminoacyl-SNACs) as substrates for the C domains from ProCAT and the NRPS EntF of 
enterobactin synthesis (Ehmann et al., 2000). These aminoacyl-SNACs serve as mimics 
of substrates bound to T domains and pass substrates directly to the C domain. This was 
an advantage as in the previous study the E domain from PheATE may have isomerised 
the substrates, meaning it only tested amino acid side-chain specificity at the C domain 
donor site. This second study tested L-Phe- and D-Phe-SNACs as donor substrates for 
ProCAT and found only D-Phe could be condensed by the C domain. In addition, the 
acceptor site specificity of the C domain from EntF was tested with six non-cognate 
L-amino acids and the corresponding D-amino acids. This found the rate of product 
formation halved when using an L-Ala-SNAC, and was greatly reduced for all other 
aminoacyl-SNACs (including the D-Ser-SNAC) compared with the wild type 
L-Ser-SNAC. The authors concluded C domains have relaxed side-chain and strong 
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stereo specificity at the donor site, and strict side-chain and stereo specificity at the 
acceptor site (Ehmann et al., 2000). 
A problem with the above substrate specificity studies is they only tested substrate 
specificity towards individual amino acids. With the exception of the initiation module, 
C domains generally receive a peptide as a donor substrate. A second problem is the small 
sample size, since the donor site side-chain specificity was only tested with Phe, Ala and 
Leu. A subsequent paper tested the donor site substrate specificity using the PheATE, 
ProCAT system with seven dipeptides and one tetrapeptide (Stein et al., 2005). The 
ProCAT module was fused with a TE domain, because an earlier study showed the 
TE domain releases a dipeptide quicker than the spontaneous DKP reaction (Schwarzer et 
al., 2001). The PheA module was loaded with the dipeptides and tetrapeptide, and 
ProCAT-TE was loaded with Pro. Released products were detected by mass spectrometry 
when using the donor tetrapeptide and 5/7 dipeptide substrates. The two dipeptides unable 
to be condensed by the C domain had a C-terminal Thr or Lys residue, whereas all the 
condensed products had either a C-terminal Phe, Leu or Ser residue. This result suggests 
C domains can sometimes discriminate based on the terminal amino acid of an incoming 
peptide (Stein et al., 2005). 
1.2.3.3 Control of condensation timing 
According to the multiple template model, non-ribosomal peptide synthesis starts at the 
initiation module and occurs by addition of monomers in the N-terminus to C-terminus 
direction. The directionality of synthesis was initially shown in studies of adding amino 
acids to NRPS extracts, whereby initiation of peptide synthesis required the first amino 
acid and absence of an amino acid would stop synthesis at a truncated peptide (Gevers et 
al., 1969; Kleinkauf et al., 1969; Lipmann et al., 1970). For example, synthesis of 
tyrocidine (with a peptide sequence of D-Phe-L-Pro-L-Phe-D-Phe-L-Asn-L-Gln-L-Phe-
L-Val-L-Orn-L-Leu) by partially purified enzyme extracts required the presence of all the 
amino acids of tyrocidine, whereas absence of a single residue resulted in a truncated 
peptide attached to the NRPS, i.e. absence of only Asn from tyrocidine extracts would 
produce a Phe-Pro-Phe-Phe tetrapeptide and no other peptides such as Gln-Phe-Val-Orn-
Leu (Lipmann et al., 1970). To explain why peptide synthesis does not initiate at 
elongation modules, it was proposed C domains contain a “waiting” position, which holds 
the aminoacyl thioester blocking it from acting as a substrate for other domains until after 
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condensation occurs (de Crecy-Lagard et al., 1997). Owing to the high acceptor site 
specificity of C domains, it was suggested that a C domain acceptor site binding pocket 
may function to hold the aminoacyl thioester until after peptide bond formation (Belshaw 
et al., 1999).  
Based on the hypothesis of the C domain holding the aminoacyl thioester, an elongation 
module could be converted into an initiation module by deletion of the C domain or 
inability of the C domain to bind the acceptor substrate due to substrate specificity. This 
was tested by Linne and Marahiel (2000) by creating a series of truncations of the second 
and third modules of TycB. Both these elongation modules could initiate synthesis when 
the C domain was deleted but not otherwise (Linne and Marahiel, 2000). Furthermore, 
TycB3 normally activates L-Phe and incorporates D-Phe into tyrocidine. Adding D-Phe 
instead of L-Phe as a substrate for TycB3 found peptide synthesis was initiated even when 
TycB3 contained a C domain. Presumably this was a result of the A domain activating 
D-Phe, but the C domain acceptor site not holding D-Phe due to stereo specificity. These 
results support that the C domain is important in timing of peptide bond formation and 
also suggest epimerisation by the E domain occurs after release from the C domain 
“waiting” position (Linne and Marahiel, 2000). 
1.2.3.4 C domain specialisation 
As discussed above, C domains have been shown to have stereo specificity towards the 
donor substrate. In agreement with this functional diversity, phylogenetic analysis 
identifies subtypes of C domain according to their incoming donor substrate or additional 
functions (Rausch et al., 2007). These subtypes are referred to as: 
L
CL- and 
D
CL domains 
named according on whether the substrate received within the donor site of the C domain 
is an L-amino or D-amino, respectively. In addition there are starter C domains that 
receive a fatty acid in the donor site, and which are sometimes present in an initiation 
module; cyclisation (Cy) domains that can catalyse heterocyclisation of the substrate in 
addition to condensation; and dual E/C domains, which catalyse epimerisation and 
condensation (Rausch et al., 2007). These subtypes of C domain all condense the donor 
substrate onto an L-isomer of the acceptor substrate. 
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1.2.4 Thioesterase domains 
The termination module responsible for peptide release contains a TE domain 
immediately downstream to the T domain. The role of the TE domain in product release 
was confirmed by module rearrangement experiments, where moving the TE domain 
within the surfactin pathway to the C-terminus of earlier modules resulted in truncated 
products and deleting the TE domain abolished surfactin synthesis altogether (Ferra et al., 
1997). In addition to product release, for Type B NRPSs, the peptide intermediates are 
thought to be held at the TE domain until synthesis of the entire peptide is complete 
(Mootz et al., 2002). 
For product release by the TE domain, a Ser-Asp-His catalytic triad suggests TE domains 
catalyse their reactions via a similar mechanism to enzymes of the α/β-hydrolase family 
(Ferra et al., 1997; Trauger et al., 2000). Mutagenesis studies found the Ser and His 
residues are essential, whereas the Asp residue is only sometimes required (Shaw-Reid et 
al., 1999; Tseng et al., 2002). The first step of catalysis is transfer of the peptide chain 
from the 4′-pp group of the T domain to the Ser residue of the TE domain catalytic triad 
via formation of an ester bond (Figure 1-6A), followed by release from the TE domain by 
hydrolysis or intramolecular cyclisation (Figure 1-6B). Intramolecular cyclisation can 
proceed via formation of amide or ester bonds. The amide bonds are formed with either 
an α-amino or side-chain amino group, whereas ester bonds are formed with residues 
containing a side-chain hydroxyl group (Figure 1-6B) (Du and Lou, 2010; Felnagle et al., 
2008). 
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Figure 1-6. TE domain reactions. (A) Peptide transfer from the T domain to the Ser residue of the 
Ser-Asp-His catalytic triad of the TE domain. R1, amino acid side chain; R2, peptide chain (B) 
Product release occurs either by hydrolysis or intramolecular cyclisation. X can be either O or N. 
Image modified from Felnagle et al. (2008). 
 
1.2.4.1 Structure of TE domains 
The crystal structure of SrfTE, the TE domain involved in surfactin biosynthesis, 
identified a similar fold to other members of the α/β hydrolase superfamily with the active 
site within a cavity covered by a loop (Bruner et al., 2002). Although size exclusion 
chromatography showed SrfTE to be monomeric, the TE domain structure was a dimer; 
possibly an artefact caused by crystallisation. The loop in one monomer was open 
allowing access to the catalytic site, whereas it was closed in the second (Bruner et al., 
2002). A second TE domain crystal structure was of FenTE from fengycin biosynthesis 
(Samel et al., 2006). This structure was similar to SrfTE, except solved in the monomeric 
state. The lid region was shorter than that of SrfTE, and molecular dynamic simulations 
suggested this loop does not cover the active site in FenTE (Samel et al., 2006). It was 
suggested that for cases like SrfTE the lid may function similarly to lids in lipases and 
sterically hinder access to the catalytic residue or occlude water during cyclisation (Samel 
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et al., 2006). However, sequence alignments of TE domains found that the size of the 
loops do not correlate to size of substrates released by TE domains. As an alternative, it 
was suggested the loop may aid in substrate binding as well as occlusion of other 
molecules (Samel et al., 2006). 
1.2.5 Type II thioesterase enzymes 
An additional enzyme often associated with NRPS pathways are TEII enzymes. It has 
been suggested that TEII enzymes may function to remove 4′-pp cofactors with aberrant 
thioesters (Schneider and Marahiel, 1998). This was supported by deletion experiments 
showing the absence of TEII enzymes greatly impairs non-ribosomal peptide production 
(Geoffroy et al., 2000; Schneider and Marahiel, 1998). In the in vivo setting, T domains 
are likely to be mis-primed with acetyl-CoA or by loading of the incorrect amino acid, 
resulting in peptide synthesis stalling (Hur et al., 2012). The ability of TEII domains to 
remove aberrant CoA from T domains was confirmed by in vitro assays (Schwarzer et al., 
2002; Yeh et al., 2004). Based on increased specificity towards amino acid versus 
peptides substrates, it was suggested that C domain acceptor site specificity and editing of 
non-cognate residues creates a more energetically efficient product; releasing 
mis-activated substrates before incorporation rather than incorporating incorrect residues, 
requiring hydrolysis of the whole peptide chain (Yeh et al., 2004). 
1.2.6 Accessory domains 
In addition to the domains discussed above, accessory domains may be present to further 
increase the diversity of NRPS products. These can be independent from the NRPS 
complex, or located within the assembly line to act during synthesis. The internally 
integrated domains include: epimerisation (E) domains that convert L-amino acids into a 
D-amino acids, methyl transferase domains that methylate amino acids, and Cy domains 
that catalyse heterocyclisation of side chains of Cys, Ser and Thr residues (Walsh et al., 
2001). The most relevant of the accessory domains to this study is the E domain.  
Generally in non-ribosomal peptide synthesis, D-amino acids are incorporated by the 
A domain activating an L-amino acid, which is then racemised by the E domain after 
attachment to the T domain and, when present, release by the C domain. The E domain is 
located immediately downstream to that T domain (Marahiel et al., 1997; Sieber and 
Marahiel, 2005). E domains share the same HHxxxDG motif as C domains and, as noted 
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above, sequence alignments suggest similarity between C and E domains (De Crécy-
Lagard et al., 1995). The donor substrate is epimerised rather than the acceptor substrate, 
meaning E domains act to epimerise aminoacyl-S-phosphopantetheine for initiation 
modules and peptidyl-S-phosphopantetheine for elongation and termination modules 
(Shiau et al., 1995; Stachelhaus and Marahiel, 1995; Stein et al., 1995; Stindl and Keller, 
1994). As discussed in Section 1.2.3.3, this timing may be controlled by the aminoacyl 
thioester being held at the acceptor site of the C domain until after condensation occurs. 
The L- to D-aminoacyl thioester conversion by E domains is incomplete, for example the 
E domain from PheATE epimerises the Phe substrate to 66 % D-Phe and 34 % L-Phe 
(Stachelhaus and Walsh, 2000). However the DKP released from PheATE and ProCAT 
contains 98 % D-Phe, indicating the E domain racemises the substrate and the D-isomer 
is subsequently selected by the C domain (Stachelhaus and Walsh, 2000).  
1.3 Engineering of novel NRPS enzymes 
In the preceding sections, the general mechanism of synthesis by NRPS enzymes and the 
domains involved within each module were discussed. Being able to successfully alter the 
specificity of pathways would enable the creation of derivatives or entirely new pathways 
of non-ribosomal peptides. In nature, the diversity of non-ribosomal peptides is thought to 
have arisen from point mutation, substitution of domains and modules for alternative 
ones, and the deletion or insertion of modules (Fischbach et al., 2008). This diversity in 
peptides and semi-autonomous modular mode of synthesis makes NRPS enzymes an 
attractive target for alteration of substrate specificity. As A domains are the initial 
determinants of monomer selection, new products could be created by substituting 
A domains within a pathway for A domains that activate alternative substrates or by 
directly altering the substrate binding pocket of the A domain. Below A domain 
substitution and binding pocket alteration studies are discussed, followed by domain 
substitution experiments that treat C-A domains as inseparable partners. Left out of this 
discussion are previous domain substitution experiments in P. aeruginosa PAO1, which 
will be discussed in Section 1.4.2. 
1.3.1 Studies on A and A-T domain substitution 
Due to their similarity, both A and A-T domain substitutions will also be considered in 
this section. The first efforts to alter the products of NRPS enzymes by domain 
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substitution replaced a Leu specifying A-T domain pair, from the final module of the 
surfactin NRPS SrfA-C, with alternative A-T domains using homologous recombination 
(Stachelhaus et al., 1995). A-T domains specifying five different substrates were 
substituted and new products detected from each variant using mass spectrometry 
(Stachelhaus et al., 1995). In a second study, Leu specifying A-T domains, from the 
second module of surfactin biosynthesis, were substituted with seven different 
A-T domains (Schneider et al., 1998). In vitro assays confirmed the A-T domain 
substitution constructs were functional in terms of adenylation and thioester formation. 
Despite this, the yield of all products was severely reduced in vivo, and the authors 
mentioned yields were similarly reduced in the first A-T domain substitution study 
(Schneider et al., 1998; Stachelhaus et al., 1995). In each of these studies, one substitution 
was for a Leu specifying A-T domain, i.e. the same substrate specified by the modified 
module. This implied the loss in activity was not solely due to issues of substrate 
specificity (Schneider et al., 1998). However, the later discovery that C domain exhibit 
strong acceptor site specificity (see Section 1.2.3.2) goes some way to explaining why the 
other ten A domain substitutions might have been non-functional.  
A third study compared the function of A and A-T domain substitutions in TycA1, the 
first module of tyrocidine A synthesis, and revealed the importance of specialised 
T domains for interacting with downstream E domains (Linne et al., 2001). The TycA1 
module is an initiation module containing A-T-E domains. As this initiation module 
contains no upstream C domain, acceptor site specificity of the C domain would not be 
expected to limit the efficacy of domain substitutions. Eight variants were created where 
either just the A, or the A-T, domains from four modules were substituted for the 
corresponding domain(s) in TycA1. All A domain and A-T domain substitutions were 
active in in vitro adenylation assays, and the A domain substitution variants were further 
shown to epimerise the activated substrate. In contrast, three A-T domain substitutions 
that do not have an immediately downstream E domain in their native setting were unable 
to epimerise the activated substrate. Alignment of T domain primary sequences identified 
two residues adjacent to the Ser 4′-pp attachment site that are conserved differently for 
T domains upstream to E domains compared to those upstream to C domains. 
Mutagenesis confirmed each of these were essential for the amino acid to be passed from 
the T domain to the E domain (Linne et al., 2001). 
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A later domain substitution experiment suggested that disruption of the T/TE domain 
interface can also result in large decreases in activity. Domain substitutions were used to 
create dimodular hybrid NRPS enzymes in an effort to synthesise L-Asp-L-Phe, a 
precursor to the sweetener aspartame (Duerfahrt et al., 2003). The fifth module of 
surfactin synthesis (which specifies Asp) and modules one and three of tyrocidine 
synthesis (both of which specify Phe) were combined to create six dimodular enzymes 
encoding an L-Asp-L-Phe dipeptide. These six enzymes differed in the location of fusion 
sites, such that the activity of an A versus C-A domain substitution could be compared as 
well as a TE versus T-TE domain substitution. The most active domain substitution was a 
C-A domain substitution variant, which gave 5.8 times greater product yield than any 
variants in which the C/A or T/TE junctions had been disrupted. The loss of activity 
observed when the C/A domain junction had been disrupted was consistent with the 
previous observations that C domains exhibit acceptor site specificity, i.e. cannot tolerate 
alternative A domains immediately downstream; whereas the lack of activity observed 
whenever the T/TE domain boundary had been disrupted suggested that the role of a 
T domain upstream to a TE domain may be particularly specialised.  
Outside of the pyoverdine system (the reasons from drawing this distinction will become 
clear shortly) there has been one further study examining an A domain substitution 
downstream to a C domain. For this substitution, the Ser specifying A domain from EntF, 
an NRPS involved in enterobactin synthesis, was replaced with an alternative Ser 
specifying A domain (Fischbach et al., 2007). This A domain substitution variant 
exhibited a 32-fold reduction in enterobactin synthesis compared to the wild type enzyme. 
This reduction was deemed to be likely due to insolubility, and directed evolution created 
a soluble variant with only a 3.8-fold reduction in activity (Fischbach et al., 2007). 
In the A and A-T domain substitution studies described above, only three substitutions 
were made where the new A domain would be compatible with the acceptor site 
specificity of the C domain. That each of these three domain substitutions exhibited a 
substantial loss in activity relative to the wild type enzyme suggests that factors other than 
C domain acceptor site specificity are also important for the success of A domain 
substitutions. An alternative hypothesis put forward for why A domain substitutions tend 
to substantially impair activity is that they generally disrupt a structurally important C/A 
domain interface (Tanovic et al., 2008). 
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1.3.2 Alteration of A domain binding pockets 
An alternative to A domain substitution is to directly alter the specificity of the A domain 
binding pocket. As the substrate specificity of A domains can be predicted from the 
binding pocket, it follows that the substrate specificity could potentially be altered by 
changes to just these residues. Studies that have attempted to alter A domain binding 
pockets have been separated here into two groups, depending on whether activity was 
measured in vitro or in vivo. 
Studies testing the activity of modified A domain binding pockets in vitro have altered the 
binding pockets using multiple methods. These include: [i] changing the binding pocket 
to match other A domains (Eppelmann et al., 2002; Stachelhaus et al., 1999); [ii] making 
in silico predictions of binding pocket mutations that would maintain contact with a new 
substrate while having the least effect on structure (Chen et al., 2009; Stevens et al., 
2006); and [iii] directed evolution where the residues lining the binding pocket are 
randomised and screening variants for activation of a new substrate (Villiers and 
Hollfelder, 2011; Zhang et al., 2013). In all these studies, the activity of mutated 
A domains was measured by the kinetics of the adenylation reaction. Alteration of the 
binding pocket ([i] above) yielded two successes where adenylation of new substrates 
occurred at similar rates to a wild type enzyme. However, specificity could not be 
changed for some A domains without a large reduction in activity (Eppelmann et al., 
2002; Stachelhaus et al., 1999). From the other binding pocket modification studies, the 
best catalytic efficiency reached was 22 % of the catalytic efficiency for the wild type 
enzyme and substrate (Zhang et al., 2013). Interestingly, the study that reached 22 % 
catalytic efficiency also measured the rate of thioester formation. This revealed that the 
modified A domains were unable to pass the activated substrate to the associated carrier 
protein; a problem that was repaired by a point mutation (Zhang et al., 2013). This 
highlights that care needs to be taken when testing NRPS activity using kinetics alone, as 
there are subsequent reactions that must be able to occur to achieve effective 
non-ribosomal peptide synthesis. 
In vivo studies of A domain specificity can be more complex, but have the advantage that 
detected products report on the combined outcomes of adenylation, thiolation and 
condensation reactions. Three in vivo studies have changed binding pockets to encode 
alternative substrates and successfully detected novel products by mass spectrometry 
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(Eppelmann et al., 2002; Thirlway et al., 2012; Uguru et al., 2004). However, yields were 
not quantified in any of these studies, making it difficult to accurately evaluate the 
success of substitutions. Another in vivo study randomised three residues of an A domain 
substrate binding pocket involved in andrimid synthesis to generate a library of 1404 
different mutants and screened for new products by mass spectrometry (Evans et al., 
2011). Four mutants were identified as being able to create new products, with two giving 
relatively high yields when fed excess substrate. A final in vivo study modified the third 
A domain in fusaricidin synthesis (Han et al., 2012). This A domain has promiscuous 
activity and can incorporate five different substrates into fusaricidin. Rather than add new 
activity, the authors of this study sought to improve the specificity of the A domain 
towards Phe, because fusaricidin containing Phe has the greatest antibiotic activity. Four 
residues of the binding pocket were mutated in various combinations to give a total of 6 
mutants. This shifted the percent production of fusaricidin containing Phe from 9.4% to 
between 18.9 % and 26.4 % of the total for three of the mutants. The increase was not 
associated with a reduction in total fusaricidin synthesis, showing this method to be 
highly useful in altering the relative abundance of products. 
Although in some cases successful, modification of A domain binding pockets often 
results in a large loss of activity. Despite trying thousands of combinations, studies that 
randomised the binding pockets have also had difficulty in producing new products. This 
suggests that residues outside the substrate binding pocket may have a larger influence 
than previously assumed. Supporting the importance of residues outside the binding 
pocket is the improved accuracy of updated algorithms for predicting A domain 
specificity based on all residues within a given distance of the A domain (Rausch et al., 
2005). 
1.3.3 C-A domain substitution 
Both the issue of C domain acceptor site specificity and that of disrupting the C/A domain 
interface can be overcome by keeping native C-A domains together during domain 
substitution experiments. The first C-A domain substitution experiments used in vitro 
models like the PheATE/ProCAT system, rather than modify modules within the context 
of a pathway. Based on evidence of C domain acceptor site specificity, Mootz et al. 
(2000) generated new NRPS enzymes treating C and A domains as inseparable units. 
Using the PheATE and ProCAT system, entire modules were fused onto ProCAT to 
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create two trimodular NRPS pathways. The added modules were a Leu termination 
module and an Orn elongation module. To enable product release, a TE domain was fused 
onto the Orn elongation module. Both trimodule pathways were active in adenylation 
assays. However, consistent with the T/TE junction being important, the Orn variant 
synthesised its peptide at a rate 14 times slower than the termination module variant. A 
similar study identified flexible regions between T and C domains based on sequence 
alignment and used these to create three dimodular NRPS enzymes (Doekel and 
Marahiel, 2000). Two of these were made by fusing an A domain onto T-C-A-T-TE 
domains (T-C-A-T-TE domains represent a termination module plus the T domain from 
the upstream module) and a third was made by combining an A domain, a native T-C-A 
domain pairing, and a native T-TE domain pairing. All three variants produced the 
predicted dipeptides. Although focused on creating new enzymes and testing them in 
vitro, rather than modifying existing pathways, these two studies suggest that not 
disrupting the C/A domain junction and fusing enzymes in certain tolerated locations can 
enable the creation of new peptides. 
The flexible region between T-C domains was further characterised using the daptomycin 
NRPS pathway (Doekel et al., 2008). Daptomycin is a 13 residue peptide that has an 
N-terminus decanoic acid group. It is synthesised by three NRPS enzymes named DptA, 
DptBC and DptD. When testing the flexibility of the T-C linker in the two module NRPS 
DptD, the location of restriction sites and addition or deletion of four residues had little 
effect on levels of daptomycin synthesis, demonstrating that this linker region is relatively 
tolerant of alteration (Doekel et al., 2008). CDA and A54145 are similar lipopeptides to 
daptomycin, having a similar structure but differing in some of the peptide sequence. 
Using the T-C linker splice site, the termination module of dptD was exchanged with the 
termination modules from CDA and A54145 synthesis. The predicted change in the final 
residue from Kyn to Trp and Ile/Val respectively were confirmed by mass spectrometry, 
and shown to have little effect on lipopeptide yield (Doekel et al., 2008). In addition, 
domain substitutions of Asn specifying C-A and C-A-T domains from the eleventh 
module of A54145 synthesis into the dptD gene were made. The C-A-T domain 
substitution disrupted the T/TE junction and resulted in no product, whereas the 
C-A domain substitution yielded lipopeptides at around 30 % to 50 % of WT levels 
(Doekel et al., 2008). 
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An earlier paper highlighted the ability to create multiple daptomycin analogues (Nguyen 
et al., 2006). First, modules 8 and 11 within the daptomycin pathway, which activate Ala 
and Ser respectively, were substituted for one another. These two domain substitutions 
yielded modified daptomycin at a level of about 16 % and 44 % compared to restriction 
site controls. Next a D-Asn module from the A54145 pathway was substituted into these 
modules as C-A-T and C-A-T-E domain substitutions. The substitutions produced 
modified daptomycin for the C-A-T and C-A-T-E domain substitutions respectively at 
8 % and 3 % of WT levels in module 8, and 15 % and 8 % in module 11. A final test 
substituted four modules from LptC for four in DptB. The altered products were 
successfully produced and confirmed by mass spectrometry, albeit with a lipopeptide 
yield of only 0.4 % of WT levels. These alterations were combined with previous 
alterations of DptD at position 12 and 13 to create a combinatorial library of 30 variants. 
In total, 21 of these variants produced altered products (Nguyen et al., 2006).  
A more recent example introduced domain substitutions in the A54145 biosynthetic 
pathway (Nguyen et al., 2010). As mentioned earlier, A54145 is a lipopeptide related to 
daptomycin. Similar to daptomycin, it is composed of a decanoic acid moiety attached to 
a 13 residue peptide. By making substitutions in multiple modules using the linkers 
between T-C domains, a total of eight variant pathways containing 1-5 changes to 
A54145 were created. Each substitution gave modified A54145 at between 0.3 % and 
15.9 % of wild type levels (Nguyen et al., 2010). These examples of substitutions that 
have kept C-A domains together as inseparable partners are not exhaustive, but are 
selected to illustrate two ideas. First, the successes of C-A domain substitutions appear 
relatively high compared to modifications of the A-domain. Secondly, in spite of this 
increased success, there are still losses in activity caused by undetermined factors. 
1.3.4 Inter-enzyme communication 
Another approach to generating modified products is by modifying interenzyme 
interactions. Many NRPS pathways are located on multiple enzymes, and the correct 
association between upstream and downstream enzymes is essential for correct peptide 
assembly. Short terminal communication-mediating (COM) domains were identified that 
are involved in mediating this interaction (Hahn and Stachelhaus, 2004). Upstream 
enzymes contain a C-terminus donor COM domain, which binds the N-terminus acceptor 
COM domain of the downstream NRPS enzyme (Hahn and Stachelhaus, 2004). These 
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COM domains can be substituted for new ones to create new products by changing the 
interactions of NRPS enzymes (Chiocchini et al., 2006; Hahn and Stachelhaus, 2006). 
Although the COM-domains can have a large effect on protein interactions, native NRPS 
partners can sometimes still interact despite COM domains being altered to non-cognate 
pairs (Chiocchini et al., 2006). As such, it was suggested factors outside the 
COM domains are likely to have an additional influence on protein interactions and this 
may be a further role of the T domain (Chiocchini et al., 2006). A recent review, 
highlighted that additional recognition elements are expected because COM domains are 
not always present; for example, the andrimid pathway contains many enzymes without 
any detectable docking domains (Koglin and Walsh, 2009).  
1.3.5 Conclusions from previous domain substitutions efforts 
An overall summary of previous domain substitution studies is that results can be highly 
variable from one system to the next, with few fully defined reasons for the losses in 
activity. The main reasons offered in reviews for why A domain substitutions lose activity 
relate to either the substrate specificity of the C domain or the C/A domain interface 
being essential (Baltz, 2012; Marahiel, 2009; Strieker et al., 2010). However, it is difficult 
to draw a conclusion on which of these is most likely based on the low number of 
A domain substitutions that have been published. The alternative of targeted A domain 
binding pocket modification would probably keep the C/A interface intact, however, it 
has been conclusively shown that the substrate specificity of some A domains cannot be 
efficiently changed just by altering the A domain binding pocket. Out of the studies 
discussed, substituting C-A domains together has produced the best results. In a recent 
review, rules for successful domain substitution were suggested. These rules were: (i) 
keep C-A domains together; (ii) C domains need to be located to receive the same type of 
substrate in their natural setting (i.e. an L-amino, D-amino or fatty acid); and (iii) the type 
and subtype of domain downstream to T domains needs to be kept constant (Baltz, 2012). 
Despite these rules, there is still frequently a large loss of activity in C-A domain 
substitutions. Further understanding for the reasons in loss of function for C-A domain 
substitutions is needed to better predict which substitutions are likely to be functional. 
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1.4 Pyoverdine as an alternative system to study domain substitution 
Pyoverdine is a yellow-green siderophore used by fluorescent pseudomonads to sequester 
iron from the environment. Due to the poor solubility of ferric iron, passive uptake of iron 
from the environment is generally unable to support bacterial growth. To increase iron 
uptake bacteria often synthesise siderophores that, when secreted, chelate iron and are 
then taken into the cell (Hider and Kong, 2010). Pyoverdine is the primary siderophore 
used by fluorescent pseudomonads (Cornelis, 2010; Visca et al., 2007). In addition to 
pyoverdine, fluorescent Pseudomonads usually contain lower affinity secondary 
siderophores, which may function when iron levels are slightly limited or have alternative 
roles (Cornelis, 2010). The structure of pyoverdine consists of a conserved fluorescent 
dihydroquinoline chromophore with both an acyl chain and a variable peptide attached to 
it. The chromophore is conserved in all pyoverdines, whereas the peptide chain varies 
greatly between strains. The structure of pyoverdine synthesised by P. aeruginosa PAO1 
is shown in Figure 1-7 (Briskot et al., 1989; Demange et al., 1990). 
 
 
Figure 1-7. Pyoverdine from P. aeruginosa PAO1 consists of an acyl chain (black), chromophore 
(green) and peptide chain (red). The acyl chain shown here is succinamide, but can also be 
succinate, or α-ketoglutarate (Briskot et al., 1989; Demange et al., 1990). 
 
In P. aeruginosa PAO1, pyoverdine is synthesised by four NRPS enzymes (Figure 1-8, 
panels A & B), which are located in the cytoplasm. The first of these, PvdL, contains four 
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modules that assemble the residues later processed into the chromophore. Due to its role 
in chromophore assembly, PvdL is conserved among all fluorescent Pseudomonads 
(Mossialos et al., 2002). The first module of PvdL is unusual as it consists of an acyl CoA 
ligase-like domain and a T domain. The acyl CoA ligase domain incorporates a myristic 
or myristoleic acid group as the first residue of pyoverdine (Drake and Gulick, 2011; 
Hannauer et al., 2012). The three other modules of PvdL add an L-Glu, D-Tyr and 
L-diaminobutyrate (L-Dab) residue before the peptide is passed to the NRPS enzymes 
required for synthesis of the pyoverdine side-chain. In P. aeruginosa PAO1 these 
enzymes are PvdI, PvdJ and finally PvdD. PvdD governs incorporation of the two L-Thr 
residues at the C-terminus of the linear pyoverdine peptide (Ackerley et al., 2003), after 
which, the TE domain releases pyoverdine via intramolecular cyclisation. The released 
pyoverdine (Figure 1-8C) is transported into the periplasm. In the periplasm, the four 
residues added by PvdL are processed into the mature chromphore, in which the myristate 
and L-Glu are replaced by an acyl group such as succinamide, and the other two residues 
are modified. Mature pyoverdine is secreted into the extracellular environment by the 
ATP-dependent efflux pump PvdRT-OpmQ (reviewed in Schalk and Guillon (2013) and 
Visca et al. (2007)). 
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Figure 1-8. Synthesis of the pyoverdine precursor. (A) Pyoverdine is synthesised by the four 
NRPS enzymes PvdL, PvdI, PvdJ and PvdD. The domain architecture of each enzyme is indicated 
by the key at the bottom of the figure. The module boundaries are delineated by lines under each 
enzyme, and the substrate specified by the A domain for each module is listed below these lines. 
(B) Non-proteinogenic residues incorporated into pyoverdine. The first module of PvdL adds a 
myristic or myristoleic acid residue. PvdH converts L-Asp β-semialdehyde (L-ASA) into L-Dab 
that is incorporated into pyoverdine. PvdA and PvdF convert L-Orn into L-N
5
-formyl-N
5
-
hydroxyornithine (L-hfOrn) that is incorporated into pyoverdine. (C) The pyoverdine precursor is 
released by the TE domain of PvdD. Figure adapted from Schalk and Guillon (2013) and Visca et 
al. (2007). 
 
Once secreted, pyoverdine can bind iron and is then taken up by a membrane bound 
receptor, FpvA. In total, over 100 pyoverdines have been identified (Meyer et al., 2008; 
Schalk, 2008) with the sequence determined by mass spectrometry for more than 60 
different pyoverdines (Meyer et al., 2008). The pyoverdines contain the same 
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chromophore but differ greatly in their peptide chains, which have diverged through 
genetic recombination and duplication events (Ravel and Cornelis, 2003; Smith et al., 
2005). The ability to take up pyoverdines can be highly strain specific, such that a strain 
may not be able to use pyoverdine synthesised by other strains (Buyer and Leong, 1986; 
Meyer et al., 1997, 2002, 2008). A reason suggested for the specificity is that pyoverdine 
has diversified to block other strains from using the siderophore (Schalk and Guillon, 
2013; Visca et al., 2007). Despite the specificity, heterologous uptake can occur with 
pyoverdines containing similar peptide chains (Schalk, 2008). In particular, P. aeruginosa 
PAO1 has been shown to exhibit promiscuity (Meyer et al., 1997, 1998, 1999). 
1.4.1 Reasons to use pyoverdine as a model for domain substitution 
Many domain substitution studies detect products using mass spectrometry without 
quantification of products. This is because products can often be difficult to detect and/or 
purify, especially when synthesised at low levels. The main feature of pyoverdine that 
makes it useful for domain substitution studies is its ease of detection and ability to be 
quantified, based on absorbance and fluorescence of the chromophore. The large variation 
in peptide chains of pyoverdines indicates that changes to the variable peptide are 
unlikely to interfere with the absorbance and fluorescence of the invariant chromophore. 
Although specificity towards pyoverdines has been previously observed, P. aeruginosa 
PAO1 is useful for this study due to its ability to take up heterologous pyoverdines. In 
particular, it has been suggested the two terminal Thr residues are unlikely to be involved 
in recognition by FpvA in P. aeruginosa PAO1 (Meyer et al., 1999). The diversity of 
pyoverdines not only indicates that nature has repeatedly surmounted existing constraints 
to domain recombination, but it also provides a rich source of related domains for use in 
domain substitution experiments. 
In this thesis, NRPS domain substitution variants were expressed in vivo and pyoverdine 
production was monitored. There are several advantages to measuring in vivo production 
of pyoverdine rather than the in vitro kinetics. Kinetic assays of NRPS domains generally 
measure a single reaction in isolation. However modifications can affect reactions not 
measured (Zhang et al., 2013) or modified NRPS enzymes may function in vivo despite 
loss of function for in vitro assays (Roche and Walsh, 2003). Moreover, purification of 
pyoverdine NRPS domains, previously attempted by Dr Owen, found them to become 
insoluble when purifying (Owen, 2010). Finally, presumably due to the size of NRPS 
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pathways, only small model systems have been used for in vitro studies. We are most 
interested in being able to modify modules in the context of entire pathways, and as such 
in vivo production would appear to be the most important metric. 
1.4.2 Previous work on the pyoverdine system 
This study improves and extends early work on A domain substitutions in the pyoverdine 
synthesising NRPS enzyme PvdD (Ackerley and Lamont, 2004). PvdD contains two Thr 
specifying modules that incorporate the final two (C-terminal) residues into pyoverdine 
(Ackerley et al., 2003). The previous work using PvdD successfully generated attenuated 
pyoverdines by in-frame deletion of the first of the two modules of pvdD (Ackerley and 
Lamont, 2004). However, attempts to generate modified pyoverdine by domain 
substitution experiments were unsuccessful. When five different A domains were 
substituted into the first Thr specifying module of PvdD, the two Thr specifying 
A domain substitutions yielded functional recombinant PvdD variants, whereas the three 
enzymes containing non-Thr specifying A domains were all inactive. This result was 
highly successful in terms of domain substitution and is consistent with the A domain 
substitutions being limited by C domain acceptor site proof-reading constraints. In 
contrast, when the corresponding C-A domains were substituted, none of the substitutions 
were functional (Ackerley and Lamont, 2004). 
The reasons for C-A domain substitutions being non-functional in PvdD are unclear. One 
possibility is the C-A domain substituted constructs from this previous study were 
inactive due to the inability of the introduced domains to communicate appropriately with 
the remainder of the pyoverdine biosynthetic machinery. Another possible explanation 
raised to explain this lack of activity was that C domains may sometimes exhibit donor 
site proofreading after all, such that the introduced C-domain might prove incompatible 
with the incoming residue supplied by the upstream NRPS module, or that a newly 
introduced amino acid substrate might not be recognised at the donor site of the C domain 
immediately downstream (Ackerley and Lamont, 2004). There is evidence of some donor 
site specificity towards the terminal residue of peptides (Stein et al., 2005), and additional 
evidence shows starter C domains (which join fatty acid residues to the first amino acid in 
a non-ribosomal peptide) can exhibit strong donor site specificity toward fatty acid 
substrates (Kraas et al., 2012). To eliminate the confounding possibility that introduction 
of a novel amino acid into a growing peptide chain might cause donor-site incompatibility 
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with the C domain immediately downstream, in this study we chose to focus on domain 
substitutions into the second module of PvdD, which (as the terminal pyoverdine 
synthetase; Figure 1-8A) has no additional C domain located downstream. An additional 
advantage is that the second module of PvdD condenses substrates in cis, i.e. attached to 
T-domains within the same enzyme, and we reasoned that C-A domain substitutions into 
this module would therefore be less likely to disrupt critical interactions between PvdD 
and the upstream NRPS, PvdJ. 
1.5 Aims of this study 
The overall aim of this thesis was to rigorously define the genetic constraints on domain 
substitution in PvdD.  
This was first addressed in Chapter 3 by testing whether A domain substitutions are 
highly functional in pyoverdine NRPS enzymes, but limited by acceptor site substrate 
specificity. Due to the low number of previously published A domain substitution studies 
downstream to C domains, it was unclear whether the primary factor restricting the 
functionality of A domain substituted NRPS constructs is C domain acceptor site 
proof-reading or disruption of critical C/A domain interactions. 
We then sought to determine, using the same genetic templates, whether C-A domain 
substitutions could produce novel pyoverdines. Previous attempts to change residues in 
pyoverdine by domain substitution were not successful. Chapter 4 examines whether new 
pyoverdines can be produced by domain substitution and found that new pyoverdines 
could sometimes be produced. The function of some C-A domain substitutions is 
important, as it enables PvdD to be used to understand why other C-A domain 
substitutions become non-functional. 
An emerging view is that conformational changes of the T domain and its interactions 
with other domains are vital for NRPS function. Chapter 5 explores whether keeping the 
T/C domain junction intact improves activity of domain substitutions, and examines the 
general portability of T domains in PvdD. This work found T domains are highly portable 
in PvdD when certain constraints are maintained. 
Due to no C domain structure having been solved in the presence of a substrate, little is 
known about the residues involved in the substrate specificity within the acceptor site of 
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the C domain. Chapter 6 aimed to isolate the region of the C domain vital for acceptor site 
specificity, and developed a plasmid useful for the directed evolution of NRPS enzymes 
in P. aeruginosa PAO1. 
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Chapter 2: Methods 
2.1 Chemical, reagents, media and enzymes 
All chemicals, reagents and media were obtained from Sigma-Aldrich (St Louis, MO, 
USA) and Thermo Fisher Scientific (Waltham, MA, USA), unless otherwise noted. 
Isopropyl β-D-1-thiogalactoside (IPTG) was obtained from Bioline (London, UK). 
EDDHA (ethylenediamine-N,N'-bis(2-hydroxyphenylacetic  acid))  was supplied by 
Professor Ian Lamont from University of Otago (Dunedin, NZ).  
Enzymes were sourced from several companies. Phusion™ high-fidelity DNA 
polymerase was purchased from Finnzymes (Espoo, Finland) and New England Biolabs 
(Ipswich, MA, USA). Biomix™ red was obtained from Bioline. Restriction enzymes 
were supplied by New England Biolabs. T4 DNA ligase was supplied by Bioline and 
Invitrogen (Carlsbad, CA, USA). 
Unless otherwise stated, all solutions were made in ultrapure water. Ultrapure water was 
prepared by distillation followed by deionisation to a minimum conductivity of 
18 MΩ·cm at 25 °C using a Barnstead™ Easypure™ II deioniser (Thermo Fisher 
Scientific). 
2.2 Oligonucleotide primers 
DNA oligonucleotide primers were supplied by Integrated DNA Technologies 
(Coralville, IA, USA) as lyophilised powders. Stock solutions were created by dissolution 
of primers in TE buffer (10 mM Tris-Cl pH 8.0, 1 mM ethylenediaminetetraacetic acid 
[EDTA]) to an oligonucleotide concentration of 100 µM. Working stocks of primers were 
made by diluting the stock solution to 10 µM in ultrapure water. All primers were stored 
at -20 °C. The sequences of primers used in this study are shown in Table 2-1. 
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Table 2-1. Oligonucleotide primers used in this study 
Function  
 Name Sequence (5′ → 3′; restriction sites underlined) 
Primers for pSMC 
 CATfwd  CCCCGAATTCCATATGCAAGCACTCATAGAGAAGGTG 
 CATrev   CCCCACTAGTCAATCCCTGGGCGAACGC 
 TTeFwd  CGCCCAGGGATTGTCTAGAGCGGCCGCGTCGCAGCAGGCCTATCGAGCGC 
 TTeRev  CCCCGAGCTCTCAGCGCCCGGCACGCTCCAGG 
Primers for pSMA 
 Thr-WT_CAfwd  GGGGTCTAGAACGACGGATGCGGTCTCGACGA 
 CATCrev   ATAGGCCTGCTGCGACGCGGCCGCTCTAGAATCAGCGCAACCGCCTGT 
Forward primers for C-A domain substitutions 
 Thr-A_CAfwd  CCCCTCTAGAGGTGTCAATCTCTTCGAG 
 Ser-B_CAfwd  CCCTCTAGAGCGGCGAGCGCTGCCCCTGTGCT 
 Lys-C_CAfwd  CCCTCTAGATTCGCCCGCCTGCCGATCCCGC 
 Thr-D_CAfwd  CCCCTCTAGAACGACGGATGCGGTCTCGACGATACCGCTTGCCGATCGG 
   CAGGAAGATATCTACCCGCTGTCGC 
 Thr-E_CAfwd  CCCCTCTAGAAATCTCTACGGGGTCACACCGA 
 Ser-F_CAfwd  CCCCTCTAGAGGGCAGGGCAATGCTGCG 
 Asp-G_CAfwd  CCCTCTAGAGATTTCGCGCTGTTGCCGATCGCG 
 Gly-H_CAfwd   CCTCTAGAAACCTCTACGGGGTGACGCGCAT 
 Ser-I_CAfwd  CCCTCTAGAGACTTTTCCCGGTTTCCGATTCC  
 hfOrn-J_CAfwd CCCCTCTAGACAGGCCCCAGGCGCG 
Forward primers for A domain substitutions 
 Thr-WT_Afwd  CCCCTCTAGACGAACAACGGTTGAGCTA 
 Thr-A_Afwd   CCCCTCTAGACGAACAACGGTTGAGCTA 
 Ser-B_Afwd   CCCCTCTAGAGGAACGCCTGGACTACGCCGAG 
 Lys-C_Afwd  GGTCTAGAGGGGCAGGCCTTGAGCTACGCC 
 Thr-D_Afwd  CCCCTCTAGATGGCGAGCAATTGAGATA 
 Thr-E_Afwd  CCCCTCTAGATGGCGAGCAATTGAGCTA 
 Ser-F_Afwd  CCCCTCTAGAGGCTGAACAACTGAGCTA 
 Asp-G_Afwd   CCCTCTAGACGATGGCTCGCTCAGTTACGGC 
 Gly-H_Afwd   CCCTCTAGACGAGCAGACCTTGAGCTACGCCG 
 Ser-I_Afwd   CCCTCTAGATGCAACCACGCTGACCTACGCCC 
Reverse primers for C-A and A domain substitutions 
 Thr-WT_Rev  CCCCGCGGCCGCATCCGGTTGCGGCAACGCCTGC 
 Thr-A_Rev  CCCCGCGGCCGCATCCGGTTGCGGCAACGCCTGC 
 Ser-B_Rev   CCCCGCGGCCGCTTGCGGTCGCGGCAGCGCCTTG 
 Lys-C_Rev  CCCCGCGGCCGCATCCGGCTTCGGCAGCGCCCGA 
 Thr-D/E_Rev  CCCCGCGGCCGCATCCGGCGCGGGCAGCGCCTTG 
 Ser-F_Rev  CCCCGCGGCCGCGTCTGGTGTCGGCAGGGC 
 Asp-G_Rev   CCCCCGCGGCCGCGTCCGGCAGCGGCAATCTGGCC 
 Gly-H_Rev   CCCCGCGGCCGCGTCAGGCGCCGGCAGCGCCTTG 
 Ser-I_Rev   CCCCGCGGCCGCATCCGGCAATGGCAAGGCCTTG 
 hfOrn-J-Rev  GCGACGCGGCCGCATCCGGGCGCGGCAGG 
T2 domain substitutions 
 TE_Fwd  CCCGCGGCCGCCCCACTAGTAATCTCTACGGGGTCACACCGA 
 TTeRev  CCCCGAGCTCTCAGCGCCCGGCACGCTCCAGG 
 T2_Fwd  CAACCGGATGCGGCCGCGTCGCAACAGGCCTATCGAGCGCCC 
 T2_Rev  CATCCGTCGTGCTAGCCAATCCCTGGGCGAACGC 
 T1_Fwd  CAACCGGATGCGGCCGCGTCGCAGCAGGCCTATCGAGCGC 
 T1_Rev  CATCCGTCGTGCTAGCGATGCATGCCGCCTGTTCCGC 
T-C-A domain substitutions 
 TCASer-B_Fwd  CCCCGCGGCCGCCCGCCGCCAGGCCGGAGAGCCT 
 TCASer-F_Fwd  CCCCCGCGGCCGCGTTGCAGGCGGCCTACATCGCT 
 TCAhfOrn-J_Fwd  CGGATGCGGCCGCGGTGCAACAGGCCTGGCAG 
T1 domain substitutions 
 CATTE_Fwd  CCCGCGGCCGCCCCACTAGTACGACGGATGCGGTCTCGACGA 
 C1F  CCCCGCGGCCGCCCGCCGCCAGGCCGGAGAGCCT 
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 C1R  CCCCGCTAGCCAGGGAAGCGGCGAAGTCTGCC 
 C2F   CCCCGCGGCCGCGTTGCAGGCGGCCTACATCGCT 
 C2R   CCCGCTAGCCGCAGCCTGGGCGAAAGCTGCC 
 C3F   CCCCGCGGCCGCCGCCCAGCGCCCGTACCAGGCG 
 C3R  CCCCGCTAGCCACCCGCTCGGCGAAGCCCGCC 
 C4F   CCCCGCGGCCGCGGCGCGCCAGGCCTAC 
 C4R   CCCCGCTAGCGCAAGCGGCTGCGAACG 
 C5F   CCCCGCGGCCGCGTTGCGCACAGGTCATGTGG 
 C5R   CCCCGCTAGCCAGGGCCTGCACGAAGTCAC 
 C6F   CCCCGCGGCCGCGGTGCAACAGGCCTGGCAG 
 C6R   CCCCGCTAGCCAGTGCGGCGACAAACC 
 E1F   CCCCGCGGCCGCGGCGGGGCAGACGCATGT  
 E1R   CCCCGCTAGCGGCGACTCGCGCCAG 
 E2F   CCCCGCGGCCGCGGTCAAACAGCGTTACACCGC 
 E2R   CCCCGCTAGCTGCCACCGAGGCCAGCTG 
 E3F   CCCCGCGGCCGCGGCCGGCAAGGCTTACGTA 
 E3R   CCCCGCTAGCGGCCACCTGGGCCAAGGC 
 E4F   CCCCGCGGCCGCGCCACAGCAGGCCTTTGTCGCT 
 E4R   CCCCGCTAGCCGCCACCCGCGCCAG 
 Ct1F   CCCCGCGGCCGCGTTGCAGCAGGTCTACGTGGCG  
 Ct1R   CCCCGCTAGCGGCAAGCTCGGCATAGGCTTGC 
 Ct2F   CCCCGCGGCCGCGTTGCAGCAGGTCTACGTGGCG 
 Ct2R   CCCCGCTAGCGACGCCGTGGCAGAACTCACCC 
 Ct3F   CCCCGCGGCCGCGTTGCAGGCGGCCTACATCGCT 
 Ct3R   CCCGCTAGCCAGCGTGGCGCAGAAGTCCGCC 
 Ct4F   CCCCGCGGCCGCCGCTCAGCAGCGCTACCAGGCA 
 Ct4R   CCCCGCTAGCGACGGCCTCGCTGAACGCTCCC 
 TE1F  same as T2_Fwd 
 TE1R   same as T2_Rev 
 TE2F  CCCCGCGGCCGCGTCACAGCAAGGCCACGTC 
 TE2R  CCCCGCTAGCCATGAAATCGGCCAGCTCACC 
 TE3F  CCCCGCGGCCGCGGCGTTGCGTGAACATGTGGCAC 
 TE3R   CCCCGCTAGCCGCCACGGCGGTCAGCTC 
 TE4F  CCCCGCGGCCGCGGGCGCGGACGCTTATCAGG 
 TE4R  CCCCGCTAGCCAGGCAGTTGACCTGGCCGCGT 
Creation of pDEC and variant C domains 
 Thr-WT_Afwd2  CCCCCACTAGTCCCCGTCGACGAACAACGGTTGAGCTACG 
 Thr-WT_Rev2  same as Thr-WT_Rev 
 Thr-WT_Cfwd  same as Thr-WT_CAfwd 
 Thr-WT_Crev  CCCCCCTCGAGGATCAGCGCAACCGCCTG 
 Lys-C _Cfwd  same as Lys-C_CAfwd 
 Lys-C _Crev  CCCCCCTCGAGCGCCAGTGCTTGCGCCTG 
 Lys-C_C12Rev  CCCCGTCGACCCCCACTAGTTGCTCGAACGGCAG 
 SilD2CSpeI fwd  CCCCACTAGTGGAAGCCTTGCAGC 
 DE_OL_1F  CGATCCAGTACGCGGACTAC 
 DE_OL_1R  GTAGTCCGCGTACTGGATCG 
 DE_OL_2F  CAGGACCTGCCGTTCGAG  
 DE_OL_2R  CTCGAACGGCAGGTCCTG 
 Thr-WT_C12Rev CCCCCACTAGTCCCCGTCGACGAACAACGGTTGAGCTACG 
 SilJC1SpeI Fwd  CCCCACTAGTGGAGGCTTTGCAGC  
 Hom_LyslpFwd GTGCTGTTCAACCATCAGGCCGACTCTCGTTCGG 
 Hom_LyslpRev ATCCAGCGTCAGGTCGAAGGCCACGGAGCTGCTC 
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2.3 Plasmids 
Table 2-2. Plasmids used in this study 
Plasmid  Short description    Source 
pSW196  Integration proficient vector; PBAD promoter. (Baynham et al., 2006) 
pSMC   pSW196 based staging plasmid allowing the  This study 
   substitution of CA domains into pvdD. 
pSMA    pSW196 based staging plasmid allowing the  This study 
   substitution of A domains into pvdD. 
pST2   pSW196 based staging plasmid allowing the  This study 
   substitution of T domains into the second  
module of pvdD. 
pTCA    pSW196 based staging plasmid allowing the  This study 
   substitution of T-C-A domains into the second  
module of pvdD. 
pST1   pSW196 based staging plasmid allowing the  This study 
   substitution of T domains into the second  
module of pvdD. 
pUCP22  Non-integrative plasmid for expression in  (West et al., 1994) 
P. aeruginosa PAO1        
pUCBAD  New vector created by adding the PBAD   This study 
promoter from pSW196 into pUCP22 
pDEC   C domain substitution plasmid constructed  This study 
from pUCBAD 
pTRN   Substitution plasmid for changing the third  This study 
    variable region of the second module of pvdd 
 
2.4 Bacterial strains 
Table 2-3. E. coli strains used in this study 
Strain  Relevant characteristics *    Source 
DH5α λpir supE 44 DlacU 169 (Ø80 lacZ  DM5) hsdR17 λ(pir) Invitrogen 
BL21   F
– 
ompT gal dcm lon hsdSB(rB
-
 mB
-
 ) λ(DE3)   Novagen 
BL21 ∆entD entD deletion strain     (Owen et al., 2012) 
* A list of standard abbreviations can be found at 
http://openwetware.org/wiki/E._coli_genotypes#Nomenclature_.26_Abbreviations 
 
Table 2-4. Pseudomonas strains used in this study* 
Strain    Relevant characteristics  Source 
P. aeruginosa PAO1  Wild type   Laboratory stocks 
P. aeruginosa PAO1 ∆pvdD  pvdD deletion mutant, Pvd- (Ackerley and Lamont, 2004) 
P. syringae pv. phaseolicola 1448A  Wild type  Laboratory stocks 
P. putida KT2440   Wild type   Laboratory stocks 
P. fluorescens SBW25   Wild type   Prof. Paul Rainey 
* Domain substitution strains were created using P. aeruginosa PAO1 ∆pvdD and are not listed in 
this table for clarity. 
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2.5 Bacterial growth and maintenance  
Media were prepared in ultrapure water and autoclaved at 121 °C for 30 min. Storage of 
media was at room temperature. 
2.5.1 Liquid media 
Luria broth (LB)* 
Tryptone   10  g·L
-1
 
Yeast extract   5  g·L
-1
 
NaCl   5  g·L
-1
 
* Supplied as a premixed powder 
 
King's B (KB) 
Bacto-peptone  20  g·L
-1
 
K2HPO4  1.5  g·L
-1
 
Glycerol  1  % (v/v) 
MgSO4  6.1  mM* 
* Added post-autoclave from a filter sterilised 1 M solution 
 
Succinate media 
K2HPO4  6  g·L
-1
 
KH2PO4  3  g·L
-1
 
(NH4)2SO4  1  g·L
-1
 
Succinate  4  g·L
-1 
MgSO4  6.1  mM* 
* Added post-autoclave from a filter sterilised 1 M solution 
 
M9 succinate*
,
** 
Na2HPO4.7H2O 6.78  g·L
-1
 
KH2PO4  3  g·L
-1
 
NH4Cl   1  g·L
-1
 
NaCl   0.5  g·L
-1
 
Succinate  4  g·L
-1 
MgSO4  6.1  mM*** 
* M9 salts provided as a premixed powder 
** Adjusted to pH 7.0 using NaOH prior to autoclaving 
*** Added post-autoclave from a filter sterilised 1 M solution 
 
2.5.2 Solid media 
To solidify media, 1.5 % (w/v) agar was added prior to autoclaving. Media was allowed 
to cool to less than 50 °C before addition of supplements. After supplements were added, 
media was poured aseptically into 90 mm Petri dishes and incubated at room temperature 
until set. Agar plates were stored at 4 °C. 
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2.5.3 Media supplements 
Antibiotic stock solutions were prepared at 1000x the concentration used in media. 
Solutions were filter sterilised and stored at -20 °C. Table 2-5 shows the media 
concentrations of antibiotics used in this study. Other supplements were IPTG and 
EDDHA. The concentration of IPTG in the stock solution was 100 mg·mL
-1
. EDDHA 
was prepared to a final stock solution concentration of 200 mg·mL
-1
 with NaOH added to 
facilitate solubility. 
Table 2-5. Concentrations of antibiotics in media 
Antibiotic  E. coli (µg·mL
-1
) P. aeruginosa PAO1 (µg·mL
-1
) 
Ampicillin  100   - 
Kanamycin  50   - 
Spectinomycin  50   - 
Gentamycin  -   50 
Tetracycline  15   100   
 
2.5.4 Growth and storage 
Unless otherwise stated, bacterial strains were grown in LB medium. Cultures were 
incubated at 37 °C for E. coli and P. aeruginosa, and 30 °C for P. putida, P. syringae and 
P. fluorescens. Liquid cultures were aerated in an orbital shaker at 200 - 300 rpm. Strains 
were stored for short periods of time on agar plates at 4 °C. For long term storage, a liquid 
culture was grown overnight, mixed in a 1:1 ratio with 80 % (v/v) glycerol and stored at 
-80 °C.  
2.6  General molecular biology methods 
2.6.1 Isolation and purification of DNA 
Genomic, plasmid and linearised DNA were isolated and purified using the kits in Table 
2-6 according to the manufacturer's instructions. DNA purified using a Zymoclean™ Gel 
DNA Recovery kit (Zymo Research; Irvine, CA, USA) was subsequently cleaned with a 
DNA Clean & Concentrator™ kit (Zymo Research) to remove traces of ethidium 
bromide. This increased the efficiency in downstream reactions. All DNA was stored at -
20 °C in ultrapure water. 
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Table 2-6. Kits used for DNA purification 
DNA  Name of kit    Supplier 
Genomic Qiagen DNeasy™ Blood & Tissue Qiagen; GmbH, Germany 
Plasmid* Zyppy™ Plasmid Miniprep  Zymo Research; Irvine, CA, USA 
  Geneaid High-Speed Plasmid Mini  Geneaid Biotech; Sijhih City, Taiwan 
Linear** DNA Clean & Concentrator™  Zymo Research 
  Zymoclean™ Gel DNA Recovery Zymo Research 
* Multiple kits were used for the same purpose 
** For the purposes of this chart, linear refers to DNA linearised by restriction digest or PCR 
amplification 
2.6.2 Confirmation of DNA products 
2.6.2.1 Agarose gel electrophoresis 
To qualitatively determine the size of DNA fragments, samples were eletrophoresed on 
1 % (w/v) agarose gels (1 % (w/v) agarose, 1x TAE buffer [40 mM Tris pH 8.0, 20 mM 
acetic acid, 1 mM EDTA], 1 µg·mL
-1 
ethidium bromide). Prior to loading, DNA samples 
were mixed with 5x DNA loading buffer (Bioline). HyperLadder™ 1 (Bioline) was added 
to an adjacent well for size determination. Gels were electrophoresed at 100 - 150 V for 
30 - 45 min, and then viewed using an ultra-violet (UV) transilluminator. 
2.6.2.2 DNA quantification 
Following purification, DNA samples were quantified using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific).  
2.6.2.3 DNA Sequencing 
Plasmids created in this study were sequenced by Macrogen Inc. (Seoul, South Korea).  
2.6.3 PCR protocols 
2.6.3.1 Standard reactions 
For plasmid construction, DNA was amplified with Phusion™ high-fidelity polymerase. 
For colony screening and diagnostic purposes Biomix Red™ was used. The standard PCR 
protocols for Phusion™ and Biomix Red™ red are shown in Table 2-7 and Table 2-8, 
respectively. These PCR protocols were optimised experimentally to maximise yield and 
specificity. 
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Table 2-7. PCR protocol used for Phusion™ polymerase 
Temperature  Time   
98 °C    1 min 
 
98 C                              15 s  
58 C                              30 s      30 cycles 
72 C                              30 s·kb-1*  
 
72 °C    5 min 
* kb = kilobase 
 
Table 2-8. PCR protocol used for Biomix Red™ polymerase 
Temperature  Time   
95 °C    5 min 
 
95 C                              20 s  
56 C                              30 s      15 cycles 
72 C                              1 min·kb-1  
 
95 C                              20 s  
52 C                              30 s      15 cycles 
72 C                              1 min·kb-1  
 
72 °C    5 min 
 
2.6.3.2 Overlap Extension PCR 
Overlap Extension PCR is a two-step process to anneal DNA fragments without using 
restriction sites. Firstly, two DNA fragments were amplified by Phusion™ high-fidelity 
polymerase. The fragments were designed such that the 3′ end of the upstream fragment 
and 5′ end of the downstream fragment contained 12 - 20 basepair (bp) of homology. This 
region of homology served as a primer for a subsequent reaction, such that the 
downstream fragment would bind to the upstream fragment and act as a reverse primer 
and vice versa. The second reaction used Biomix Red™ and proceeded for five cycles 
with only the two fragments to enable the full length product to form. Then the forward 
and reverse primers for the full length product were added to allow exponential 
amplification of the annealed fragments for 30 cycles. The protocol for the second 
reaction is shown below in Table 2-9. 
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Table 2-9. Overlap extension protocol used for Biomix Red™ polymerase 
Temperature  Time   
95 °C    5 min 
 
95 C                              20 s  
56 C                              30 s      5 cycles 
72 C                              1 min·kb-1  
 
      Primers added 
 
95 C                              20 s  
60 C                              30 s      30 cycles 
72 C                              1 min·kb-1  
 
72 °C    5 min 
 
2.6.3.3 Site-directed mutagenesis 
Site-directed mutagenesis was used to alter the sequence of a gene already within a 
plasmid. The protocol was similar to the QuikChange™ Site-Directed Mutagenesis Kit 
(Agilent Technologies; Santa Clara, CA, USA), except an amplicon was used instead of 
primers due to the large region to be changed. In brief, a short piece of DNA was 
amplified that had homology on each end to where it was to be inserted into a plasmid. 
This amplicon was then used as the primer in a PCR reaction to amplify the plasmid. The 
resulting product was cleaned and restriction digested overnight using DpnI to remove 
any of the original plasmid. Following restriction digest, the PCR amplified plasmid was 
transformed into E. coli.  
2.6.3.4 STaggered Elongation Process PCR 
For STaggered Elongation Process (STEP) PCR based recombination (Zhao et al., 1998), 
two fragments of DNA containing moderate levels homology were amplified using 
Phusion™. These were purified and eluted in ultrapure water. A second reaction used 
both purified fragments as template and the forward primer for one fragment and the 
reverse primer for the other fragment. In the PCR protocol for the second reaction (Table 
2-10), a low annealing temperature and short annealing/extension step was used to cause 
DNA extension to halt before complete extension. This meant that, in homologous 
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regions, incomplete products could bind either sequence and act as a primer. The result of 
this template switching was amplicons consisting of sequence from both gene fragments. 
Table 2-10. Protocol for StEP PCR recombination 
Temperature  Time   
98 °C    1 min 
 
98 C                              20 s      80 cycles 
56 C                              5 s  
 
72 °C    5 min 
 
2.6.4 Restriction enzyme digest 
Restriction digests were carried out according to the manufacturer's protocol. After 
restriction digest, linearised DNA was cleaned (Section 2.6.1) and stored at -20 °C. For 
difficult to digest DNA, digests were incubated overnight. The next day, additional 
enzyme, buffers and ultrapure water were added, doubling the volume. This was left to 
digest for at least 4 h before purification of digested DNA.  
2.6.5 Ligation 
T4 DNA Ligase was used for ligation of DNA according to manufacturer instructions. 
Ligations typically used between a 1:1 and 3:1 molar insert to vector ratio and were either 
transformed as is or purified with a DNA Clean & Concentrator™ kit (Section 2.6.1) 
before transformation. 
2.7 Bacterial transformation 
2.7.1 E. coli transformation by the calcium chloride method  
To make E. coli competent for transformation, a culture of DH5α was grown in liquid LB 
until stationary-phase. The culture was diluted to an OD600 of 0.05 in LB supplemented 
with 10 mM MgCl2 and grown until an OD600 of 0.4 was reached. From this point the 
cells were kept on ice as much as possible. The culture was centrifuged for 20 minutes at 
4,000 rpm, 4 °C to pellet the bacteria. The pellet was resuspended in 1 vol of TFB I 
(50 mM MnCl2, 10 mM CaCl2, 30 mM CH3CO2K, 15 % (v/v) glycerol) and incubated on 
ice for 2 h. The bacteria was centrifuged, the supernatant discarded, and the pellet 
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resuspended in 0.1 vol of TFB II (10 mM NaMOPS pH 7, 75 mM CaCl2, 10 mM KCl, 
15 % (v/v) glycerol). Following resuspension, 100 µL volumes were aliquoted into 
Eppendorf tubes, snap-frozen and stored at -80 °C.  
For each transformation, a 100 µL aliquot of competent cells was defrosted on ice. DNA 
was added in a volume of less than 10 µL and the cells were incubated on ice for 
20-30 min. The sample was heat shocked at 42 °C for 2 min, then incubated on ice for 
2 min. A volume of 1 mL of LB was added and the cells recovered at 37 °C, 250 rpm for 
40 min. Recovered cells were spread on solid media supplemented with the relevant 
antibiotics and incubated at 37 °C overnight. 
Colonies with correct plasmid sequences were screened for using PCR based methods and 
confirmed with restriction digest analysis and DNA sequencing. 
2.7.2 P. aeruginosa transformation by electroporation 
For the transformation of P. aeruginosa, a culture was grown in liquid media overnight 
until late stationary-phase. For each transformation, a total of 3 mL of culture was 
aliquoted into two eppendorf tubes. These were centrifuged at 4000 rpm for 20 min. The 
supernatant was discarded and the pellet resuspended in 1 mL of 300 mM sucrose. The 
centrifugation and resuspension step was repeated. Next, the cells were centrifuged and 
both pellets resuspended together in 100 µL of 300 mM sucrose. Competent P. 
aeruginosa cells were prepared at room temperature and used immediately for 
transformation. 
For each plasmid to be transformed, a volume of less than 5 µL of purified plasmid was 
added to a 100 µL aliquot of competent cells. This step was modified for transforming 
integration plasmids such as pSW196, where approximately 10 µg of plasmid DNA was 
required. To achieve this amount of DNA, when competent cells were being prepared, 
50 µL of 600 mM sucrose was mixed with 50 µL of purified plasmid and used for the 
final resuspension. The cells containing added plasmid DNA were next added to a 2 mm 
electroporation cuvette. Cells were electroporated using a GenePulser Xcell™ 
electroporation system (Bio-Rad Laboratories, Inc.; Hercules, CA, USA) with the default 
settings for P. aeruginosa. Immediately following electroporation, 1 mL of LB was added 
to the electroporation cuvette. The culture was poured into a 15 mL falcon tube and 
recovered at 200 rpm, 37 °C for between 2 to 3 h. Recovered transformations were spread 
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on solid media plates containing the necessary antibiotics and incubated at 37 °C 
overnight. 
Integrating plasmids were constructed in E. coli and confirmed by sequencing prior to 
transformation. Non-integrative plasmids were screened for using PCR, restriction digest 
analysis and DNA sequencing. As extraction of plasmid DNA from P. aeruginosa 
resulted in low yields, plasmids were transformed into and extracted from E. coli to use 
for restriction digest analysis and DNA sequencing.  
2.8 Creation of the domain substitution plasmids 
2.8.1 Creation of the plasmids pSMC and pSMA 
To create pSMC, the first module of pvdD containing C-A-T domains was PCR amplified 
using the primers CATfwd and CATrev. The amplicon was restriction digested and 
ligated into pSW196 using the 5′ EcoRI and 3′ XbaI restriction sites added during PCR by 
the primers. The location of the XbaI restriction site was chosen based on studies showing 
the highly variable stretch of amino acids between the T domain and C domain is tolerant 
of change (Doekel et al., 2008; Mootz et al., 2000). The location is 37 residues 
downstream to the conserved Ser residue of the T domain from the first module (Figure 
3-2). The restriction site altered the coding sequence from ER→TR. Due to being within 
the linker region it was predicted this change would have minimal affect on enzyme 
function. After confirming integration of the first module, the T-TE domains from the 
second module of pvdD were amplified with primers TTeFwd and TTeRev, and then 
ligated downstream to the first module using the introduced 5′ NotI and 3′ SacI restriction 
sites. The location of the NotI site was chosen based on domain substitutions being 
previously successful in the first module of pvdD (Ackerley and Lamont, 2004). The NotI 
restriction site was located by aligning the first and second modules of pvdD and selecting 
the region in the second module equivalent to where the restriction site was added 
previously. The amino acid sequence in this location was identical between the first and 
second modules. At this point the plasmid pSMC was constructed and contained the 
C-A-T domains from the first module and T-TE domains from the second module of 
pvdD separated by a SpeI and NotI restriction site. New C-A domains could be ligated 
into pSMC using the restriction sites XbaI and NotI. The restriction enzyme recognition 
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site for XbaI differs from SpeI, but creates the same overhang 5′ overhang, meaning 
ligation of these sites creates a sequence unable to be digested by either XbaI or SpeI. 
The A domain substitution plasmid, pSMA, was created by ligating the C domain from 
the second module of pvdD into pSMC using a 5′ XbaI and a 3′ NotI restriction site added 
during PCR amplification by the primers Thr-WT_CAfwd and CATCrev. Ligation of the 
C domain into pSMC using XbaI destroyed the SpeI restriction site of pSMC. A new SpeI 
restriction site was added downstream to the introduced C domain by the reverse primer. 
Like the NotI restriction site, the location of the new SpeI restriction site was selected by 
sequence alignment with the first module of pvdD and is based on previous pvdD 
A domain substitutions (Ackerley and Lamont, 2004). This enabled A domains to be 
ligated into the plasmid using the restriction sites XbaI and NotI. 
2.8.2 Creation of domain substitution plasmids for Chapter 5 
2.8.2.1 Creation of the plasmid pST2 
To construct the T2 domain substitution plasmid, the terminal T-TE domains from the 
plasmid pSMC:Thr-WT (pSMC containing the C-A domains from the second module of 
pvdD) were excised by digestion with NotI and SalI, and then replaced with the pvdD 
TE domain amplified using the primers TE_Fwd and TTeRev (Table 2-1) and digested 
with NotI and SalI. The primer TE_Fwd added a new SpeI restriction site downstream to 
the NotI restriction site to enable the subsequent insertion of new T domains. The 
resulting plasmid named pST2 contained a copy of pvdD lacking the T domain from the 
second module and containing SpeI and NotI restriction sites to insert new T domains into 
the second module of pvdD. 
2.8.2.2 Creation of the plasmid pTCA 
The T-C-A domain substitution plasmid pTCA was created in a similar manner to pSMC. 
The difference was that for the first step, C-A domains were ligated into pSW196 instead 
of C-A-T domains. These C-A domains from the first module were amplified using 
primers CATfwd and Thr-A_Rev (Table 2-1) and ligated into pSW196 using EcoRI and 
NotI restriction sites. Next the T-TE domains were ligated downstream to the 
C-A domains using the 5′ NotI and 3′ SacI restriction sites introduced by the primers 
during PCR. The resulting plasmid contained the C-A domains from the first module of 
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pvdD and the T-TE domains from the second module. A NotI restriction site between 
these allowed insertion of T-C-A domains from other modules. 
2.8.2.3 Creation of pST1 
The domain substitution plasmid pST1 was created to substitute new T domains into the 
first module of pvdD. It was created by PCR amplification of the entire second module of 
pvdD using primers CATTE_Fwd and TTeRev (Table 2-1), and ligation using NotI and 
SalI restriction sites into the intermediate plasmid from the creation of pTCA that 
contained the C-A domains from the first module. The primer CATTE_Fwd added NotI 
and SpeI restriction sites between the domains from the first module and the second 
module of pvdD, which allowed the subsequent insertion of T domains using these 
restriction sites. 
2.8.3 Creation of the directed evolution plasmid and loop substitution 
for Chapter 6 
2.8.3.1 Creation of the plasmid pDEC 
To create a plasmid with tighter regulation of gene expression for substitution of 
C domains, the PBAD promoter was excised from pSW196 using the restriction sites NsiI 
and SacI and ligated into pUCP22 using the restriction sites PstI and SacI. The resulting 
plasmid was named pUCBAD. Next, the pvdD gene lacking the C-A domains from the 
second module was excised from the plasmid pSMC using NheI and SacI restriction sites 
and annealed into the pUCBAD vector using the restriction sites NheI and SacI. The 
A domain from the second module was then PCR amplified using primers 
Thr-WT_Afwd2 and Thr-WT_Rev, and ligated into this vector using SpeI and NotI 
restriction sites. The resulting plasmid containing pvdD that was lacking the second 
C domain was named pDEC. The forward primer Thr-WT_Afwd2, for amplifying the 
A domain, added a SalI restriction site downstream to the SpeI restriction site to allow 
directional cloning of the C domain. The C domain was inserted with XbaI and XhoI 
restriction sites added by the primers Thr-WT_CAfwd and Thr-WT_Crev. The XhoI/SalI 
fusion site was silent following ligation, i.e. did not alter the primary sequence of pvdD. 
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2.8.3.2 Creation of the chimeric C domain constructs 
Three chimeric C domains were created in the pDEC plasmid. The first of these was 
J12-D3. This plasmid was created by PCR amplifying the first two variable regions of 
JCLys using the primers Lys-C_CAfwd and Lys-C_C12Rev , and ligating these into pDEC 
using XbaI and SalI restriction sites. The reverse primer added a SpeI restriction site so 
that the third variable region of DCThr could be amplified and ligated into this new 
plasmid. This plasmid was created this way so that the third variable region could easily 
be modified. The J1-D23 chimeric C domain was created using overlap PCR whereby the 
J1 fragment was amplified using the primers Lys-C_CAfwd and DE_OL_1R and the D23 
fragment was amplified using the primers DE_OL_1F and Thr-WT_Crev. These were 
then used in an overlap PCR reaction according to methods in Section 2.6.3.2. The 
J1-D2-J3 chimera was created in a similar way, in which the J1-D2 fragment was 
amplified from the J1-D23 chimeric C domain using the primers Lys-C_CAfwd and 
DE_OL_2R and the J3 fragment was amplified using the primers DE_OL_2F and 
Lys-C_Crev. The resulting chimeric C domain from overlap PCR of these fragments was 
ligated into the pDEC plasmid.  
2.8.3.3 Creation of the loop substitution construct 
To replace the loop covering the active site for the second C domain of pvdD, a 
site-directed mutagenesis technique was used. In brief, the loop from the pvdJ C domain 
was amplified with primers Hom_LyslpFwd and Hom_LyslpRev. These primers added 
homology to the pvdD gene at each end of the amplicon. The amplified loop was then 
used to amplify a PCR2.1 plasmid containing the C domain from pvdD according to 
methods in Section 2.6.3.3. The resulting amplified plasmid had the loop from pvdD 
replaced with that from pvdJ. The C domain from this plasmid was subsequently PCR 
amplified then cloned into pDEC using the restriction sites XbaI and XhoI for the 
C domain and SpeI and SalI for the vector. 
2.8.3.4 Construction of the plasmid pTRN 
A new plasmid was needed to insert the recombined third variable regions from the 
second C domain of pvdD and the first C domain from pvdJ into the pvdD C domain. For 
this, the first two variable regions of the pvdD C domain were PCR amplified using the 
primers Thr-WT_CAfwd and Thr-WT_C12Rev. This was ligated into the pDEC vector 
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using a 5′ SpeI/XbaI and a 3′ SalI/SalI ligation. The resulting plasmid named pTRN 
contained SpeI and SalI restriction sites to insert the recombined third variable region. 
2.9 Analysis of pyoverdine production by recombinant and WT P. 
aeruginosa PAO1 strains 
2.9.1 Assessment of strains grown on KB agar plates 
Single colonies were picked from an LB agar plate using a pipette tip and the pipette tip 
stabbed into a KB agar plate supplemented with the relevant antibiotics and L-arabinose. 
For assessing growth under severe iron limitation, the KB agar plates were supplemented 
with 200 µg·mL EDDHA. KB agar plates were incubated at 37 °C for 24 - 36 h, then 
viewed and photographed in a UV-transilluminator. 
2.9.2 Pyoverdine synthesis in liquid media 
Liquid media assays of pyoverdine production were carried out in 96-well plates. Strains 
were grown in triplicate for 24 h in 200 µL LB supplemented with the appropriate 
antibiotics. Each well was diluted 20x in a new 96-well plate and to a total volume of 
200 µL using M9 succinate media supplemented with antibiotics and 0.2 % (w/v) 
L-arabinose. The concentration of L-arabinose was selected based on initial tests as part 
of my honours’ project. The cultures in the second plate were grown for 24 h at 37 °C 
under aeration. The culture from each well was then transferred to a microcentrifuge tube 
and centrifuged to pellet cells. A 100 µL volume of supernatant was transferred to a clean 
96-well plate and 100 µL of fresh M9 media added. The absorbance (400 nm) and 
fluorescence (emission 440 nm, excitation 400 nm) was measured using a microplate 
reader. 
2.9.3 MALDI-TOF/TOF mass spectrometry 
α-Cyano-4-hydroxycinnamic acid (CHCA) matrix (Beavis et al., 1992) was prepared by 
combining 500 µL acetonitrile, 500 µL ultrapure water, 1 µL trifluoroacetic acid and 
10 µg of CHCA. The solution was vortexed, followed by centrifugation for 5 min to 
separate insoluble CHCA. The supernatant was transferred to a clean tube and used in 
mass spectrometry.   
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Samples for mass spectrometry were taken from cultures grown in M9 media expressing 
pyoverdine as per Section 2.9.2. A 1 µL sample of supernatant was mixed with CHCA 
matrix solution in a sample to matrix ratio of 1:20 (v/v). The sample was mixed by 
pipetting, then 1 µL spotted onto an Opti-TOF® 384 well MALDI plate (Applied 
Biosystems, Foster City, CA) and allowed to dry at room temperature. From Chapter 5 
onwards, the sample to matrix ratio was adjusted to 1:5 (v/v). This allowed easier 
detection of peaks with low abundance. The new ratio altered the size of the peak 
corresponding to loss of H2O for all pyoverdines and increased the abundance of a 
non-annotated peak for the truncated pyoverdine product. Nonetheless, this was clearly 
the same product. Samples were analysed using a MALDI TOF/TOF 5800 mass 
spectrometer (Applied Biosystems) in positive ion mode. Each spot was externally 
calibrated using cal2 calibration mixture (Applied Biosystems). 
2.9.4 Screening the StEP library 
After transformation of the StEP ligations, the bacteria were recovered before spreading 
on LB agar plates supplemented with gentimycin. Plates were then incubated at 37 °C for 
24 hours. Colonies were then picked with a toothpick and inoculated into a 96-well plate 
containing 100 µL of M9 media supplemented with 0.1 % L-arabinose. The cultures in 
the 96-well plate were grown for 24 h at 37 °C under aeration. After 24 h, 100 µL of fresh 
M9 media was added to each well, and then the fluorescence (excitation 400 nm, 
emission 440 nm) was measured using a microplate reader. 
2.10 Bioinformatics 
2.10.1 Prediction of NRPS substrate specificity 
The substrate specificity of A domains was predicted using the NRPS/PKS analysis web 
server (http://nrps.igs.umaryland.edu/nrps/), which makes predictions based on the eight 
residues lining the substrate binding pocket (Bachmann and Ravel, 2009). 
2.10.2 Multiple sequence alignments and phylogenies 
Multiple sequence alignments of amino acids were created using the ClustalW algorithm. 
Phlyogenetic trees were created from alignments using the maximum likelihood method 
and Jones-Taylor-Thornton model (Jones et al., 1992). Data sets were bootstrapped using 
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1000 resampling events (Felsenstein, 1985). Evolutionary analysis was performed using 
MEGA 5.2.1 (Tamura et al., 2011). 
2.10.3 Pairwise sequence alignment 
Pairwise sequence alignment was performed using the Needle pairwise alignment tool 
available at http://www.ebi.ac.uk/Tools/psa/emboss_needle/. This generates alignments 
based on the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970) 
2.10.4 Structural model creation and selection 
Structural models of the C domain from the second module of PvdD were created using 
multiple methods. The best structural models created from each method were submitted 
to the QMEAN server to obtain QMEAN6 and QMEANclust scores (Benkert et al., 
2009a). 
2.10.4.1 Automated modelling servers 
The sequence of the condensation domain from the second module of PvdD was 
submitted to the servers listed in Table 2-11. These all create models from a protein 
sequence and required no further user input. 
2.10.4.2 Model creation using SWISS-MODEL 
The structure of TycC (PDB code: 2JGP) was used for modelling as it was predicted to be 
the most suitable by the Swiss-Model server (http://swissmodel.expasy.org/) (Arnold et 
al., 2006). The sequence of the C domain from Thr-WT was aligned to TycC in Swiss 
PDB Viewer (Guex and Peitsch, 1996, 1997) and several alignments were submitted to 
the Swiss-Model server. The best model was selected by QMEAN6. 
2.10.4.3 Model creation using Modeller 9.11 
Models were created in Modeller 9.11 (Eswar et al., 2001) using modified Python 2 
(Python Software Corporation; Wilmington, DE, USA) scripts available in tutorials found 
at http://salilab.org/modeller/tutorial/. Models were built using basic alignment and 
alignment to multiple templates. At least 50 models were created by each method and the 
best models selected by QMEAN6. The loop between residues 363 and 373 of the best 
model was optimised because this was a region of high error in the models. 
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Table 2-11. Automated structural modelling servers. 
Server    URL  
      Reference 
3D-Jigsaw   http://bmm.cancerresearchuk.org/~3djigsaw/ 
     (Bates et al., 2001) 
CPHmodels 3.2   http://www.cbs.dtu.dk/services/CPHmodels/   
     (Nielsen et al., 2010) 
ESyPred3D   http://www.unamur.be/sciences/biologie/urbm/bioinfo/esypred/  
     (Lambert et al., 2002) 
SPARKSX   http://sparks.informatics.iupui.edu/sparks-x/ 
     (Yang et al., 2011) 
nFOLD    http://www.reading.ac.uk/bioinf/nFOLD/  
     (Jones et al., 2005) 
3D-Jigsaw Populus  http://bmm.cancerresearchuk.org/~populus/  
     (Offman et al., 2006) 
RaptorX   http://raptorx.uchicago.edu/  
     (Källberg et al., 2012) 
FUGUE   http://tardis.nibio.go.jp/fugue/prfsearch.html  
     (Shi et al., 2001) 
M4T    http://manaslu.aecom.yu.edu/M4T/  
     (Rykunov et al., 2009) 
I-TASSER   http://zhanglab.ccmb.med.umich.edu/I-TASSER/  
     (Zhang, 2008) 
Chunk-TASSER http://cssb.biology.gatech.edu/skolnick/webservice/chunk-
TASSER/index.html  
     (Zhou and Skolnick, 2007) 
MULTICOM   http://casp.rnet.missouri.edu/multicom_3d.html  
     (Wang et al., 2010) 
Phyre2    http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index 
     (Kelley and Sternberg, 2009) 
 
MUFOLD   http://mufold.org/prediction.php 
     (Zhang et al., 2010) 
 
TASSER-VMT http://cssb.biology.gatech.edu/skolnick/webservice/TASSER-
VMT/index.html    
     (Zhou and Skolnick, 2011) 
Pro-sp3-TASSER http://cssb.biology.gatech.edu/skolnick/webservice/pro-sp3-
TASSER/index.html 
 (Zhou and Skolnick, 2009)  
 
2.10.5 Viewing of homology and structural models 
Homology and structural models were viewed in Swiss-PdbViewer and PyMol (Version 
1.5.0.4; Schrödinger, LLC). All structural pictures were rendered in PyMol. 
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Chapter 3: Construction and characterisation of pvdD A domain 
substitution variants 
3.1 Introduction 
Owing to their role in the selection and activation of monomers, A domains are 
sometimes referred to as the gatekeepers of non-ribosomal peptide synthesis (Keating and 
Walsh, 1999; May et al., 2002; Villiers and Hollfelder, 2011). Despite this role, early 
attempts to create new products by substitution of A domains (as discussed in Section 
1.3.1) met limited success. The fact that such experiments generally gave drastically 
reduced yields, or no product at all, suggests that additional barriers to recombination 
exist. Two main hypotheses to explain why constructs bearing substituted A domains are 
frequently non-functional are: (i) that substrate specificity within the acceptor site of the 
C domain blocks addition of non-cognate substrates activated by substituted A domains 
(Belshaw et al., 1999; Ehmann et al., 2000); and (ii) introducing new A domains disrupts 
essential interactions between the C and A domain (Tanovic et al., 2008). These 
hypotheses led to a shift from A domain substitutions towards: (i) substituting 
C-A domains as catalytic partners; or (ii) directly altering the substrate binding pocket of 
A domains. However, despite a relatively large number of studies focusing on these 
alternatives, the outcome has generally been a large reduction in enzyme activity. On the 
other hand limited information is available on A domain substitutions. As a consequence 
it is unknown which of the two hypotheses above is the primary cause for loss of function 
in A domain substitutions; or, as mentioned in a recent review, whether A domains can be 
functionally substituted at all (Baltz, 2012). 
This chapter extends earlier work by Associate Professor David Ackerley on A domain 
substitutions in the pyoverdine synthesising NRPS enzyme, PvdD. PvdD contains two 
Thr specifying modules that incorporate the final two residues into pyoverdine (Ackerley 
et al., 2003). In previous work, five A domains were substituted into the first module of 
pvdD (Ackerley and Lamont, 2004). The two PvdD variants that were substituted with 
Thr specifying A domains were found to synthesise pyoverdine, whereas no pyoverdine 
synthesis was detected from the three non-Thr specifying A domain variants. These 
results support the hypothesis of A domain substitutions primarily being limited by 
C domain acceptor site specificity, but are limited by the small sample size. Moreover, 
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because this earlier study focused on the first module of pvdD, a possible confounding 
effect was a potential inability of the downstream C domain to tolerate alternative amino 
acid residues in its donor site. In the work described in this chapter the decision was made 
to instead focus on the second module of PvdD, which has no C domain downstream, 
thereby eliminating the possibility of a downstream C domain being unable to receive 
alternative residues at its donor site. 
The aim of the research described in this chapter was to assess whether the main barrier to 
successful A domain substitutions is acceptor site substrate specificity of the C domain or 
disruption of the C/A domain junction. To achieve this, a staging plasmid was built for 
substituting A domains into the second module of pvdD. A total of nine modules, three of 
which specify Thr, were selected as a source of alternative A domains. These modules 
were sourced from the pyoverdine NRPS genes of four fluorescent pseudomonads. The 
genetic regions defining the alternative A domains were amplified by PCR and ligated 
into the A domain substitution plasmid to create variants of pvdD. These variants were 
transformed into a pvdD deletion mutant and assessed for pyoverdine production using 
the fluorescent and siderophore properties of pyoverdine as initial screens, followed by a 
more detailed mass spectrometry analysis. 
3.2 Construction of the A domain substitution staging plasmid and 
A domain substitution variants 
To construct variants of pvdD containing alternative A domains, a staging plasmid 
(pSMA; Figure 3-1A) was built, in which alternative A domains could be substituted into 
pvdD. To construct pSMA, a C-A domain substitution plasmid (pSMC; Figure 3-1B) was 
first constructed, and then modified by introducing the C domain from the second module 
of pvdD. The C-A domain substitution plasmid would later be required for the research 
described in Chapter 4, and this strategy of construction allowed both plasmids to be built 
consistently, and in the fewest steps. The C-A domain substitution plasmid, pSMC, was 
designed in conjunction with former Ackerley laboratory PhD student, Dr Owen. The 
substitution constructs were built in the integrative plasmid pSW196 (Figure 3-1C) 
(Baynham et al., 2006). pSW196 was originally created from mini-CTX1; a plasmid that 
integrates into the P. aeruginosa chromosome using the integrase ϕCTX (Hoang et al., 
2000). The main difference between mini-CTX1 and pSW196 is the addition of the 
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tightly controlled L-arabinose inducible PBAD promoter derived from pBAD30 (Guzman 
et al., 1995). The features of chromosomal integration and the tight regulation of 
expression were considered to be important, since high-level overexpression of PvdD was 
found to lower the overall levels of pyoverdine synthesis in earlier work (Ackerley and 
Lamont, 2004). 
 
Figure 3-1. Domain arrangement within substitution plasmids, and plasmid map of pSW196. (A) 
The domain architecture of the A domain substitution plasmid constructed and used in this 
chapter. Domains coloured blue and red were derived from the first and second module of pvdD, 
respectively. Domains in green were absent in the substitution plasmids and indicate where 
alternative domains would be added. X refers to a SpeI restriction site that was destroyed when 
ligating C-A and A domains into the plasmids via a compatible XbaI sticky end. (B) The domains 
and restriction sites within the staging plasmid pSMC created for use in Chapter 4. See (A) for 
colour coding and definition of X. (C) Plasmid map of pSW196, used as a base for the 
construction of staging plasmids. 
 
 
Full details of the construction of plasmids pSMC and pSMA are given in Section 2.8.1. 
For both plasmids, the location of the NotI site to be used as a fusion site between the 
A and T domains of the second module was chosen based on the equivalent location 
having previously been shown to be permissive of A domain substitutions in the first 
module of pvdD (Ackerley and Lamont, 2004). Introduction of this NotI site did not result 
in any change to the primary sequence of the protein. For pSMC, the location of the 
intended SpeI/XbaI fusion site (“X” in Figure 3-1B) was chosen based on studies 
showing the highly variable stretch of amino acids between the T and C domain is 
tolerant of change (Doekel et al., 2008; Mootz et al., 2000). At a protein level, this 
location is 37 residues downstream of the conserved Ser residue of the T domain from the 
first module of PvdD, and introduction of the restriction site altered the translated 
sequence from ER to TR (Figure 3-2). Due to its location within the linker region, it was 
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predicted this change would have minimal effect on enzyme function. Finally, to create 
pSMA, ligation of the pvdD C domain into pSMC using XbaI destroyed the SpeI 
restriction site present in pSMC and changed the coding sequence from ER to TR. This 
enabled a new SpeI restriction site to be added downstream of the introduced C domain 
by the reverse primer. As with the NotI restriction site, the location of the new SpeI 
restriction site (“X” in Figure 3-1A) was based on previously successful A domain 
substitutions into the first module of pvdD (Ackerley and Lamont, 2004). 
 
 
Figure 3-2. Location the of upstream restriction site for pSMC. Protein sequence showing the 
conserved Ser residue of the T domain from the first module of PvdD in relation to residues 
altered by introduction of the restriction site for C-A domain substitution. The location was 
selected to be 37 residues downstream to the conserved Ser residue of the T domain.  
 
Having created pSMA, nine A domains were amplified by PCR and ligated into the 
plasmid via a XbaI/SpeI fusion at the 5′ end, and a NotI/NotI fusion at the 3′ end. The 
various modules the A domains were sourced from are shown in Figure 3-3, labelled A to 
I. They specify a range of substrates and were sourced from four fluorescent 
Pseudomonas strains. The primers used to amplify each A domain are listed in Table 2-1. 
Once constructed, the A domain substitution variants were sequenced to confirm no 
mutations had been introduced during PCR or cloning. The sequences matched the 
database sequences, except for a silent point mutation in module F, and a C→G 
substitution at position 2455 of module C that changed the encoded amino acid from Pro 
to Ala. This mutation in module C was confirmed to be within the genomic sequence of 
the P. aeruginosa PAO1 strain and is located in an NRPS module involved in pyoverdine 
synthesis. Since P. aeruginosa PAO1 synthesises pyoverdine, this mutation was deemed 
unlikely to inhibit production in the context of the A domain substitution. This domain 
was later confirmed as functional in the context of a C-A domain substitution (see Section 
4.3). 
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Figure 3-3. NRPS genes with modules used for domain substitution highlighted and labelled from 
A to I. (A) Domain architecture of the four NRPS genes involved in P. aeruginosa PAO1 
pyoverdine synthesis. (B) Domain architecture of genes involved in the synthesis of pyoverdine 
variable peptide chains from three other Pseudomonas strains. Accession numbers and substrate 
predictions of genes used for domain substitution are shown in Appendix A. Dab, 
2,4-diaminobutyric acid; hfOrn, L-N
5
-formyl-N
5
-hydroxyornithine; hOrn, N
5
-hydroxyornithine. 
 
The A domain substitution variants were transformed into a pvdD deletion mutant 
previously created and characterised as being unable to synthesise pyoverdine (Ackerley 
and Lamont, 2004). The resulting strains, expressing variants of pvdD that contain 
alternative A domains, are referred to in this chapter by the substrate specified by the new 
A domain followed by the letter of the module in Figure 3-3; for example, the strain 
expressing the variant containing the A domain from the first module of pvdD is referred 
to as strain Thr-A. In addition to the A domain substitutions, a positive control containing 
the restriction sites was created by PCR amplification of the A domain from the second 
module of pvdD, using the primers Thr-WT_Afwd and Thr-WT_Rev (Table 2-1), and 
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ligation of the product into pSMA. This wild type restriction site control is referred to as 
Thr-WT. 
3.3 Evaluation of pyoverdine synthesis by A domain substitution 
strains 
3.3.1 Growth of A domain substitution strains on solid KB media 
Previous work conducting A domain substitutions in pvdD assessed their function based 
on the fluorescence and siderophore activity when grown on solid KB media, both in the 
absence and presence of the iron chelator EDDHA (Ackerley and Lamont, 2004). KB 
media was designed as a low iron medium for the induction of pyoverdine expression 
(King et al., 1954) and the presence of pyoverdine can be observed under UV light due to 
its fluorescence. In the presence of EDDHA, mutants deficient in pyoverdine production 
are unable to grow due to the inability to passively uptake iron (McMorran et al., 2001). 
To test the function of the nine A domain substitution strains, each strain, in addition to a 
pvdD deletion mutant negative control (pvdD deletion strain containing the empty 
pSW196 plasmid from which pSMA was derived) and Thr-WT positive control, was 
inoculated onto solid KB media containing 0.2 % L-arabinose to induce pvdD expression. 
This was repeated both in the absence and presence of EDDHA. These plates were then 
incubated for 24 h at 37 °C, after which photographs were taken on a UV transilluminator 
(Figure 3-4). No differences were observed between the Thr-WT restriction site control 
and wild type strain under either of these conditions (data not shown).  
The three Thr specifying A domain substitution strains, namely Thr-A, Thr-D and Thr-E, 
had increased levels of fluorescence compared to the negative control, and were also 
viable in the presence of EDDHA. The strain Thr-E had noticeably reduced fluorescence 
and viability relative to strains Thr-A, Thr-D and Thr-WT, indicating reduced pyoverdine 
synthesis; however, it was still clearly viable. In contrast, none of the non-Thr A domain 
substitution strains were viable in the presence of EDDHA and all appeared to have levels 
of fluorescence similar to the negative control. Due to the subjective nature of this test, it 
was difficult to ascertain whether there might have been small increases in fluorescence. 
In addition, for growth in the presence of EDDHA it was unknown whether substitution 
of the terminal Thr of pyoverdine for an alternative residue might interfere with iron 
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binding or uptake and thereby cause A domain substitution strains to become non-viable. 
However, there is evidence P. aeruginosa PAO1 can use pyoverdines from some other 
strains (Meyer et al., 1997, 1998, 1999), and it has been suggested that the two terminal 
Thr residues are of P. aeruginosa PAO1 pyoverdine are not involved in specificity by 
FpvA (Meyer et al., 1999). To better address these issues, a more quantitative analysis 
was required. 
 
Figure 3-4. Fluorescence of A domain substitutions strains on KB agar media in the absence (-) or 
presence (+) of EDDHA. Plates were inoculated with Thr-WT, A domain substitution strains A to 
I, and the pvdD deletion mutant (del) then incubated for 24 h at 37 °C. Photographs were taken 
under UV light. 
 
3.3.2 Pyoverdine production by A domain substitution strains grown in 
liquid media 
To more accurately quantify levels of pyoverdine, assays were performed in liquid media. 
Pyoverdine can be detected by spectrophotometry using absorbance (400 nm) and 
fluorescence (excitation 400 nm, emission 450 nm) (Hannauer et al., 2010; Yeterian et al., 
2009). Initial fluorescence tests found emission at 440 nm to give a stronger signal than 
450 nm, and as such this wavelength was used here. It was also found absorbance was 
linear across a wide range, whereas fluorescence was rapidly saturated (Appendix B). 
This meant absorbance was more accurate in terms of quantifying pyoverdine levels than 
fluorescence. However, fluorescence was more sensitive and able to detect pyoverdine at 
a much lower levels. As a consequence, both absorbance and fluorescence were used on 
different occasions throughout this research to most appropriately assess levels of 
pyoverdine synthesis. 
The A domain substitution strains were grown for 24 h in M9 media and both the 
absorbance and fluorescence of the supernatant were measured (Figure 3-5). The 
wild type strain had 78 % and 90 % the levels of absorbance and fluorescence of the 
Thr-WT restriction site control strain, respectively (data not shown). This indicated 
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complementation of pvdD by a single-gene copy expressed from the genome-integrated 
plasmid pSW196 was not reducing pyoverdine production as had been found in previous 
work using a high copy number plasmid (Ackerley and Lamont, 2004). The three Thr 
specifying A domain substitution strains exhibited increased absorbance and fluorescence 
compared to all other strains. The two substitution strains Thr-A and Thr-D, which 
exhibited the highest levels of growth in the presence of EDDHA, had similar levels of 
fluorescence and absorbance to the Thr-WT strain. The strain Thr-E had absorbance 
levels approximately 29 % of Thr-WT, confirming lower levels of pyoverdine synthesis. 
In contrast, the remaining (non-Thr specifying) A domain substitution strains all had 
levels of absorbance similar to the pvdD deletion mutant, with possibly a small increase 
in absorbance observed for strain Ser-F. Interestingly, each of the non-Thr specifying 
A domain substitution strains appeared to have a small increase in fluorescence compared 
to the pvdD deletion strain. This small increase in fluorescence suggested the non-Thr 
specifying A domain substitution strains may have been producing, albeit at very low 
levels, an unknown pyoverdine-like product. 
 
Figure 3-5. Percentage of pyoverdine production from A domain substitution strains grown in 
liquid media. Values are expressed as a percentage relative to the absorbance (400 nm) or 
fluorescence (ex. 400 nm/ em. 440 nm) measured for the Thr-WT strain, having first been zeroed 
against the absorbance/fluorescence of the pvdD deletion mutant. Data are the mean of 6 
independent replicates, and error bars indicate 1 standard deviation. 
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3.4 MALDI-TOF MS/MS confirmation of pyoverdine production 
3.4.1 Pyoverdine produced by Thr specifying A domain substitutions 
The synthesis of wild type pyoverdine by Thr specifying A domain substitution strains 
was next confirmed by MALDI-TOF MS/MS. To detect pyoverdine, strains were grown 
in liquid M9 media as in Section 3.3.2 and the supernatant used directly for analysis. The 
most dominant acyl chain on pyoverdine from P. aeruginosa PAO1 is a succinamide 
moiety (Demange et al., 1990). This pyoverdine has an m/z of 1333.6 (Hannauer et al., 
2012) and, consistent with production of wild type pyoverdine, an ion with a m/z ratio 
within 0.05 % of 1333.6 was detected in the supernatant from each of the Thr specifying 
A domain substitution strains (Figure 3-6). A second major ion detected at 1031.5 m/z 
corresponds to the peptide chain attached to two carbons of the chromophore following a 
retro-Diels-Alder (RDA) process opening the tetrahydropyrimidine ring (Demange et al., 
1990). 
 
 
Figure 3-6. Mass spectra obtained from the supernatant of each of the Thr specifying A domain 
substitution strains and Thr-WT. Arrows indicate peaks at 1031.5 and 1333.6 m/z, corresponding 
to the peptide chain released by the RDA reaction and wild type pyoverdine, respectively. 
 
To analyse the pyoverdine products further and increase the sensitivity of detection, 
collision-induced dissociation (CID) was performed on the 1333.6 m/z ion (Figure 3-7, 
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Table 3-1). The five most abundant ions detected after CID from all four Thr specifying 
A domain substitution strains were of m/z 890.5, 1031.5, 1234.6, 1291.6 and 1316.6 
(Figure 3-7, indicated by arrows). Four of these, namely 890.5, 1031.5, 1234.6 and 
1316.6 m/z, correspond to C-terminal ions (losing part of the pyoverdine at the 
chromophore terminus). The first two of these correspond to the Y7"-ion and the peptide 
chain released during RDA fragmentation of the chromophore (Demange et al., 1990). 
The nomenclature for pyoverdine Y-ions, in addition to A- and B-ions (discussed below), 
is illustrated in Figure 3-8. The last two ions are consistent with pyoverdine losing: (i) the 
succinamide acyl group; and (ii) the NH3 group from the chromophore (Fuchs and 
Budzikiewicz, 2000). Smaller C-terminal ions are likely absent, because the chromophore 
stabilises the positive charge, causing Y"-ions to be rare (Fuchs and Budzikiewicz, 2000). 
An exception to the stabilisation is when the fragment contains a basic residue such as 
arginine (Fuchs and Budzikiewicz, 2000), as seen here by the presence of the Y7"-ion. 
The other highly abundant ion has an m/z of 1291.6 and is consistent with loss of CH2N2 
from the arginine residue (Hannauer et al., 2012). These five ions are emphasised here 
because containing the residues added by pvdD and their high abundance proved useful in 
verifying pyoverdine synthesised at low levels by other strains. 
 
 
Figure 3-7. CID spectra of pyoverdine synthesised by Thr-WT and the three Thr specifying A 
domain substitution strains. The five most abundant irons are indicated by arrows. 
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Table 3-1. Ions detected by CID of pyoverdine from Thr specifying A domain substitution strains. 
 
Thr-WT Thr-A Thr-D Thr-E Calculated 
 Ion m/z m/z Composition 
[RDA + H - Suca]
+
 204.12 204.10 204.08 204.08 204.08 C10H10N3O2 
A1 - Suca 317.20 317.18 317.18 ND 317.12 C15H17N4O4 
A1 - NH3 399.22 399.21 399.19 399.23 399.13 C19H19N4O6 
A1 416.22 416.19 416.18 416.21 416.16 C19H22N5O6 
B1 444.19 444.17 444.16 444.15 444.15 C20H22N5O7 
B2 600.29 600.29 600.26 600.25 600.25 C26H34N9O8 
B3 687.33 687.31 687.35 ND 687.29 C29H39N10O10 
B4 845.43 845.43 845.39 845.41 845.35 C35H49N12O13 
Y7" 890.55 890.52 890.50 890.49 890.47 C35H64N13O14 
[RDAb + H]
+
 1031.60 1031.57 1031.54 1031.52 1031.51 C41H71N14O17 
[M + H - Suca]
+
 1234.67 1234.64 1234.60 1234.59 1234.58 C51H80N17O19 
[M + H - CH2N2]
+
 1291.69 1291.65 1291.60 1291.58 1291.59 C54H83N16O21 
[M + H - NH3]
+
 1316.60 1316.57 1316.54 1316.54 1316.59 C55H82N17O21 
MS/MS precursor 1333.63 1333.63 1333.58 1333.62 1333.61 C55H85N18O21 
Shaded cells indicate ions expected to contain the residue added by the second module of PvdD. 
Suca, succinamide; RDA, chromophoric fragment from the RDA process; RDAb, peptide chain 
fragment released by the RDA process; ND, not detected. 
 
 
Figure 3-8. Nomenclature for pyoverdine ions formed by CID of pyoverdine as suggested by 
Fuchs and Budzikiewicz (Fuchs and Budzikiewicz, 2000). Dashed lines indicate location of 
fragmentation. Contrary to the common nomenclature where the N-terminus is depicted to the left 
(Roepstorff and Fohlman, 1984), the nomenclature for pyoverdines depict with N-terminus to the 
right (Fuchs and Budzikiewicz, 2000). 
 
Additional annotated ions are associated with the chromophore and B-ions. The 
fragmentation patterns from CID of multiple pyoverdine chromophores with different 
acyl chains and different first amino acids in the variable peptide chain have been 
analysed in depth (Budzikiewicz et al., 2007). Characteristic of a pyoverdine 
chromophore containing a succinamide acyl chain and linked to Ser as the first residue of 
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the variable peptide chain, ions of  m/z  204.1, 317.1, 399.1 and 416.1 were detected by 
CID of pyoverdine from strains Thr-WT, Thr-A and Thr-D (Budzikiewicz et al., 2007). 
The ion of m/z 317.1 was not detected from strain Thr-E but the other three were; because 
the ion of m/z 317.1 is of low abundance, its absence seems likely to be due to increased 
noise rather than the existence of fundamentally different pyoverdine species. For strains 
Thr-WT, Thr-A and Thr-D, the N-terminal ions B1 to B4 were detected at 444.2, 600.3, 
687.3 and 845.4 m/z, confirming the sequence of pyoverdine up until the cyclic portion. 
The same ions were observed for strain Thr-E with the exception of the ion at 687.3 m/z. 
Again, this was likely obscured by the increased background signal. Larger B-ions were 
not detected, consistent with the cyclic portion of the pyoverdine peptide chain not 
fragmenting during CID of [M + H]
+
 ions (Fuchs and Budzikiewicz, 2000). These results 
confirmed that wild type pyoverdine was being synthesised by the Thr specifying 
A domain substitution strains and were consistent with ions reported from CID of 
pyoverdine containing a succinate acyl group (Mossialos et al., 2002).  
3.4.2 Pyoverdine produced by non-Thr specifying A domain 
substitutions 
In Section 3.3.2, low levels of increased fluorescence compared to the pvdD deletion 
strain were detected in the supernatant of non-Thr A domain substitution strains. This 
suggested that these A domain substitution strains may be producing low levels of 
pyoverdine. The supernatant from these strains was therefore analysed by mass 
spectrometry to confirm whether the increase in fluorescence was indeed due to 
pyoverdine synthesis and, if so, to identify which substrates were being incorporated into 
the terminal position of pyoverdine. 
Due to the low levels of pyoverdine present, there was greater noise in the mass 
spectrometry results than had been observed for the Thr specifying A domain substitution 
strains. Despite this, from all strains a product of 1333.6 m/z was detected and no peaks 
corresponding to the addition of new residues was present above the 20 signal/noise ratio 
set for CID (Figure 3-9). Additionally, the 1333.6 m/z product was not detected from the 
negative control pvdD deletion strain. Analysis of the 1333.6 m/z species by CID detected 
the five most abundant ions characteristic of pyoverdine fragmentation were present in 
spectra from each strain except for the Y7" ion from strain Ser-F (Figure 3-10, Table 3-2). 
Other peaks were mostly absent, which seemed likely to be due to increased levels of 
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noise in these spectra caused by the low abundance of the precursor ion. Nonetheless, 
these results confirmed that the non-Thr specifying A domain substitution strains were 
synthesising low levels of WT pyoverdine. 
 
 
Figure 3-9. MALDI-TOF spectra obtained using the supernatant of non-Thr specifying A domain 
substitution strains. Arrows indicate location of peak at 1333.6 m/z. 
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Figure 3-10. CID spectra of pyoverdine synthesised by non-Thr specifying A domain substitution 
strains. Arrows indicate the abundant ions characteristic of pyoverdine fragmentation. 
 
 
 
Table 3-2. Ions detected by CID of pyoverdine from non-Thr specifying A domain substitution 
strains. 
 
Ser-B Lys-C Ser-F Asp-G Gly-H Ser-I 
Ion m/z 
[RDA + H - Suca]
+
 ND 204.14 ND ND ND ND 
A1 - Suca ND ND ND ND ND ND 
A1 - NH3 ND ND ND ND ND ND 
A1 ND ND ND 416.19 ND ND 
B1 ND ND ND 444.17 ND ND 
B2 600.19 600.26 600.32 600.31 600.19 ND 
B3 ND ND ND ND ND ND 
B4 ND ND ND ND ND ND 
Y7" 890.48 890.53 ND 890.49 890.48 890.54 
[RDAb + H]
+
 1031.43 1031.57 1031.61 1031.60 1031.43 1031.60 
[M + H - Suca]
+
 1234.51 1234.64 1234.68 1234.64 1234.54 1234.65 
[M + H - CH2N2]
+
 1291.54 1291.67 1291.71 1291.66 1291.59 1291.66 
[M + H - NH3]
+
 1316.52 1316.61 1316.64 1316.60 1316.52 1316.60 
MS/MS precursor 1333.57 1333.55 1333.55 1333.58 1333.61 1333.57 
Shaded cells indicate ions expected to contain the residue added by the second module of PvdD. 
Suca, succinamide; RDA, chromophoric fragment from the RDA process; RDAb, peptide chain 
fragment released by the RDA process; ND, not detected. 
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3.5 Discussion 
In this chapter an A domain substitution vector was created, targeting the second 
A domain of PvdD for change, and tested via substitution of nine alternative A domains. 
The Thr specifying A domain substitution strains all produced wild type pyoverdine, 
although a two-third decrease in pyoverdine levels relative to Thr-WT was observed for 
strain Thr-E. In contrast, non-Thr specifying A domain substitution strains made only 
trace amounts of pyoverdine, which was also shown to be wild type pyoverdine. 
One possible reason for the high success of Thr specifying A domain substitutions is a 
closer similarity of these A domains to the Thr-WT A domain. In fact, the Thr specifying 
A domains had an average of 76.5 % amino acid identity to the Thr-WT A domain, 
compared to only 47.5 % for the A domains that specify alternative residues (Table 3-3). 
These numbers are slightly skewed by Thr-A sharing 99.6 % amino acid sequence 
identity to the Thr-WT A domain, the two modules of pvdD having almost certainly 
arisen due to a gene duplication event (Merriman et al., 1995). Nonetheless, the other two 
Thr specifying A domain substitutions still had an average of 17.3 % greater sequence 
identity to the Thr-WT A domain than did the remaining A domains tested in this study, 
and on this basis could perhaps be expected to have a greater likelihood of being active in 
the PvdD context. Even so, the observation that 3/3 Thr specifying A domains were 
active, while 6/6 non-Thr specifying A domains were inactive provides strong evidence 
that substrate specificity plays a major role in determining whether an A domain 
substituted construct will be active. These observations are consistent with the previous 
smaller scale study conducted in the first module of pvdD (Ackerley and Lamont, 2004). 
Moreover, in the previous study, the introduced Thr specifying A domains shared no 
greater amino acid identity with the PvdD A domains than the alternative A domains 
introduced in this work (Table 3-3). Collectively, these results strongly indicate that Thr 
specifying A domain substitutions are highly successful and that the loss in function seen 
with the non-Thr specifying A domain substitutions was unlikely to be a consequence of 
overall reduction in sequence identity. 
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Table 3-3. Amino acid sequence identity of introduced A domains with the module 2 PvdD A 
domain that was substituted. 
Substitution*  Identity  Similarity Gaps 
Thr-A   99.6  99.8  0.0 
Ser-B   50.6  64.1  7.3 
Lys-C   52.3  64.9  5.9 
Thr-D   64.7  77.4  2.3 
Thr-E   65.1  77.3  3.5 
Ser-F   47.6  61.5  5.7 
Asp-G   40.7  56.3  5.3 
Gly-H   47.1  62.3  6.8 
Ser-I   46.8  61.7  6.9 
Thr-snbC m1  53.2  64.5  4.5 
Thr-syrB m9  44.1  60.2  5.4 
Cys-acvA m2  36.2  54.0  11.8 
Ser-pvdI m1  51.4  64.8  5.7 
Val-acvA m3  36.4  54.7  10.8 
* Substitutions created in this study are aligned to the A domain from Thr-WT. Substitutions from 
previous work (highlighted in bold) were aligned to the A domain from the first module. 
Nomenclature for A domain substitutions from previous work is the substrate activated by the 
module, followed by the gene the module was sourced and the module within the named gene 
(Ackerley and Lamont, 2004). 
 
The two main hypothesised reasons for loss of function for A domain substitutions are 
that they are limited by C domain acceptor site substrate specificity and/or disruption of 
the C-A junction. The high success rate of Thr specifying A domain substitutions in this 
work, together with the previous work in pvdD (Ackerley and Lamont, 2004) implies 
disruption of the C/A junction in pvdD is not a major cause for loss in function. Instead, 
this data fits better with the view that PvdD A domain substitutions are limited mainly by 
C domain acceptor site substrate specificity. Further support for this hypothesis is the 
production of low levels of wild type pyoverdine and absence of modified pyoverdine by 
non-Thr specifying A domain substitutions. An explanation for this result is low-level 
‘leaky’ activation of Thr by A domains that specify other substrates. This is supported by 
a large number of A domains having been observed to exhibit low-level promiscuous 
activities in in vitro kinetic studies (Doekel and Marahiel, 2000; Mootz and Marahiel, 
1997; Stevens et al., 2006; Takahashi et al., 2007; Villiers and Hollfelder, 2009). 
Selection of Thr at the acceptor site of the C domain would leave other substrates 
attached to the T domain, where they would likely be released by TEII enzymes due to 
decreased catalytic turnover (Yeh et al., 2004).  
The production of wild type pyoverdine was particularly interesting in that it allowed a 
direct comparison of the relative strengths of the substrate specificities of the A domain 
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and the acceptor site of the C domain. If these specificities were approximately 
equivalent, then both modified and wild type pyoverdines should be produced. As no 
modified pyoverdine species were observed, it can be concluded that the C domain 
proof-reading is more stringent in PvdD. Given that some modules with C domains have 
been identified that can incorporate alternative substrates (often similar substrates and at 
lowered levels) into the peptide (Han et al., 2012; Konz et al., 1999; Lawen and Traber, 
1993; Peypoux et al., 1991), this may not be the case for all C domains. 
In conclusion, these results indicate that A domain substitutions have potential to be 
highly successful in PvdD but are limited by the substrate specificity within the C domain 
acceptor site. One implication of this result is that A domain substitution could potentially 
be a viable approach to domain substitutions if the C domain acceptor site specificity 
could be altered or relaxed. Currently little is known of the mechanism of acceptor site 
substrate specificity and residues involved. Out of the C domain structures discussed in 
Section 1.2.3.1, none were solved in complex with substrate and although Keating et al. 
(2002) suggested residues that may be involved in substrate specificity, these have not 
been confirmed. Moreover, phylogenetic studies did not identify any specificity 
conferring residues (Rausch et al., 2007; Roongsawang et al., 2005). As an alternative to 
bypass C domain acceptor site specificity, the following chapters examine whether 
C-A domain substitutions can be functional in PvdD and factors that may limit the 
success of C-A domain substitutions.  
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Chapter 4: Substitution of C-A domains in pvdD  
4.1 Introduction 
The previous chapter suggests A domain substitutions are limited mainly by the acceptor 
site specificity of the C domain. A way to bypass the limitation of C domain acceptor site 
substrate specificity is to substitute C-A domains as functional pairs. The relaxed donor 
site specificity of C domains (Section 1.2.3.2) implies that substituting C-A domains to a 
new location would not interfere with C domain specificity. A second advantage of 
substituting C-A domains together is it keeps the C/A domain interface intact, which may 
still have a minor influence on the activity of PvdD variants. Nevertheless as discussed in 
Section 1.3.3, C-A domain substitutions often lose activity and result in yields of the 
modified peptide being greatly diminished relative to that produced by the wild type 
NRPS system. In practical terms this issue limits the number of substitutions possible 
within a single biosynthetic chain, and hence the diversity of modified products that can 
potentially be made. For predictable outcomes, there is a need for greater understanding 
of the factors limiting C-A domain substitution. 
Previous C-A domain substitutions in the first module of pvdD were all non-functional 
(Ackerley and Lamont, 2004). This could have been due to issues caused by using 
distantly related C-A domains with low homology or by disrupting the interaction with 
the upstream enzyme PvdJ. Another explanation raised for this lack of activity was that 
C domains may sometimes exhibit donor site proofreading after all, such that the 
introduced C domain might prove incompatible with the incoming residue supplied by the 
upstream NRPS module, or that a newly introduced amino acid substrate might not be 
recognised at the donor site of the C domain immediately downstream (Ackerley and 
Lamont, 2004). While the previous in vitro observations of Belshaw et al (1999) and 
Ehmann et al (2000) failed to identify any C domains exhibiting strong amino acid 
side-chain specificity at the donor position, there is some evidence of C domains with 
donor site specificity towards peptides (Stein et al., 2005) and fatty acids (Kraas et al., 
2012). As mentioned previously, using the second module of PvdD eliminates any 
problems with potential downstream donor site specificity as the terminal pyoverdine 
synthetase has no C domain located downstream. A further advantage is that the second 
module of PvdD condenses substrates in cis, i.e. attached to T domains within the same 
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enzyme. Thus C-A domain substitutions in this module are less likely to disrupt 
interenzyme interactions. 
This chapter aims to determine whether C-A domain substitutions can be successful 
within pvdD and whether new products can be incorporated into pyoverdine. A total of 
nine C-A domain substitution variants were created using the vector pSMC (construction 
described in Section 3.2). The domains were sourced from the same modules as the 
A domain substitutions. These were tested in a similar manner to the A domain 
substitution strains and it was found that three C-A domain substitutions created 
functional PvdD enzymes. Interestingly, the other C-A domain substitutions displayed 
low levels of increased fluorescence relative to the pvdD deletion strain. Mass 
spectrometry was used to identify the products that were being synthesised by the 
C-A domain substitution strains. 
4.2 Creation of C-A domain substitution strains 
The plasmid pSMC made in Section 3.2 was used to create C-A domain substitutions. 
This plasmid contained a copy of pvdD lacking the C-A domains from the second module 
and containing a SpeI and NotI restriction site in their place. Nine C-A domains from 
modules A to I, also used for A domain substitution in Chapter 3, were amplified by PCR, 
restriction digested, and ligated into pSMC using the restriction sites XbaI and NotI. 
Plasmid sequences were confirmed by sequencing, and sequences matched the database 
sequences except for the point mutations within two A domains discussed in Section 3.2, 
The plasmids were transformed into the P. aeruginosa PAO1 pvdD deletion strain. The 
resulting strains were named according to the convention used for the A domain 
substitution strains but differentiated A domain substitutions by starting with CA (for 
example, the variant containing the C-A domains from the first module of pvdD is 
referred to as strain CAThr-A). The positive control strain containing the restriction sites 
and C-A domains from the second module of PvdD was named CAThr-WT and showed 
no reduction in pyoverdine synthesis compared to wild type P. aeruginosa PAO1 (not 
shown). 
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4.3 Evaluating levels of pyoverdine synthesis 
4.3.1 Fluorescence of C-A domain substitution strains on solidified KB 
media 
When grown on solid media, only the C-A domain substitution strains containing 
C-A domains derived from modules Thr-A and Lys-C (Figure 3-3) had levels of 
fluorescence that were visibly higher than the background of the pvdD mutant control 
(Figure 4-1). In the presence of EDDHA, strains CAThr-A, CALys-C, and CASer-F were 
the only strains that remained viable (Figure 4-1). These results suggest novel residues 
can be incorporated into pyoverdine, and that these variant pyoverdines are then able to 
transport iron into P. aeruginosa PAO1. Interestingly, in contrast to the A domain 
substitutions, only one C-A domain substitution that activates Thr was functional and the 
other two were non-functional. Of these two non-functional Thr C-A domain 
substitutions, strain CAThr-D contains a C domain that naturally receives a D-isomer 
from the upstream module and was expected to be non-functional due to the 
stereospecificity of C domain donor sites (Belshaw et al., 1999; Ehmann et al., 2000). 
More surprisingly strain CAThr-E, which not only contains an A domain that was 
functional in the A domain substitution experiments but also a C domain that “expects” in 
its native context to receive an L-Thr residue in its donor site, had no detectable levels of 
fluorescence. This observation, together with the apparent activity of strains CAThr-A 
and CALys-C (which contain C domains that do not receive L-Thr in their native 
contexts), strongly suggests that C domain proof-reading of amino acid identity at the 
donor sites is not the main factor limiting the success of C-A domain substitution 
experiments.  
 
Figure 4-1. Fluorescence of C-A domain substitution strains on KB agar plates in the absence (-) 
or presence (+) of EDDHA. Plates were inoculated with the positive control strain CAThr-WT 
(WT), C-A domain substitution strains A to I (as per letter designations in Figure 1), and the pvdD 
deletion pyoverdine negative control (Del), then incubated for 24 h at 37 °C. Photographs were 
taken under UV light. 
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4.3.2 Pyoverdine production of C-A domain substitution strains in liquid 
media 
When absorbance of the supernatant of C-A domain substitution strains grown in liquid 
media was measured (Figure 4-2, blue bars), strains CAThr-A and CALys-C had high 
levels of absorbance at 83 % and 76 % of the CAThr-WT positive control. Strain 
CASer-F, which exhibited low levels of growth on solidified King’s B media containing 
EDDHA (Figure 3A), exhibited lower levels of absorbance at 18 % of CAThr-WT levels. 
In contrast, the other C-A domain substitution strains all had much lower levels of 
absorbance at levels similar to the pvdD deletion strain. Nonetheless, when fluorescence 
of the supernatant was measured (Figure 4-2, red bars), all C-A domain substitutions had 
increased levels of fluorescence relative to the pvdD deletion strain, except for strain 
CAAsp-G. Although strain CAAsp-G had increased absorbance, it seems most likely this 
was due to an artefact because fluorescence is more sensitive in detection of pyoverdine 
at lower levels. These results suggested that, similar to A domain substitutions, most 
C-A domain substitution strains still synthesised low levels of a pyoverdine product. 
 
Figure 4-2. Liquid media assays of relative levels of pyoverdine production by C-A domain 
substitution strains. Values are expressed as a percentage of absorbance (400 nm) or fluorescence 
(ex. 400 nm/ em. 440 nm) relative to the CAThr-WT strain, having been zeroed against the 
background levels recorded for the pvdD deletion mutant. Data are the mean of 6 independent 
replicates, and error bars indicate 1 standard deviation. 
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4.4 MALDI-TOF MS/MS confirmation of pyoverdine production 
4.4.1 Pyoverdine produced by highly functional C-A domain 
substitutions 
The synthesis of wild type pyoverdine by strain CAThr-A and incorporation of Lys and 
Ser into pyoverdine by strains CALys-C and CASer-F was confirmed by mass 
spectrometry. Substitution of the terminal residue of pyoverdine for Lys and Ser was 
calculated to change the m/z of pyoverdine [M + H]
+
 ions to 1360.7 (C57H90N19O20) and 
1319.6 (C54H83N18O21), respectively. Mass spectrum analysis of the supernatants from the 
C-A domain substitution strains (Figure 4-3) detected products of m/z 1333.6 from 
CAThr-A, 1360.7 from CALys-C and 1319.6 from CASer-F, as well as the corresponding 
peptide fragments caused by RDA process degradation of the chromophore. From the 
CID spectra of the m/z 1360.7 and 1319.6 pyoverdine species, the five abundant ions 
expected to contain the new Lys and Ser residues (Figure 4-4, indicated by arrows; Table 
4-1, shaded cells) had changes in mass consistent with the altered residue. These results 
confirmed that the CALys-C and CASer-F domain substitution strains were incorporating 
new residues into pyoverdine.  
 
Figure 4-3. MALDI-TOF spectra obtained using the supernatant from functional C-A domain 
substitution variants. Blue arrows highlight the peaks consistent with the RDA peptide and 
pyoverdine. Red arrow indicates a truncated pyoverdine product that will be discussed in Section 
4.4.2. 
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Figure 4-4. Fragmentation spectra of the main pyoverdine species from functional C-A domain 
substitution strains. Arrows indicate abundant ions used to confirm modifications to the 
C-terminus of pyoverdine. 
 
Table 4-1. Ions detected by CID of major pyoverdine species produced from highly functional 
C-A domain substitution strains. 
 
Thr-WT Thr-A Lys-C Ser-F 
Ion m/z 
[RDA + H - Suca]
+
 204.11 204.11 204.11 204.12 
A1 - Suca 317.19 317.18 317.18 317.16 
A1 - NH3 399.22 399.21 399.21 399.21 
A1 416.21 416.19 416.20 416.18 
B1 444.19 444.18 444.19 444.17 
B2 600.29 600.27 600.28 600.28 
B3 687.35 687.33 687.32 687.27 
B4 845.45 845.40 845.39 845.36 
Y7" 890.55 890.51 917.57 876.49 
[RDAb + H]
+
 1031.60 1031.57 1058.62 1017.54 
[M + H - Suca]
+
 1234.68 1234.62 1261.68 1220.58 
[M + H - CH2N2]
+
 1291.70 1291.64 1318.69 1277.61 
[M + H - NH3]
+
 1316.61 1316.55 1343.59 1302.53 
MS/MS precursor 1333.62 1333.64 1360.71 1319.64 
Shaded cells indicate ions expected to contain the residue added by the second module of PvdD. 
Suca, succinamide; RDA, chromophoric fragment from the RDA process; RDAb, peptide chain 
fragment released by the RDA process; ND, not detected. 
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4.4.2 Pyoverdine produced by C-A domain substitutions with limited 
activity 
Mass spectrometry was next used to detect pyoverdine in the supernatant of the 
C-A domain substitution strains that showed low levels of fluorescence when grown in 
liquid media (Figure 4-5). Unlike A domain substitutions, C-A domain substitutions are 
not limited by C domain acceptor site substrate specificity. Thus we predicted these might 
all be synthesising low levels of pyoverdine that had the terminal residue modified. 
However, neither wild type nor pyoverdine with the terminal residue modified were 
detected in the supernatant. Instead, a pyoverdine product of only 991.5 m/z was detected 
in all these strains except for strain CAAsp-G. The absence of pyoverdine from strain 
CAAsp-G fits with the fluorescence data showing no increase by CAAsp-G relative to the 
pyoverdine negative control (Figure 4-2, red bars). The 991.5 m/z product was also 
detected as a minor peak during the mass spectrometry of CAThr-A, CALys-C and 
CASer-F (Figure 4-3; although unlabelled in the spectra for CASer-F). The 991.5 m/z ion 
is equivalent to pyoverdine lacking the three last C-terminal residues (C41H63N14O15; 
calculated 991.4592 m/z). This product has been previously detected as a breakdown 
product of pyoverdine, generated when the final Thr residue was not incorporated onto 
pyoverdine (Ackerley and Lamont, 2004). CID of the 991.5 m/z product identified ions 
consistent with the C-terminal ions missing the three terminal residues (Figure 4-6, Table 
4-2). Although the less abundant ions were not detected with all strains, a near complete 
spectrum was obtained from strain CASer-B. 
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Figure 4-5. MALDI-TOF spectra obtained using the supernatant from functional C-A domain 
substitution variants with low levels or no fluorescence. Arrows highlight the truncated 
pyoverdine species. 
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Figure 4-6. CID spectra of truncated pyoverdines obtained from C-A domain substitution strains. 
Arrows indicate ions corresponding to the five most abundant ions for wild type pyoverdine. 
 
Table 4-2. CID of truncated pyoverdine produced by C-A domain substitution strains. 
 
Thr-A Ser-B Lys-C Thr-D Thr-E Ser-F Gly-H Ser-I 
Ion m/z 
[RDA + H - Suca]
+ ND 204.16 204.11 ND ND ND 204.06 ND 
A1 - Suca ND 317.20 ND ND ND ND ND ND 
A1 - NH3 ND 399.30 ND ND ND ND ND ND 
A1 ND 416.19 416.18 416.23 416.30 416.16 416.14 416.07 
B1 444.15 444.18 444.16 ND ND ND 444.12 ND 
B2 600.25 600.28 600.31 600.41 ND 600.35 600.18 600.24 
B3 ND ND 687.34 ND ND 687.36 ND 687.29 
B4 845.43 845.41 845.38 845.45 ND ND 845.31 845.28 
Y7" 548.34 548.38 548.33 548.38 548.40 548.31 548.26 548.25 
[RDAb + H]
+ 689.34 689.41 689.39 689.46 689.43 689.40 689.29 689.27 
[M + H - Suca]
+ 892.44 892.49 892.44 892.55 892.52 892.43 892.35 892.35 
[M + H - CH2N2]
+ 949.47 949.52 949.47 949.54 949.54 949.47 949.36 949.38 
[M + H - NH3]
+ 974.39 974.47 974.39 974.49 974.48 974.40 974.34 974.34 
MS/MS precursor 991.48 991.43 991.49 991.40 991.43 991.49 991.40 991.46 
Shaded cells indicate ions expected to contain the residue added by the second module of PvdD. 
Suca, succinamide; RDA, chromophoric fragment from the RDA process; RDAb, peptide chain 
fragment released by the RDA process. *Cells for ions detected by CID are empty due to 
corresponding precursor ion remaining undetected. 
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4.5 Discussion 
In this chapter nine C-A domain substitution strains were created and tested for 
pyoverdine production. Three of these strains were able to incorporate the residue 
specified by the new A domain into pyoverdine. Of these, two incorporated novel amino 
acid residues into pyoverdine, confirming that modified pyoverdine peptides can be 
generated in high yield via C-A domain substitution. Moreover, the production of 
modified pyoverdines by strains CALys-C and CASer-F shows the new A domains in the 
C-A domain construct can load their predicted substrates onto the second T domain of 
PvdD and the TE domain can release the modified peptides without causing a substantial 
loss in activity. These results support the view that these A domains had the potential to 
be functional as A domain substitutions but were limited by C domain acceptor site 
specificity. 
A direct implication of the hypothesis that A domain substitutions are mainly limited by 
substrate specificity is that the loss of function by C-A domain substitutions is caused by 
the introduction of the C domain. This was most likely the case for strains CAThr-D and 
CAThr-E since their respective A domain substitution strains were shown to be functional 
in Chapter 3. Of these, the loss of activity observed for CAThr-D could be explained in 
terms of the incompatible donor site stereo specificity of the new C domain (since it 
normally receives D-Thr). In contrast it is unknown why the C-A domain substitution for 
CAThr-E was non-functional. Moreover, similar to the A domain substitution results, it 
was expected that C-A domain substitution strains exhibiting low levels of fluorescence 
would be synthesising full-length pyoverdine modified at the final residue. The 
production of a truncated product by these C-A domain substitutions supports that the 
cause for loss in function is not associated with the A domain. 
There are potentially a few reasons for how C-A domain substitutions could produce a 
truncated product. The absence of this product and decreased fluorescence exhibited by 
the pvdD deletion strain suggest that the truncated product is released from the modified 
PvdD enzymes. The reason for no release from PvdJ is unknown, but could be due to 
lower release of stalled peptides from T domains that act in trans or that a downstream 
C domain was involved in release. A potential way the truncated pyoverdine could form, 
after release from PvdD, is if changing the final residue of pyoverdine creates an unstable 
pyoverdine that degrades to a more stable product. This seems unlikely because 
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pyoverdines with a terminal Thr, Lys or Ser residue were able to be detected, suggesting a 
relatively high tolerance for alternative terminal residues and that strains CAThr-E, 
CASer-B and CASer-I could have synthesised a pyoverdine sufficiently stable for 
detection. Instead, we believe the detection of the truncated product and absence of 
full-length modified pyoverdines suggests that addition of a new C domain is causing 
peptide assembly to stall on the first T domain of PvdD, i.e. immediately upstream to the 
introduced C domain. As a result, this would mean condensation is not occurring at the 
newly introduced C domain and the pyoverdine missing the terminal Thr is released. As 
seen previously, the pyoverdine missing the terminal residue would partially degrade to 
form a pyoverdine missing the terminal three residues (Ackerley and Lamont, 2004). 
Based on this hypothesis, in trying to understanding why C-A domain substitutions in 
PvdD lose activity, we should look for factors that may cause peptide synthesis to stall. 
Three potential causes for peptide synthesis stalling are discussed below. 
Previous work on domain substitution in PvdD suggested donor site specificity of the 
C domain could be a cause for the loss in activity of C-A domain substitutions (Ackerley 
and Lamont, 2004). Some specificity towards the terminal residue of the incoming 
peptide has been identified towards the C-terminus residue (Stein et al., 2005). In this 
regard the CAThr-E construct is very similar to PvdD module 2, in that the new C domain 
in its native context receives L-Thr residues at both the donor and acceptor sites. That this 
strain produced the truncated product suggests it was non-functional due to a reason other 
than C domain donor site substrate specificity. Moreover, both the functional CAThr-A 
and CALys-C strains contain C domains that normally receive hfOrn as the C-terminal 
residue in their donor sites, yet are clearly able to cope with L-Thr being in that position. 
In fact, despite the C domain from strain CASer-F naturally receiving Thr at its donor 
site, the two strains CAThr-A and CALys-C produced the highest levels of pyoverdine. 
The loss of function by strain CAThr-E, and strains CAThr-A and CALys-C being the 
most functional substitutions indicates factors other than C domain donor site specificity 
are limiting the activity of C-A domain substitution strains.  
A second possible explanation for why peptide synthesis might have stalled is that 
C domains in a new context could be unable to accommodate some incoming peptides 
due to steric constraints. This hypothesis is related to substrate specificity, however is 
based on an entire peptide (not just the C-terminal residue) being unable to fit within the 
substrate channel of the new C domain. Structural studies of C domains show the 
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catalytic centre covered by a lid region within a channel between two subdomains 
(Bloudoff et al., 2013; Keating et al., 2002; Samel et al., 2007; Tanovic et al., 2008), and 
it may be that some new incoming peptide chains are physically blocked from reaching 
the catalytic centre. Moreover, previous in vitro studies on C domain donor site 
specificity focused on single residues (Belshaw et al., 1999; Ehmann et al., 2000) or at 
most a tetrapeptide (Stein et al., 2005), rather than the larger peptide chains that 
substituted C domains further down an NRPS assembly line would normally receive. An 
experiment, which suggests peptide size can be important, tested the stereo specificity of 
the fifth C domain from tyrocidine synthesis (Clugston et al., 2003). For this C domain, 
there was no stereo specificity when an aminoacyl-CoA was loaded onto the upstream 
module. In contrast, when the native tetrapeptide containing either a terminal D- or 
L-amino acid was loaded onto the upstream module, only the D-isomer containing 
pentapeptide was formed; a result likely caused by racemisation of the terminal 
tetrapeptide residue by the upstream E domain and stereo specificity by the C domain. In 
addition, when the E domain of the upstream module was mutated to become 
non-functional, only the tetramer with a terminal D-amino acid was able to produce the 
peptapeptide. This suggests that, as well as stereo specificity, the size of an incoming 
peptide can be an important factor. Further tests of C domain donor site specificity using 
a range of peptides rather than single amino acids may be needed to interrogate the 
tolerance of C domains for alternative peptide chains. 
A third possible cause for the loss of activity observed with most C-A domain 
substitutions is that introduced C-A domains may not communicate correctly with the 
neighbouring PvdD T domains. During a catalytic cycle T domains function to transfer 
substrates between multiple domains. Crystal structures of T domains suggest large 
conformational changes are needed for the T domain to transfer its substrate between 
catalytic domains (Section 1.2.2.1) and domain substitution experiments suggest 
T domains can be specific to the type of downstream domain (Section 1.3). These 
interactions are not completely understood, but suggest the T domain from the first 
module of PvdD may not be able to interact properly with the new C domains causing 
peptide synthesis to stall. 
The work in this chapter confirms that modified pyoverdines can be created by 
C-A domain substitution. However unlike A domain substitutions, which appear limited 
by C domain acceptor site specificity, it is difficult to identify a specific cause for why the 
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majority of C-A domain substitutions lose activity. The potential causes raised in this 
discussion were that C domains may be inflexible in the peptide chains they can receive 
or may disrupt interactions with the upstream T domain. Of these hypotheses, the second 
could easily be bypassed because substituting T-C-A domains as a functional catalytic 
unit would keep the T-C domain interactions intact. One example of a previously 
functional T-C-A domain substitution has been published (Doekel and Marahiel, 2000) in 
which two module NRPS pathways were created and tested for activity. In total, one 
T-C-A and two T-C-A-T-TE domain substitutions were made and found to be functional 
in in vitro assays. However, without a larger sample size and direct comparison to 
C-A domain substitutions, it is unclear whether T-C-A domain substitution may offer a 
better alternative to C-A domain substitution. The following chapter compares the success 
of T-C-A versus C-A domain substitution, and examines rules governing interactions 
between T domains and downstream TE and C domains. 
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Chapter 5: Investigation of the influence of T domains on the activity of 
C-A domain substitutions  
5.1 Introduction 
In the preceding chapters, staging plasmids were constructed in which A and 
C-A domains could be introduced into the second module of pvdD. For A domain 
substitution strains, the major cause for loss of function appeared to be due to the acceptor 
site specificity of the C domain from PvdD. In contrast, the reasons for loss of function 
for C-A domain substitutions were less clear.  
Based on the production of a truncated product by the “non-functional” C-A domain 
substitution strains, it was hypothesised that the introduction of a heterologous C domain 
can cause peptide synthesis to stall, due to disruption of the ability of the T domain to 
pass its tethered substrate to the downstream C domain. This chapter tested the ability of 
T domains to interact with new catalytic partners. A particular focus was whether the 
T domain may be inhibited in its ability to interact with new downstream C domains 
introduced by C-A domain substitution. 
5.1.1 Additional nomenclature 
Two new nomenclatures, described below and summarised in Figure 5-1, are used in this 
chapter to identify the type of domain immediately downstream to a T domain or to refer 
to specific interactions between a T domain and a specific catalytic partner.  
The first nomenclature recognises the potential specialisation of T domains according to 
the type of domain located immediately downstream. When relevant, the type of 
downstream domain will be indicated in subscript. For example, T domains with C or 
E domains located immediately downstream will be referred to as TC or TE domains, 
respectively. Furthermore, to differentiate TC domains that interact in cis with a 
downstream C domain from T domains that interact in trans with a downstream 
C domain, the latter will be referred to as TCt domains (i.e. unless specifically marked TCt, 
a TC domain can be assumed to be linked to the downstream C domain in cis). The reason 
for this distinction is that TCt domains may have additional recognition elements, in 
addition to COM domains, to allow them to associate with the correct downstream 
C domain (Chiocchini et al., 2006; Koglin and Walsh, 2009).  
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The second nomenclature is to distinguish between T domain interactions with different 
catalytic partners. In this context the term “interactions” refers to the ability of the 
T domain to receive its substrate from the upstream A domain or to then pass that 
substrate to another catalytic partner domain. If a domain substitution is functional, that 
indicates the new T domain interactions created by the domain substitution are not 
substantially inhibited. Five different interactions that are considered in this chapter are as 
follows:  
I. A/T domain interactions; the ability of the T domain to receive a substrate 
activated by the upstream A domain. 
II. C-/T domain interactions; the ability of a T domain to pass its substrate to the 
upstream C domain for condensation to occur (the “-” in C-/T indicates that these 
domains are not immediately adjacent to one another in the protein primary 
sequence). 
III. T/C domain interactions; the ability of a T domain to pass its tethered substrate to 
a downstream C domain. 
IV. T/TE domain interactions; the ability of a T domain to pass its tethered substrate 
to a downstream TE domain.  
V. T/E domain interactions; the ability of a T domain to pass its substrate to a 
downstream E domain for epimerisation. 
 
 
 
Figure 5-1. Nomenclature for T domain types and interactions shown for a hypothetical three 
module NRPS. Three T domain types are shown as TE, TC and TTE domains depending on the 
domain immediately downstream. TCt domains are similar to TC domains except interact with the 
downstream domain in trans. The interactions between T domains and catalytic domains are 
labelled as per the description in the above text. 
 
5.1.2 Evidence of T domain interactions being inhibited by domain 
substitution 
As discussed in Section 1.2.2.1, the previously solved structures of T domains in 
association with surrounding domains indicate that T domains undergo dramatic 
conformational changes to be within a functionally relevant distance of all their 
surrounding catalytic partners. NMR (Frueh et al., 2008) and X-ray crystal (Liu et al., 
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2011) structures of the T-TE domains from EntF have shown that the T-TE domains have 
a tight interface, and it has been suggested that this may explain why disrupting the T/TE 
junction destroys activity (Strieker et al., 2010). In addition, alignment (Owen, 2010) and 
domain substitution studies (Section 1.3) suggest TE and TTE domains are particularly 
specialised. 
The interactions between T domains and their catalytic partners can be highly sensitive to 
single residue changes. The sensitivity of T domain interactions was previously tested 
using the TTE and TE domains of EntF, a single module NRPS involved in enterobactin 
synthesis (Zhou et al., 2006). By randomly mutating single residues of the EntF 
TTE domain to Ala, a process referred to as Ala scanning mutagenesis, it was found that 
key residues at positions +1, +21 and +24 relative to the conserved Ser residue that is the 
4′-pp attachment site were intolerant of change for the in vivo production of enterobactin. 
In vitro assays determined that changing the +1 position to Ala impaired attachment of 
the 4′-pp group by the PPTase, and mutations at the +21 and +24 positions inhibited T/TE 
domain interactions (Zhou et al., 2006). Similar results were obtained using Ala scanning 
mutagenesis on the aryl-carrier protein (ArCP) domain of the NRPS EntB (Lai et al., 
2006). Although not a T domain, the EntB ArCP is similar to a TCt domain as it passes the 
attached substrate to the in trans C domain of EntF. Important residues of the ArCP were 
identified at the +4 and +23 positions relative to the conserved Ser, and the +19 position 
to a lesser extent, such that mutation of these residues inhibited the ArCP from passing 
the substrate to the downstream C domain. The +19 to +24 residues from both these 
studies are located within helix III of the carrier protein domains, indicating that helix III 
is particularly important for interaction with downstream domains (Lai et al., 2006; Zhou 
et al., 2006). 
Later work substituted the ArCP of EntB for two alternative ArCPs (Zhou et al., 2007). 
Enterobactin functions as a siderophore, and the two variants with substituted ArCPs 
showed severely impaired growth in the presence of an iron chelator. The two ArCPs 
were mutated by error-prone PCR and improved variants in enterobactin production 
selected for by growth on media containing this iron chelator. After three rounds of 
mutagenesis and selection, rates of growth for both variant ArCP strains went from being 
severely inhibited on this medium to approximately half that of the wild type strain. 
Strains containing variants of one of the ArCPs were analysed for in vitro enterobactin 
synthesis and found to have a ~500 fold increase in the rate of enterobactin synthesis 
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compared to the corresponding non-evolved ArCP strain. Convergent mutations 
improving activity for both ArCPs were identified at the -8, +1, +23 and +24 positions 
relative to the conserved Ser residue. Analysing the -8, +1 and +24 mutants using in vitro 
assays revealed that the -8 position improved the interaction equivalent to an A/T domain 
interaction, the +1 position with the PPTase and the +24 position improved interactions 
equivalent to A/T and T/C domain interactions. Overall it was concluded that three 
different locations of the ArCPs interact with the PPTase, A domain and C domain (Zhou 
et al., 2007). 
The sensitivity of T domain interactions to single residue mutations raises the question: 
how portable are T domains in relation to new domains? In addition to the work described 
above, the portability of T domains was previously tested by making domain substitutions 
within the yersiniabactin synthesising NRPS pathway (Suo, 2005). There are three 
T domains involved in yersiniabactin synthesis: the first is upstream to a cyclisation (Cy) 
domain, the second upstream to a ketoacyl reductase domain (a polyketide synthetase 
domain) and the third upstream to a TE domain. Substituting the first T domain with 
either the second or third T domains resulted in diminished yersiniabactin synthesis, at a 
rate of 30 % or 11 % of the wild type enzyme, respectively. Substituting the second 
T domain with the first or third T domains abolished the cyclisation activity of the 
upstream Cy domain, causing synthesis of a non-cyclised product at a reduced rate (Suo, 
2005). This study showed that T domain substitutions can reduce activity. However, all 
these T domains differed in terms of the domain found immediately downstream in their 
native context, suggesting the substituted T domains may have been incompatible types. 
5.1.2.1 T domain substitutions and evolution in BpsA 
Previous work in the Ackerley lab, by Dr Owen, tested T domain interactions using blue 
pigment synthetase-encoding gene A (bpsA), that he developed for use as an NRPS 
domain substitution model. BpsA is a single module NRPS expressed by Streptomyces 
lavendulae ATCC11924, which functions to dimerise two L-Gln residues into the blue 
pigment indigoidine (Figure 5-2) (Takahashi et al., 2007). As can be seen in Figure 5-2A, 
the A domain is unusual in that an oxidation (Ox) domain is located between motifs A8 
and A9. This Ox domain functions to dehydrogenate the side-chain of L-Gln during 
indigoidine synthesis (Figure 5-2B). Homologous genes have been identified in other 
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indigoidine synthesising bacteria, including Erwinia chrysanthemi, Vogesella indigofera 
and Phaeobacter sp. Strain Y4I (Cude et al., 2012; Reverchon et al., 2002). 
 
 
 
Figure 5-2. BpsA and indigoidine synthesis. (A) Domain architecture of the BpsA enzyme 
(Takahashi et al., 2007). The oxidation (Ox) domain highlighted in yellow is located between the 
A8 and A9 motifs of the A domain. (B) Proposed mechanism of indigoidine synthesis. The 
A domain activates L-Gln and attaches it to the T domain of BpsA. Two carbon atoms of the 
L-Gln side-chain are dehydrogenated by the Ox domain to form a double bond. The L-Gln residue 
is then cyclised during release by the TE domain. The released intermediates spontaneously 
dimerise in the presence of oxygen to form indigoidine. Basic mechanism as per Walsh and 
Wencewicz (2012) with additional details derived from Reverchon et al. (2002) and Takahashi et 
al. (2007). 
 
In Dr Owen’s work (2010), the TTE domain from BpsA was substituted for six alternative 
T domains and one ArCP. Three of these were TTE domains and four (including the 
ArCP) were TC domains. The BpsA variants substituted with alternative TTE domains 
retained low levels of activity in vivo, whereas the ArCP and TC domains were 
completely inhibited in activity (Table 5-1). Among the T domains substituted into BpsA 
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were the two T domains from pvdD. It was shown that the activity of the BpsA variant 
containing the TC domain from the first module of pvdD could be significantly restored 
by directed evolution. From the improved TC domain variants, the +4 and +24 residues 
relative to the conserved Ser were found to be particularly important for restoration of 
activity. For example, one of the most successful mutants, named 3kf0(I/I), contained 
T→I and F→I mutations at the +4 and +24 positions, respectively, and exhibited 56 % in 
vivo activity relative to wild type BpsA. In naming 3kf0(I/I) and other BpsA variants, the 
letters in brackets indicate the new residues introduced at the +4 and +24 positions, 
respectively. Based on homology modeling, Dr Owen suggested that the +4 and +24 
residues were located at the T/TE interface and may be important for T/TE domain 
interaction. When he analysed T domain sequences from a range of pseudomonads, he 
found T domain sequences were conserved differently at the +4 and +24 locations 
depending on whether the immediately downstream domain was a C, E or TE domain 
(Table 5-2). These results suggested the +4 and +24 positions may generally be vital for 
T/TE domain interactions. 
Table 5-1. In vivo synthesis of indigoidine by BpsA variants. 
Recombinant BpsA proteins made 
Substitution In-vivo activity*  
E. coli  EntF PCP  5.1 +/- 0.3 % 
P. syringae 1926 PCP  5.3 +/-0.3 % 
P. aeruginosa PvdD PCP2  4.9 +/-0.4 % 
P. aeruginosa PvdD PCP1  0 % 
P. syringae 1926 PCP2 0 % 
B. subtilis DhbF PCP1  0 % 
E. coli  EntB ArCP  0 % 
Shaded cells indicate TTE domains, whereas unshaded cells are TC domains. P. aeruginosa PvdD 
PCP1 and PCP2 correspond to the first and second T domains from pvdD, respectively. *Activity 
measured as the relative amount of indigoidine present in the supernatant after growth for 16 to 20 
hours. Indigoidine levels were estimated based on levels of absorbance at 590 nm. Table provided 
by Dr Owen. 
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Table 5-2. Residues found at the +4 and +24 positions of Pseudomonas pyoverdine NRPS 
T domains relative to the 4′-pp attachment site. 
Domain type   +4    +24 
TC or TCt   Variable (T,V,M,S,A)  F (1xL) 
TE    L, I    F 
TTE    V, L, I, M   F, L, I, M* 
Data taken from Pseudomonas T domain alignments presented in Owen (2010). Sample size for 
each type of T domain ranged from 16-20. *Differs from Table A1.1 in Owen (2010), because the 
entry in the table for this position was incorrect based on the sequence alignments presented. 
 
5.2 Chapter overview and aims 
All the previous studies discussed above have focused either on T domain interactions 
with domains other than C domains or the in trans interaction between ArCPs and a 
C domain. They suggest that T domains can be specialised in their interactions with 
downstream domains, and that substantial losses in activity can be caused by small 
changes that inhibit T domain interactions with catalytic partners. Typically C-A domain 
substitution results in a new T/C domain interaction, i.e. the upstream TC domain having 
to interact with a new downstream C domain. The primary aim of this chapter was to 
determine whether C-A domain substitutions frequently lose activity as a consequence of 
the new T/C domain interaction being impaired.  
This chapter begins with a contribution to work that was initiated by Dr Owen (2010), a 
previous doctoral student under Associate Professor David Ackerley, examining 
T/TE domain interactions. Dr Owen’s preliminary studies of T/TE domain interactions 
were further expanded here to determine the generality of his previous results. Based on 
those results, it was then hypothesised that C-A domain substitutions may inhibit T/C 
interaction and, as a consequence, that T-C-A domain substitutions may prove a more 
successful strategy for generating functional recombinant NRPS templates. To address 
this I generated three T-C-A domain substitution variants and tested the activity of these 
in comparison to the corresponding C-A domain substitution variants. The small sample 
size of three was a consequence of the PCR amplification and cloning being technically 
difficult for large T-C-A domain substitution constructs. Consequently, an alternative 
strategy of T domain substitutions in the first module of pvdD was adopted to investigate 
the effect of disrupting T/C domain interactions. Substitution of TC domains into the first 
module of PvdD creates new T/C domain interactions (with the C domain of PvdD 
module 2) that are equivalent to the new T/C domain interactions caused by C-A domain 
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substitutions. The only real difference is that substitution of TC domains also affects the 
upstream (module 1) A/T domain interaction, whereas C-A domain substitutions affect 
the downstream (module 2) A/T domain interaction; however, the results of Chapters 3 
and 4 suggest that disruption of A/T domain interactions is not a major factor in impairing 
recombinant PvdD function. 
As an adjunct to the TC domain substitution study, TCt, TE and TTE domains were also 
substituted into the first module of pvdD to test whether other types of T domain can 
function upstream to a C domain. 
5.3 Substitution of evolved pvdD T domains back into pvdD  
Work by Dr Owen (Owen, 2010) found that TC domains did not function upstream to the 
TE domain of BpsA, and that indigoidine synthesis could be restored to BpsA TC domain 
substitution variants by a few point mutations. To expand this work, using a different 
model system, it was decided to substitute the TC domain from the first module of pvdD 
for the TTE domain from the second module. In addition, variants of the pvdD TC domain 
that had been evolved for improved function in bpsA, carrying mutations at the +4 and 
+24 positions, were substituted at the pvdD TTE position. These substitutions are referred 
to as T2 domain substitutions to indicate their location in the second module of pvdD. The 
evolved T domains used for T2 domain substitutions were sourced from the BpsA 
variants 3kf0(I/I), 3PF2(T/L) and 3kf13(A/L). The BpsA variants 3PF2(T/L) and 
3kf13(A/L) exhibit levels of in vivo indigoidine synthesis between 15 - 25 % that of the 
most active variant 3kf0(I/I) (Dr Owen, personal communication) and were selected to 
provide T domains from moderately active variants. 
The T2 domain substitution plasmid, named pST2 (Figure 5-3), was constructed as per 
Section 2.8.2.1. It featured the same NotI restriction site as the A and C-A domain 
substitution plasmids, and a SpeI restriction site added between the T and TE domain of 
the second module. The TC domain from pvdD and its three improved variants were each 
amplified by PCR and ligated into the pST2 plasmid using a NotI/NotI fusion at the 5′ 
end and NheI/SpeI fusion at the 3′ end. This NheI/SpeI fusion changed the coding 
sequence from ER to AS, however, since this change was within the flexible linker region 
it was thought to be unlikely to influence activity. As a restriction site control, the 
TTE domain from pvdD was PCR amplified and ligated into the pST2 plasmid. When 
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transformed into the pvdD deletion strain, this control showed no reduction in pyoverdine 
production compared with wild type P. aeruginosa PAO1 (not shown). 
 
Figure 5-3. The domain organisation within the substitution plasmid pST2. Domains coloured 
blue and red were derived from the first and second module of pvdD, respectively. Domains in 
green were absent in the substitution plasmid and indicate the location where alternative domains 
would be inserted. X refers to a SpeI restriction site that was destroyed when ligating T domains 
into the plasmids via a compatible NheI sticky end. 
 
5.3.1 Growth on solid media of T2 domain substitution strains 
The four T2 domain substitution constructs and the restriction site control construct were 
transformed into P. aeruginosa PAO1 ∆pvdD, and the resulting strains tested for function 
by growth on solidified KB media (Figure 5-4). The strain containing the substituted 
TC domain showed low levels of increased fluorescence compared to the pvdD deletion 
strain. This strain also exhibited low levels of growth on EDDHA supplemented media. 
In comparison, the three T2 domain substitutions with TC domains that had been evolved 
for improved function in BpsA, were found to have increased levels of growth and 
fluorescence relative to the TC domain substitution. The substitution strain containing the 
3kf0(I/I) T domain, appeared to be the most active as measured by fluorescence and its 
ability to grow in the presence of EDDHA. 
 
 
Figure 5-4. Fluorescence of T2 domain substitution strains on KB agar media in the (A) absence 
or (B) presence of EDDHA. Plates were inoculated with the T2 domain restriction site control 
(T2), T2 domain substitution strains, and the pvdD deletion mutant (del) then incubated for 24 h at 
37 °C. TC refers to the pvdD T1→T2 substitution, whereas residues at the +4 and +24 positions 
are indicated for evolved T domains. Photographs were taken under UV light. 
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5.3.2 Pyoverdine production in liquid media by T2 domain substitution 
strains 
The T2 domain substitution strains were grown in liquid media to quantitatively assess 
pyoverdine production relative to the T2 restriction site control (Figure 5-5). The pvdD 
variant containing the substituted TC domain from pvdD exhibited approximately 6 % of 
wild type levels of pyoverdine, as measured by absorbance. Although function was 
substantially impaired, this result contrasted with TC domain substitutions in BpsA, which 
had in each case resulted in no indigoidine synthesis at all. The substitution variants with 
the TC domain evolved for improved activity in BpsA all synthesised relatively similar 
levels of pyoverdine, between 18 - 24 % of wild type levels based on absorbance. This 
indicated that increased fluorescence by the 3kf0(I/I) T domain substitution strain when 
grown on solid media may have been due to the subjective nature of the test. Nonetheless, 
these results confirm that TC domains evolved to function upstream to the BpsA 
TE domain can also have improved function upstream to the pvdD TE domain. 
 
 
Figure 5-5. Pyoverdine production of T2 domain substitutions detected when grown in liquid 
media. Tc refers to the pvdD T1→T2 substitution, whereas residues at the +4 and +24 positions 
are indicated for evolved T domains. Values are expressed as a percentage relative to the 
absorbance (400 nm) or fluorescence (ex. 400 nm/ em. 440 nm) measured for the T2 domain 
restriction site control strain, having first been zeroed against the absorbance/fluorescence of the 
pvdD deletion mutant. Data are the mean of 6 independent replicates, and error bars indicate 
1 standard deviation. Tc, pvdD T1→T2 substitution; I/I, 3kf0(I/I); T/L, 3PF2(T/L); A/L, 
3kf13(A/L) 
 
95 
 
 
 
5.3.3 Mass spectrometry of T2 domain substitution strains 
The T2 domain substitutions were next analysed by mass spectrometry to confirm the 
synthesis of wild type pyoverdine (Figure 5-6). All four T2 domain substitution strains 
were confirmed to be synthesising wild type pyoverdine by the presence of a peak 
corresponding to 1333.6 m/z. It was decided to not present CID data as no new 
pyoverdines were synthesised and the previous chapters showed that the 1333.6 m/z 
product was only present when wild type pyoverdine is synthesised. 
 
 
Figure 5-6. Mass analysis of T2 domain substitution strains. Arrows indicate the peak 
corresponding to wild type pyoverdine. 
 
5.4 Bioinformatics of T domains 
As discussed previously, bioinformatics of T domains by Dr Owen focused on T domains 
from pseudomonads and highlighted differences in the +4 and +24 residues relative to the 
Ser residue that serves as the 4′-pp attachment site dependent on the type of downstream 
domain. The reason for limiting sequences to a single genus was to highlight the 
differences in sequence that were specific for interaction with the downstream domain, 
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based on the assumption that the pyoverdine NRPS enzymes have evolved via repeated 
gene duplication and/or recombination events (Smith et al., 2005), leading to accelerated 
mutation of sequences required for optimal inter-domain interactions between 
recombined modules (Owen, 2010).  
To determine whether the +4 and +24 positions were conserved dependent on the type of 
T domain for other bacteria, more extensive alignments were made using T domains from 
a diverse range of bacterial species (Figure 5-7, Appendix C). In addition, the residues 
implicated for T domain interactions in other studies, namely the -8, +1, +19, and +23 
positions relative to the 4′-pp attachment site (Lai et al., 2006; Zhou et al., 2006, 2007), 
were also examined. In these alignments, the residues at the +1, +4, +19 and +23 
positions were highly similar between TC and TTE domains, but each of these differed 
from TE domains. In contrast, the -8 position contained similar residues for all T domain 
types, and the +24 position was highly conserved as Phe for all T domains. These 
observations suggested that, despite the functional differences observed in both BpsA and 
PvdD assays described in this chapter, TC and TTE domains are highly similar to one 
another. 
 
 
Figure 5-7. Sequence logos of T domains from bacterial strains other than pseudomonads based 
on clustalW alignments. All T domains were aligned together and separate graphs created for (A) 
TC domains, (B) TTE domains or (C) TE domains. Full alignments are shown in Appendix C. Each 
position of the sequence alignment in Appendix C is indicated by one column in the sequence 
logo. The height of the column indicates the sequence conservation measured in bits, and the 
height of individual letters within a column indicates their relative frequency at that position 
(Crooks et al., 2004). Residues implicated in other studies to be important for interaction with 
other domains are indicated by arrows. Image created using Weblogo (Crooks et al., 2004). 
 
-8 0 1 4 19 23 24 
(A) 
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The similarity between TC and TTE domains suggests that these domains may be able to 
interconvert between types relatively easily. Despite biochemical evidence of key 
residues for T/TE domain interactions (Owen, 2010; Zhou et al., 2006), the sequence 
alignments showed that residues at these positions are conserved similarly between 
TC and TTE domains. This indicates that the residues important for T/TE domain 
interactions might be more specific for each T-TE domain combination, rather than 
optimisations for general T/TE domain interaction. This is highlighted by the original 
BpsA T domain substitution work of Dr Owen where, despite TTE domains retaining 
function in their new environment, indigoidine synthesis was decreased to approximately 
5 % of wild type levels (Table 5-1). Given that T/TE domain interactions appear 
important for function and that TC and TTE domains are similar, this raised the questions 
of whether T/C domain interactions may also be prone to disruption and, consequently, 
whether C-A domain substitutions might disrupt T/C domain interactions.  
Based on the T domain mutagenesis studies discussed in Sections 5.1, an inhibited T/C 
domain interaction could probably be restored by introducing only a few point mutations. 
However, if the important residues for correct T/C interaction differ between different 
T-C domain combinations, then this may require optimisation for each new T-C domain 
combination. An alternative strategy that might prove effective would be to keep 
evolutionarily optimised T/C domain interactions intact by substituting T-C-A domains 
together. 
5.5 Attempts to avoid disruption of the T/C interface via T-C-A domain 
substitutions 
This section compares the activity of T-C-A with C-A domain substitutions. 
T-C-A domain substitutions alter upstream T domain interactions of two T domains, e.g. 
the A/T and C-/T domain interactions for both the T domain introduced as part of the 
T-C-A domains and the T domain of the second module of pvdD. However, 
T-C-A domain substitutions keep the T/C domain interactions intact. As a consequence, if 
disrupting the T/C domain interactions cause C-A domain substitutions to lose activity, 
then T-C-A domain substitutions would likely be more successful. The 100 % success 
rate observed for five threonine-specifying A domain substitutions into PvdD (Ackerley 
and Lamont, 2004; Chapter 3) suggests that disruption of an established A/T domain 
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interaction is not a major factor limiting recombinant NRPS function. It is less clear 
whether the C-/T domain interaction may be disrupted, however, the T/C domain 
interaction was hypothesised to be more important due to the importance of T domain 
interactions with downstream domains as discussed in Section 5.1. 
As mentioned earlier in Section 1.3.3, one T-C-A domain substitution has previously 
been created in the context of a dimodular enzyme and tested in vitro (Doekel and 
Marahiel, 2000). This previous work showed that T-C-A domain substitution can be 
successful, but differs from the experiments in this section as it did not seek to determine 
whether T-C-A domain substitution may offer a better alternative to C-A domain 
substitution and, as such, did not compare activity of the T-C-A domains substitution with 
an equivalent C-A domain substitution. 
To make T-C-A domain substitutions, the vector pTCA (Figure 5-8) was constructed 
(Section 2.8.2.2) in a similar manner to the C-A domain substitution plasmid created in 
Section 3.2. The plasmid pTCA contained two NotI restriction sites for the 
non-directional insertion of T-C-A domains; however, this did not matter as the correct 
orientation of each inserted T-C-A domain was confirmed during PCR screening and 
sequencing. Synthesis of these constructs proved to be technically very challenging, due 
to difficulties encountered in amplifying and cloning large PCR products. Nonetheless, 
three T-C-A domain substitutions were ultimately successfully created, sequence-verified 
and transformed into the P. aeruginosa PAO1 pvdD deletion strain. These 
T-C-A domains were amplified using primers in Table 2-1 from modules Ser-B, Ser-F 
and hfOrn-J with the T domains for each T-C-A domain amplicon being from the 
upstream module (Figure 5-9). Following the same nomenclature used for C-A domain 
substitutions, the resulting strains containing these variant pvdD constructs will be 
referred to as TCASer-B, TCASer-F and TCAhfOrn-J, respectively. In addition, the 
C-A domain substitution strain CAhfOrn-J was created, so that it could be compared to 
TCAhfOrn-J. 
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Figure 5-8. Domain organisation within the T-C-A domain substitution plasmid. Domains 
coloured blue and red were derived from the first and second module of pvdD, respectively. 
Domains in green were absent in the substitution plasmid and indicate where alternative domains 
would be added. 
 
 
 
 
 
Figure 5-9. Location of domains used to source T-C-A domains for substitution. (A) Domain 
architecture of the four NRPS genes involved in P. aeruginosa PAO1 pyoverdine synthesis. (B) 
Domain architecture of genes involved in the synthesis of pyoverdine variable peptide chains 
from three other Pseudomonas strains. Figure modified from Figure 3-3. 
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5.5.1 Growth on solid media of T-C-A and C-A domain substitution 
strains 
The CAThr-WT control, pvdD deletion strain, three T-C-A domain substitutions and the 
corresponding C-A domain substitution strains were spotted onto KB agar plates both 
with and without EDDHA (Figure 5-10). Out of the C-A domain substitution strains, 
CASer-F and CAhfOrn-J were fluorescent under UV and able to grow in the presence of 
EDDHA and CASer-B was not. The T-C-A domain substitution strains showed similar 
results to their corresponding C-A domain substitution strains in terms of fluorescence 
and growth in the presence of EDDHA. The fluorescence visible from the CAhfOrn-J and 
TCAhfOrn-J substitution strains suggested the successful creation of pyoverdine 
containing a terminal hfOrn residue. The substituted C domain from these two strains 
naturally receives a Lys residue at its donor site, supporting the previous conclusion 
(Section 4.5) that C domain side-chain specificity at the donor site is generally relaxed. 
The lack of any substantial difference between T-C-A and C-A domain substitutions 
suggested that retaining a native T/C interface might not provide a general means for 
improving the activity of NRPS domain recombination relative to the previously tested 
C-A domain substitution strategy. 
 
 
Figure 5-10. Growth of C-A versus T-C-A domain substitution strains on solid media, both (A) 
without and (B) with EDDHA. The substrate specified by each module was removed from 
nomenclature for clarity. Plates were inoculated with the restriction site control (WT), domain 
substitution strains, and the pvdD deletion mutant (del) then incubated for 24 h at 37 °C. 
Photographs were taken under UV light. 
 
 
WT CA-B CA-F CA-J (B) (A) 
del TCA-B TCA-F TCA-J 
WT CA-B CA-F CA-J 
del TCA-B TCA-F TCA-J 
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5.5.2 Growth in liquid media of T-C-A and C-A domain substitution 
strains 
To more accurately quantify the levels of pyoverdine production, the absorbance (Figure 
5-11A) and fluorescence (Figure 5-11B) of the T-C-A and C-A domain substitution 
strains were measured from the supernatant of 24 h cultures. For the domain substitutions 
with domains from modules Ser-B and hfOrn-J, there appeared to be little difference 
between T-C-A and C-A domain substitutions. On the other hand, slight increases in 
absorbance and fluorescence were detected for strain TCASer-F compared to CASer-F. 
Nonetheless, the differences were small and overall these results indicated that keeping 
the native T/C domain interactions intact had little effect for improving pyoverdine 
synthesis. 
 
 
Figure 5-11. Pyoverdine production in liquid media from T-C-A versus C-A domain substitution 
strains. Values are expressed as a percentage relative to (A) the absorbance (400 nm) or (C) the 
fluorescence (ex. 400 nm/ em. 440 nm) measured for the CAThr-WT strain, having first been 
zeroed against the absorbance/fluorescence of the pvdD deletion mutant. Data are the mean of 6 
independent replicates, and error bars indicate 1 standard deviation. 
 
5.5.3 Mass spectrometry of T-C-A and C-A domain substitution strains 
The T-C-A domain substitution strains and the corresponding C-A domain substitution 
strains were then analysed by mass spectrometry to confirm the production of the 
expected pyoverdines. Both TCASer-B and TCASer-F were found to be synthesising the 
same pyoverdine as their corresponding C-A domain substitutions, i.e. the truncated 
pyoverdine and full-length pyoverdine containing a terminal Ser residue, respectively. 
The strains TCAhfOrn-J and CAhfOrn-J both synthesised a product of approximately 
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1390.6 m/z, consistent with the terminal residue of pyoverdine being replaced with an 
hfOrn residue (C57H88N19O22). As this pyoverdine was new and therefore not previously 
analysed, CID of this product was performed (Figure 5-12; Table 5-3). The five ions 
corresponding to the abundant ions analysed from other pyoverdines were consistent with 
the Thr residue being replaced by hfOrn (Figure 5-12) and full spectra were obtained 
confirming the remainder of pyoverdine (Table 5-3). 
 
 
Figure 5-12. Mass spectra obtained from the supernatant of each of the T-C-A and C-A domain 
substitution strains tested in this section. Arrows indicate the most abundant peak corresponding 
to pyoverdine. 
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Figure 5-13. CID spectra of the pyoverdine synthesised by the strains TCAhfOrn-J and 
CAhfOrn-J. The five most abundant irons are indicated by arrows. 
 
Table 5-3. Ions detected by CID of the pyoverdine synthesised by the strains TCAhfOrn-J and 
CAhfOrn-J. 
 
TCAhfOrn CAhfOrn 
Ion m/z 
[RDA + H - Suca]
+
 204.12 204.12 
A1 - Suca 317.22 317.20 
A1 - NH3 399.20 399.22 
A1 416.22 416.22 
B1 444.20 444.22 
B2 600.31 600.33 
B3 687.34 687.31 
B4 845.42 845.44 
Y7" 947.56 947.58 
[RDAb + H]
+
 1088.61 1088.63 
[M + H - Suca]
+
 1291.66 1291.69 
[M + H - CH2N2]
+
 1348.68 1348.71 
[M + H - NH3]
+
 1373.55 1373.60 
MS/MS precursor 1390.55 1390.59 
Shaded cells indicate ions expected to contain the residue added by the second module of PvdD. 
Suca, succinamide; RDA, chromophoric fragment from the RDA process; RDAb, peptide chain 
fragment released by the RDA process; ND, not detected. 
104 
 
5.6 Analysing the effect of disrupting the T-C junction via T domain 
substitutions  
The T-C-A domain substitutions described in the previous section provided initial 
evidence that disruption of T/C interactions was not a primary factor in the loss of 
function observed for most C-A domain substitution constructs. However, both T-C-A 
and C-A domain substitutions were relatively difficult to construct because of low 
ligation efficiency of the relatively large insert into the vector. As an alternative means of 
investigating the effect of disrupting T-C domain interactions, it was decided to make 
T domain substitutions in the first module of pvdD. These T domain substitutions are 
referred to as T1 domain substitutions in this thesis. As substituting TC domains into this 
position would disrupt a previously optimised T/C domain interaction, a high success of 
substitutions of the T1 domain for alternative TC domains would be further evidence 
against the hypothesis that disrupting T/C domain interactions is a major factor in causing 
C-A domain substitutions to become non-functional. An added benefit of T1 domain 
substitutions was that, identical to the C-A domain substitution plasmid, the T1 domain 
substitution plasmid (pST1) had one fusion site added between an A and a T domain and 
a second between a T and a C domain (Figure 5-14A). Moreover, both T and C-A domain 
substitutions are highly similar in the T domain interactions changed, i.e. both T1 and 
C-A domain substitutions create new A/T domain, C-/T domain and T/C domain 
interactions (Figure 5-14B). Consequently, T1 domain substitutions mimic C-A domain 
substitutions in the fusion sites used and domain interactions altered. Thus, T1 domain 
substitutions not only test whether the T/C domain interaction is likely to be disrupted by 
C-A domain substitutions, but also whether any T domain interactions would be disrupted 
by using the fusion sites in this study. 
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Figure 5-14. Comparison of T domain substitutions to C-A domain substitutions. (A) Location of 
restriction sites in the pST1 and pSMC plasmids. (B) T domain interactions altered by T domain 
substitutions compared with C-A domain substitutions. In both types of substitution, interactions 
between T domains and new domains are (i) an A domain passes a substrate to a new T domain, 
(ii) a T domain passes a substrate to a new upstream C domain and (iii) a T domain passes a 
substrate to a new downstream C domain. 
 
5.6.1 Creation of T domain substitution variants 
The primary aim of this section was to test the ability of substituted TC domains to 
interact with their new C domain partners. As discussed above, it was expected that this 
would mimic C-A domain substitutions in terms of the location of the fusion sites and the 
T domain interactions that were thereby altered. Despite there being a number of studies 
that have previously focused on T domain interactions (Section 5.1), extensive literature 
searches identified no previous studies that had previously evaluated the ability of 
substituted T domains to interact with C domains. This may be because of greater 
difficulty in testing in cis interactions compared to in trans interactions (Zhou et al., 
2006). The most similar studies to T domain substitution upstream to a C domain 
examined the in trans interactions between the ArCPs and the C domain of EntF (Lai et 
al., 2006; Zhou et al., 2007) or T domain substitutions that were conducted in the 
yersiniabactin synthetases upstream to a Cy domain (Suo, 2005). In addition, it has been 
suggested that keeping the type of T domain constant is important during recombination 
experiments (Baltz, 2012). With a secondary aim of providing greater understanding of 
these issues, TCt, TE and TTE domains were also substituted into the first module of pvdD. 
The T1 domain substitution plasmid, named pST1 and shown above in Figure 5-14A, was 
constructed as described in Section 2.8.2. Once created, eighteen T domains from 
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upstream of C, E or TE domains (Figure 5-15) as well as the T domain from the first 
module of pvdD were PCR amplified using primers from Table 2-1 and ligated into pST1 
via NotI/NotI fusions at the 5′ end and NheI/SpeI fusions at the 3′ end. The eighteen 
T domain variants are referred to by the labels in Figure 5-15, in which T domains are 
labelled according to their type, e.g. C1-C6 refers to TC domains, Ct1-Ct4 to TCt domains, 
etc. 
 
 
 
Figure 5-15. Location of T domains in Pseudomonas NRPS pathways used for T1 domain 
substitution. (A) Domain architecture of the four NRPS genes involved in P. aeruginosa PAO1 
pyoverdine synthesis. (B) Domain architecture of genes involved in the synthesis of pyoverdine 
variable peptide chains from three other Pseudomonas strains. Figure modified from Figure 3-3. 
107 
 
 
 
5.6.2 Pyoverdine production by T domain substitution strains 
5.6.2.1 Growth of T domain substitution strains on solid media 
The T1 domain substitution variants were transformed into the P. aeruginosa PAO1 pvdD 
deletion strain and tested for pyoverdine production on solid media (Figure 5-16). It was 
found that all six TC domain variants were fluorescent at levels indistinguishable from the 
restriction site control and were all highly viable in the presence of EDDHA (Figure 
5-16A). For the other types of substituted T domain (Figure 5-16, panels B - D), the 
strains generally showed similar fluorescence and growth in the presence of EDDHA as 
the restriction site control. The exceptions to this were the strains Ct2, Ct4 and TE3 that 
showed low levels fluorescence and low viability in the presence of EDDHA, and strains 
Ct3, E4 and TE1 that showed no increase in fluorescence and did not grow at all in the 
presence of EDDHA. 
 
Figure 5-16. Growth of T1 domain substitution strains on solid media. Substitutions are grouped 
as (A) TC domain substitutions, (B) TCt domain substitutions, (C) TE domain substitutions and (D) 
TTE domain substitutions. For each type of substitution, the top figure is for growth on KB media 
and the bottom figure is for growth on KB media supplemented with EDDHA. T1 refers to the 
restriction site control containing the native TC domain ligated back into pST1. Plates were 
incubated for 24 h at 37 °C, and photographs were taken under UV light. 
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5.6.2.2 Growth in liquid media of T1 domain substitution strains 
When grown in liquid media, the levels of absorbance of all the T1 domain substitution 
strains that were highly viable on EDDHA (Figure 5-16) were found to be similar to the 
T1 restriction site control, with the exception of slightly reduced absorbance observed for 
strain TE4 (Figure 5-17A). Strains Ct2, Ct4 and TE3, which all had low levels of viability 
in the presence of EDDHA, nonetheless all gave increased absorbance compared to the 
pvdD deletion control (at levels between 14 - 26 % of the restriction site control). The 
three strains not viable in the presence of EDDHA, namely strains Ct3, E4, and TE1, all 
showed levels of absorbance similar to the deletion control strain. For these strains, there 
appeared to be no increase in fluorescence (Figure 5-17B).  
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Figure 5-17. Pyoverdine production from T1 domain substitution strains grown in liquid media. 
Values are expressed as a percentage relative to the (A) absorbance (400 nm) or (B) fluorescence 
(ex. 400 nm/ em. 440 nm) measured for the Thr-WT strain, having first been zeroed against the 
absorbance/fluorescence of the pvdD deletion mutant. Data are the mean of 6 independent 
replicates, and error bars indicate 1 standard deviation. 
 
 
 
 
 
 
(A) 
(B) 
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In summary, these results indicate that TC domain substitution strains were all highly 
active in pyoverdine production. As TC domain substitutions disrupt the same T domain 
interactions as C-A domain substitutions, these results are inconsistent with the 
hypothesis that the non-functional C-A domain substitutions in Chapter 4 were inhibited 
by a disruption of the native T/C domain interface. For other T domain types, there 
appears to be some reduction in pyoverdine synthesis, however, only three appeared 
completely inhibited in pyoverdine synthesis. This indicates a relatively high portability 
for other types of T domain to function upstream of a C domain – in contrast with low 
TC domain portability upstream of the TE domain in the BpsA model (Section 5.1.2.1). 
5.6.3 Mass spectrometry of T domain substitution strains 
Next the T1 domain substitution strains with impaired function and one functional strain 
(namely strain C4) were analysed by mass spectrometry. Strain C4 was selected randomly 
to serve as a control as the functional T domain substitutions were most likely 
synthesising wild type pyoverdine due to wild type levels of activity and growth on 
EDDHA containing media. The strains Ct2, Ct4, TE3 and C4, that synthesised at least 
some pyoverdine as judged by absorbance, were all found to be synthesising wild type 
pyoverdine. Strain Ct3 was detected to synthesise the truncated 991.5 m/z product. In 
contrast, no pyoverdine production was detected from strains E4 and TE1. The absence of 
these products would suggest that peptide synthesis is stalling before reaching the new 
T domain or that the stalled peptide product is more stable on these T domains. Overall, 
these results indicate that only 3/18 T domain substitutions were completely inhibited in 
wild type pyoverdine production. The high success of T domain substitutions in wild type 
pyoverdine synthesis illustrated that T domains are highly portable in the context of 
pvdD. 
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Figure 5-18. Mass spectra obtained from the supernatant of each of the T1 domain substitution 
strains. Arrows indicate peaks at 991.5 and 1333.6 m/z, corresponding to the truncated and 
wild type pyoverdine, respectively. 
 
5.6.4 Amino acid sequence alignments of T domains 
The sequences of T domains were aligned in an attempt to highlight any key differences 
between functional T domains and non-functional T domain substitutions. Based on 
112 
 
mutagenesis studies, positions at -8, +1, +4, +19, +23 and +24 relative to the conserved 
4′-pp Ser attachment site have been implicated in T domain interaction with the 
surrounding domains (Lai et al., 2006; Owen, 2010; Zhou et al., 2006, 2007). In general, 
residues that were present at these locations in strains that exhibited less than 80 % of 
wild type levels of pyoverdine synthesis could also be found at the equivalent location in 
the T domain from at least one highly active strain. However, some exceptions to this 
were seen at the -8, +19, 23 and +24 positions. At the -8 position, the strain Ct4 contained 
an Asp residue. Interestingly, this position was more variable across the functional 
strains. The +19 position was highly variable for all T domains. The T domains from Ct3 
and TE3 contained Gly and Arg residues at this position, respectively, which were not 
observed in any of the functional T domain constructs. At the +23 position, the T domain 
from Ct2 contained a Met residue. All T domains from other strains contained a Leu 
residue at this position except for the functional strains C3 and TE2, which contained a 
Val and Phe residue, respectively. At the +24 position all strains except the T domains 
upstream to TE domains contained a Phe residue. The impaired TTE domain substitution 
strains contained either a Met or Ile residue at this position, whereas the functional strain 
contained a Leu residue. The differences between functional T domains and 
non-functional domains at these positions could be involved in the loss of function. 
Ultimately however, no clear patterns emerged from the sequence alignments. 
 
Figure 5-19. Alignment of T domains substituted into the first module of pvdD. T domains that 
allowed high levels of pyoverdine production are numbered 2-12 in left most column and those 
that cause impaired pyoverdine production are numbered 13-19. WT-T1 (1) refers to the native TC 
domain from pvdD. Arrows indicate residues previously implicated in interaction with other 
NRPS domains. Alignment generated in Geneious version 5.5.7 created by Biomatters. Available 
from http://www.geneious.com/. 
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5.7 Discussion 
The first part of this chapter tested whether the TC domain from the first module of pvdD 
could function when substituted to act as the second T domain in pvdD; and whether its 
ability to function could be improved by directed evolution performed in the bpsA 
environment to improve communication with the BpsA TE domain. This work showed 
the domain substitution of the native TC domain into the T2 position severely impaired 
pyoverdine production, whereas evolved TC domains that had gained activity in the bpsA 
context had also gained activity in the pvdD T2 position. However, there was not a direct 
correlation between activity in BpsA and PvdD, with all evolved TC domains having 
similar levels of activity in PvdD. This suggested that although there may be some 
generality in terms of residues that are important for T/TE domain interactions, there may 
also be unique differences for each T-TE combination.  
To examine how widespread the importance of the +4 and +24 positions might be, 
sequence alignments were generated of T domains from outside the pseudomonads. This 
found that the +4 and +24 positions exhibited no absolute differences between TC and TTE 
domains. Interestingly, the TC and TTE domains had several differences to TE domains. 
This supports some type of specificity for TE domains as observed when A and A-T 
domain substitutions were made upstream to the E domain of TycA (Linne et al., 2001). 
This difference could perhaps be due to TE domains interacting with multiple downstream 
domains, i.e. interacting with both a downstream E and C domain.  
The lack of clear sequence differences between TC and TTE domains is interesting, as it 
has been shown in several systems that T/TE interactions can be inhibited by domain 
substitution (Doekel et al., 2008; Duerfahrt et al., 2003; Mootz et al., 2000; Owen, 2010). 
This raised the question of whether T/C domain interactions, which are altered by 
C-A
 
domain substitution, are also susceptible to disruption. The importance of the T/C 
domain interaction was first examined by T-C-A domain substitutions, which sought to 
keep the native T/C domain interaction intact. Although the sample size was small, the 
three T-C-A domain substitutions all had highly similar levels of pyoverdine synthesis 
compared to the corresponding C-A domain substitutions. This indicated that disrupting 
T/C domain interactions was not causing C-A domain substitutions to lose activity. 
However, the examination of T-C-A domain substitutions was limited by the difficulty in 
amplifying and ligating larger DNA fragments. Moreover, a scarcity of C-A domain 
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substitutions with an upstream TC domain meant every additional T-C-A domain 
substitution required the corresponding C-A domain substitution to be constructed.  
As an alternative means of testing whether C-A domain substitutions might inhibit 
T/C domain interactions, TC domain substitutions were made in the first module of pvdD. 
As discussed in Section 5.6, TC domain substitutions alter the native T/C domain 
interaction and a high success rate of TC domain substitution at this position would show 
that the T/C domain interaction is not inhibited by domain substitution. All six TC domain 
substitution strains were highly functional in pyoverdine synthesis at levels 
indistinguishable from the restriction site control strain. This strongly indicated that not 
only is the T/C interface tolerant of change, but also that T domain interactions with other 
domains would unlikely be disrupted by C-A domain substitution.  
To test the portability of other different types of T domain, TCt, TE and TTE domain 
substitutions were also made into the first module of pvdD. These domain substitutions 
had a high success rate with only one out of four of each type of T domain having 
wild type pyoverdine production entirely abolished. That three out of four TCt domain 
substitutions showed reduced pyoverdine production is of interest, as they only differ 
from TC domains in that the interaction with the downstream C domain is in trans. A 
potential cause for this difference is that TCt  domains may require a more specific 
T/C domain interaction to ensure association with the correct downstream NRPS in the 
multienzyme assembly line (Chiocchini et al., 2006; Koglin and Walsh, 2009). 
When the sequences of the non-functional substituted T domains were aligned against the 
functional T domain sequences, there appeared to be no clear cut pattern to the residues 
identified in other studies as being important for inter-domain communication. This fits 
with the hypothesis that residues vital for correct T domain interaction are likely to differ 
between T domains. It was decided to not attempt to identify the mutations that would 
restore activity to these T1 domain substitutions because the overall high success rate of 
T1 domain substitutions strongly suggests that T domain interactions, in the context of an 
elongation module, are highly tolerant of change. Despite this tolerance, the variability of 
TCt, TE and TTE domain substitutions supports the rule that the type of domain 
downstream to a T domain should ideally be kept constant to maximise the likelihood of 
successful domain substitution. 
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To summarise, the collective results of all domain substitution experiments in this thesis 
indicate that a major limiting factor for A domain substitutions is the C domain acceptor 
site specificity. This suggests that the loss of activity of the A domain and/or ability of the 
A domain to communicate with the downstream T domain is unlikely to be the primary 
cause for loss in function of C-A domain substitutions. The implications of this chapter 
are that C-A domain substitutions in PvdD are unlikely to inhibit T domain interactions. 
This in turn suggests that the frequent loss in activity observed with C-A domain 
substitutions is due to a factor inherent to the C domain rather than any surrounding 
domains. One hypothesis discussed earlier (Section 4.5) that fits with these results is 
C-A domain substitutions may be limited by steric constraints at the donor site.  
  
116 
 
  
117 
 
 
 
Chapter 6: Investigation of the acceptor site substrate specificity of a 
C domain 
6.1 Introduction 
The ability to functionally substitute Thr specifying A domains (Chapter 3)  and any 
TC domain (Chapter 5) into PvdD suggests that the large loss of function observed for 
C-A domain substitutions (Chapter 4) was not a consequence of introduction of the new 
A domain or of disrupting T domain interactions. This in turn suggests that the 
introduction of new C domains as part of C-A domain substitutions may have been the 
cause for the loss of function. It was hypothesised that this loss of function may have 
been caused by some C domains being unable to receive a non-cognate donor peptide due 
to steric constraints. This would also explain why the previous C domain donor site 
specificity study using single amino acids found no side-chain donor site specificity 
(Belshaw et al., 1999) and yet there was side-chain specificity identified for some 
dipeptides (Stein et al., 2005). Similarly, for donor site stereo specificity, Clugston et al. 
(2003) observed C domain stereo specificity towards a tetrapeptide, but not towards the 
single amino acid substrate. The studies by Stein et al. (2005) and Clugston et al. (2003) 
indicate that the size and composition of the incoming donor peptide can influence 
activity. Thus, both A and C-A domain substitutions may be limited by the C domain – 
the former by acceptor site selectivity, and the latter by donor site constraints. Overall, a 
greater understanding of C domain specificity is needed as it may aid in future efforts to 
perform functional NRPS domain substitutions. 
Despite the potential importance of C domain specificity, little is known about the 
residues involved. Based on solved structures, the native substrates were modeled into the 
C domain active site of VibH (Keating et al., 2002) and the first C domain involved in 
CDA synthesis (Bloudoff et al., 2013). While it might be expected that this would provide 
reasonable estimates of the residues involved in determining specificity, confirming the 
exact nature of substrate docking would require the structure to be solved in complex with 
the substrate, and this has not yet been achieved (Bloudoff et al., 2013).  
Another potential way to identify specificity conferring residues is via sequence analysis. 
However, from phylogenetic studies it was found that C domains align according to the 
type of donor substrate (e.g. fatty acid, D-amino acid or L-amino acid) rather than by the 
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side-chain of either the donor or acceptor substrates, and consequently no specificity 
conferring residues have been definitively identified on this basis (von Döhren et al., 
1999; Rausch et al., 2007; Roongsawang et al., 2005). 
This chapter aimed to identify, or at least narrow down, the location of residues involved 
in acceptor site specificity of the C domain using mutagenesis. Previous C domain 
mutagenesis studies have focused on the identification of catalytic residues rather than 
those involved in substrate specificity (Bergendahl et al., 2002; Keating et al., 2002; 
Roche and Walsh, 2003; Stachelhaus et al., 1998). In this study, the reason for choosing 
to examine specificity at the acceptor site instead of the donor site was because the tight 
amino acid side-chain specificity inferred at the C domain acceptor site (Sections 1.2.3.2) 
suggests the specificity conferring residues are more defined than the residues that might 
be generating steric constraints at the donor site. Relaxation of acceptor site specificity 
also builds on the A domain substitution work in Chapter 3, where it was concluded that 
altering or relaxing C domain acceptor site specificity might allow non-Thr specifying 
A domain substitutions to successfully synthesise new peptides (Section 3.5). A limitation 
of changing acceptor site specificity is that it might in turn generate problems with steric 
constraints at the donor site of the downstream C domain. However, as A domain 
substitutions alter only one residue of the donor peptide – in contrast with C-A domain 
substitutions, which potentially change the entire peptide received by the substituted 
C domain – the A domain substitutions seem less likely to induce steric limitations. 
Moreover, this study focused on the terminal module of PvdD, meaning that donor site 
specificity of a downstream C domain would not be a problem. 
As a model system to examine the substrate specificity of C domains, it was chosen to 
focus on the first C domain of PvdJ, and to try and identify residues that could be altered 
to change the acceptor site specificity from L-Lys to L-Thr. In this chapter, the first 
C domain from pvdJ is referred to as JCLys and the second C domain from pvdD as DCThr. 
The J and D in the nomenclature JCLys and DCThr refer to the domains being sourced from 
pvdJ and pvdD, respectively. It was hypothesised that changing the key acceptor site 
residues of JCLys to those from DCThr would alter the acceptor site specificity of JCLys to 
Thr. JCLys was selected based on this C domain domain having previous been shown to 
function in PvdD as a C-A domain substitution (Section 4.3), proving that this C domain 
is able to receive the pyoverdine intermediate from the first module of PvdD. Also, JCLys 
has a relatively high amino acid sequence identity to DCThr (73.6 % identity). The high 
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sequence identity is useful for differentiating the residues likely to be involved specificity 
towards Lys over Thr. 
6.2 Prediction of the residues most likely to be involved in substrate 
specificity 
6.2.1 Sequence comparison of JCLys and DCThr  
This section aimed to narrow down the residues likely to be involved in C domain 
acceptor substrate specificity. Despite the high sequence similarity between JCLys and 
DCThr, there were still too many differences across a large stretch of DNA for precisely 
targeted techniques to offer much hope of altering the substrate specificity of JCLys. When 
the two C domains were aligned, it was observed that there were three regions of high 
sequence diversity interspersed by regions of high sequence identity (Figure 6-1). These 
regions of high sequence diversity are labelled 1 to 3 in Figure 6-1 and will be referred to 
as variable regions 1, 2 and 3. To guide the prediction for which of these regions were 
likely to be important for Thr specificity, a homology model of DCThr was created to 
identify residues within 15 Å of the second His residue of the HHxxxDG motif proposed 
to be involved in catalysis (as described in Section 1.2.3.2). This distance was chosen 
based on a meta-analysis by Morley and Kazlauskas (2005) of multiple random 
mutagenesis studies that found changing residues within 15 Å of the catalytic residues 
was most likely to alter the substrate specificity of enzymes. 
6.2.1 Structural comparison of variable regions of JCLys and DCThr 
Homology modelling is based on the core tertiary structure of proteins being conserved to 
a higher level than amino acid sequence. This is shown by proteins that have sequence 
identity of over 50 % having few structural differences within the core of the protein 
(Lesk and Chothia, 1986). As such, the main structural differences between similar 
proteins are generally found in regions on the end of secondary structure, loops between 
secondary structure and peripheral secondary structure elements (Lesk and Chothia, 
1986). It has been suggested, as a general guideline, that when the sequence identity is 
greater than 25 - 30 % it is likely a homology model of sufficient quality for identifying 
residues for site-directed mutagenesis can be created (Cavasotto and Phatak, 2009; 
Hillisch et al., 2004). 
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Figure 6-1. Nucleotide sequence alignment of JCLys and DCThr. The three highly variable regions 
are highlighted in yellow and indicated by 1-3 in the right hand column. The C domains were split 
into three regions based on these variable sections with the recombination site for each region 
indicated in bold and underlined. Alignment performed according to Section 2.10.3. 
 
6.2.1.1 Creation and selection of a structural model of DCThr 
Using the template identification tool from the Swiss-Model server 
(http://swissmodel.expasy.org/), the crystal structure of the T-C domains spanning 
modules 5 and 6 of TycC involved in tyrocidine synthesis (pdb: 2JGP) (Samel et al., 
2007) was judged to be the best template for homology modelling based on 38 % amino 
acid sequence identity with DCThr. In addition to the 2JGP structure, it was decided to 
JCLys   1 ----FARLPIPQTRQEMDNLPLSYAQERQWFLWQLEPESSAYHIPTALRL      
              .:.:|:...:|.   |.||:|||||||||||||||:|||||:|||| 
DCThr    1 TTDAVSTIPLADRQQP---LALSFAQERQWFLWQLEPESAAYHIPSALRL      
 
JCLys   47 RGRLDIASLQRSFAALVERHESLRTRIARMGDEWVQVVSADVSLALEVEV      
          |||||:.:|||||.:||.|||:||||....|....|.|...||:::|.|  
DCThr   48 RGRLDVDALQRSFDSLVARHETLRTRFRLEGGRSYQQVQPAVSVSIERE-      
 
JCLys   97 QRGLDEQRLLERVEAEIARPFDLEQGPLLRVTLLEVDADEHVLVMVQHHI     
          |.|  |:.|:||::|.:.:|||||:||||||.||::..|:||||:||||| 
DCThr   97 QFG--EEGLIERIQAIVVQPFDLERGPLLRVNLLQLAEDDHVLVLVQHHI     
 
JCLys  147 VSDGWSMQLMVEELVQLYAAYSQGLDVVLPALPIQYADYALWQRSWMEAG     
          ||||||||:||||||||||||||||||||||||||||||||||||||||| 
DCThr  145 VSDGWSMQVMVEELVQLYAAYSQGLDVVLPALPIQYADYALWQRSWMEAG     
 
JCLys  197 EKERQLAYWTGLLGGEQPVIELPLDHPRQPLRSYRGAQLDLELEPHLALA     
          |||||||||||||||||||:|||.|.||...:|:|||||..||...|..| 
DCThr  195 EKERQLAYWTGLLGGEQPVLELPFDRPRPARQSHRGAQLGFELSRELVEA     
 
JCLys  247 LKQLVQRKGVTMFMLLLASFQALLHRYSGQADIRVGVPIANRNRVETERL     
          ::.|.||:|.:.||||||||||||:||||||||||||||||||||||||| 
DCThr  245 VRALAQREGASSFMLLLASFQALLYRYSGQADIRVGVPIANRNRVETERL     
 
JCLys  297 IGFFVNTQVLKADINGRMGFDELLAQARQRALEAQAHQDLPFEQLVEALQ     
          |||||||||||||::||||||||||||||||||||||||||||||||||| 
DCThr  295 IGFFVNTQVLKADLDGRMGFDELLAQARQRALEAQAHQDLPFEQLVEALQ     
 
JCLys  347 PERSLGHNPLFQVMFNHQADSRSANQGVQLPGLSLERMEWRSSSVAFDLT     
          |||:..|||||||:||||::.||....|||..|.||.:.|...:..|||| 
DCThr  345 PERNASHNPLFQVLFNHQSEIRSVTPEVQLEDLRLEGLAWDGQTAQFDLT     
 
JCLys  397 LDVHEAEDGIWASFGYATDLFEASTVERLARHWQNLLRGIVAEPGRPVAE     
          ||:.|.|:||||||.||||||:||||||||.||:||||||||.|.:.:.| 
DCThr  395 LDIQEDENGIWASFDYATDLFDASTVERLAGHWRNLLRGIVANPRQRLGE     
 
JCLys  447 LPLLLD 
          || ||| 
DCThr  445 LP-LLD 
 
1 
2 
3 
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create homology models using the C domain structures from VibH (pdb: 1L5A) (Keating 
et al., 2002) and SrfA-C (pdb: 2VSQ) (Tanovic et al., 2008) that had 17 % and 23 % 
sequence identity, respectively, as well as an E domain structure from TycA (pdb: 2XHG) 
(to be published; Samel, Heine, Marahiel, Essen) with 19 % sequence identity. Multiple 
structures were used to create homology models, because when sequence identity 
between the template and model drops below 40 %, using multiple template modelling 
along with selection of good models has been shown to generally yield better quality 
models (Larsson et al., 2008). In addition to using Modeller 9.11, homology models were 
created using the semi-automated Swiss-Model servers and several fully-automated 
servers (Section 2.10.4). The aim of this was to create a diverse set of homology models 
from which the best model could be selected. 
The quality of the top models from each method (52 in total) was then estimated using 
QMEAN6 and QMEANclust. The statistical potential QMEAN6 was used as it provides a 
measure of the “degree of nativeness” of models, in other words, whether the model is 
characteristic of experimental structures. It is based on calculating statistical potentials 
from 6 variables within the model, which is then normalised to high quality experimental 
structures giving a Z-score (Benkert et al., 2008, 2011). QMEAN6 has been shown to 
perform well at predicting model quality when compared to either other statistical 
potentials (Benkert et al., 2009b; Rykunov et al., 2009) or other quality estimation 
methods (Benkert et al., 2008). In contrast, QMEANclust was developed to select the 
most accurate model from a set of models (Benkert et al., 2009b). It incorporates the 
information from QMEAN6 together with the structural density of local structures from 
many models. In this context, structural density refers to how similar a structure is to the 
other structures in a group. The reason for focusing on structural density is that local 
structures that are maintained in a similar conformation in a diverse set of models are 
more likely to be correct (Benkert et al., 2009b; Ginalski et al., 2003; Shortle et al., 1998). 
The evaluation of QMEANclust in CASP8 and CASP9, a series of large-scale 
bioinformatic experiments testing the accuracy of structural model prediction tools, found 
that QMEANclust was among the top model quality predictors in terms of predicting the 
global accuracy of models (Cozzetto et al., 2009; Kryshtafovych et al., 2011) and stood 
out as the best at predicting accuracy at the residue level during CASP8 (Cozzetto et al., 
2009). 
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From the 52 models analysed by QMEAN6 and QMEANclust (0), the model 
RaptorXmsa was selected to work with as it scored well in both measurements. 
QMEANclust found that most areas of RaptorXmsa were predicted to have high accuracy 
at the residue level and that the areas of predicted inaccuracy were located in loops, the 
ends of secondary structure and one peripheral helix (Figure 6-2A). The model 
RaptorXmsa aligned well to the C domain structure from TycC (Figure 6-2B) with a 
root-mean-square deviation for the backbone α carbons of 0.381 Å. Overall, these results 
suggest that the core residues of the model are likely to be of high enough accuracy for 
predicting the residues in close proximity to the conserved catalytic His residue. 
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Figure 6-2. Analysis of the structural model RaptorXmsa. (A) The predicted error at the residue 
level based on QMEANclust. The backbone is coloured according to the level of predicted error 
measured in Å. (B) Alignment of RaptorXmsa (green) to the C domain from the structure 2JGP 
(orange). 
(A) 
(B) 
< 1 Å           > 3.5 Å 
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6.2.1.2 Analysis of non-identical residues between JCLys and DCThr  
The residues that were non-identical in the alignment of JCLys and DCThr were mapped 
onto the model of DCThr and coloured according to the three variable regions of the 
C domain (Figure 6-3). These residues were deemed to be of particular interest as they 
were most likely to be involved in differentiation between Thr and Lys. The non-identical 
residues from the first variable region (Figure 6-3, red) were entirely located within one 
subdomain of the C domain and those from the second variable region (Figure 6-3, blue) 
were located within the other subdomain. The non-identical residues of the third variable 
region (Figure 6-3, green) were located in the same subdomain as the second variable 
region, with the addition of a large loop predicted to flex over the catalytic channel to the 
subdomain containing the first variable region.  
 
Figure 6-3. Residues differing between JCLys and DCThr mapped onto the model of DCThr. 
Non-identical residues within variable regions 1, 2 and 3 are coloured red, blue and green, 
respectively. Non-identical residues and variable regions were based on sequence alignment 
shown in Figure 6-1. The catalytic His residue is indicated by an arrow and coloured in cyan. 
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6.2.1.3 Analysis of residues within 15 Å of the conserved catalytic 
His residue 
Next the residues within 15 Å of the catalytic His side-chain were examined (Figure 6-4). 
This showed that all three variable regions had non-identical residues close to the 
catalytic His residue. The non-identical residues of the first variable region within 15 Å 
(Figure 6-4, red) were thought unlikely to be involved in substrate specificity because 
they did not have a direct line of sight to the catalytic residue. From the second variable 
region, there was only one non-identical residue within 15 Å of the catalytic His (Figure 
6-4, blue). The third variable region had six non-identical residues within 15 Å (Figure 
6-4, green), all of which had a direct line to the catalytic His. These observations 
suggested that the third variable region was the most likely region to be involved in 
substrate specificity. Four out of six of the non-identical residues from the third variable 
region were within the flexible loop covering the catalytic channel. This loop interacts 
through hydrogen bonding with the other subdomain in all C domain crystal structures 
(Bloudoff et al., 2013; Keating et al., 2002; Samel et al., 2007; Tanovic et al., 2008). 
Moreover, the surface area of this loop in contact with the other subdomain suggests that 
it may remain intact during catalysis, though it may need to open to let the peptide chain 
through (Bloudoff et al., 2013). One way the loop could be involved in determining 
substrate specificity is if the correct acceptor substrate is required for it to open.  
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Figure 6-4. Residues non-identical to JCLys and within 15 Å of the catalytic His residue of DCThr. 
Residues within 15 Å of the catalytic His residue were identified in Swiss-PdbViewer (Guex and 
Peitsch, 1996). Non-identical residues within variable regions 1, 2 and 3 are coloured red, blue 
and green, respectively. 
 
6.3 Probing the role of residues close to the catalytic His residue 
From the modeling described in the section above, it was predicted that non-identical 
residues from the third variable region of JCLys and DCThr were most likely to be involved 
in determining acceptor site specificity and those from the first variable region were least 
likely to be involved. The strategy for research described in this section aimed to confirm 
the role of residues in the third variable region before focusing on the substrate specificity 
at the residue level. The reason for this approach was to mitigate any errors due to 
modelling or conformational changes that result from substrate binding and catalysis. The 
A and T domains of NRPS enzymes have been shown to be highly dynamic in structural 
studies (Sections 1.2.1.1 and 1.2.2.1) and analysis of C domains also suggests some 
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rotation between the subdomains that shifts the average distance between backbone α 
carbons by 6 – 11 Å (Bloudoff et al., 2013). It was suggested this shift could be part of a 
catalytic mechanism (Bloudoff et al., 2013). However, the differences in C domain 
structures may be due to the structures all being created from different types of C domain, 
i.e. three of the structures are of different types of C domain based on their donor site 
specificity and VibH has unusual features as described in Section 1.2.3.1. 
6.3.1 Testing the function of chimeric C domains 
6.3.1.1 Creation of a vector suitable for directed evolution 
A secondary aim of the research described in this section was to create a substitution 
construct suitable for directed evolution. The plasmid pSW196 was useful in the work 
described in previous chapters, but its integration into P. aeruginosa PAO1 had relatively 
low efficiency. This did not pose a problem for domain substitutions because the 
constructs were constructed in E. coli before being transformed into P. aeruginosa PAO1, 
and because a large number of recombinant P. aeruginosa colonies were not required for 
further study. However, adopting a random or semi-random strategy to identify the 
residues involved in substrate specificity could involve screening large libraries of 
mutants. Since low transformation efficiency could be a problem for library screening, it 
was decided to use a non-integrating plasmid for the work described in this chapter. 
Previous work using plasmid based complementation of pvdD found that a lower copy 
number plasmid containing pvdD resulted in increased pyoverdine levels compared to a 
high copy number plasmid (Ackerley and Lamont, 2004). This may have been due to the 
lower copy number plasmid over-expressing PvdD to a lower level, and hence 
establishing a better stoichiometric ratio between PvdD and the other pyoverdine NRPS 
enzymes (Ackerley and Lamont, 2004). To address this issue, during construction of 
pDEC (the C domain substitution plasmid used in this chapter) the PBAD promoter from 
pSW196 was incorporated into the base plasmid pUCP22 (West et al., 1994). The 
pUCP22 plasmid contains a PTAC promoter and was the high copy number plasmid used 
previously (Ackerley and Lamont, 2004). The PBAD promoter was added since it has 
tighter regulation than the PTAC promoter (Guzman et al., 1995). The domain architecture 
within pDEC is shown in Figure 6-5 and its construction is described in Section 2.8.3.1. 
This plasmid contained a version of pvdD lacking DCThr (i.e. without the second 
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C domain of pvdD) and contained restriction sites to insert new C domains in its place. 
The upstream restriction site was SpeI (labelled “X” in Figure 6-5) and allowed insertion 
of C domains via SpeI/XbaI fusion at the 5′ terminus. This restriction site was identical to 
the one used in pSMC for C-A domain substitutions (Figure 3-1B). The downstream site 
was SalI (labelled “S”) to allow insertion of C domains via XhoI/SalI fusion at the 3′ 
terminus. This restriction site was designed to be a silent, i.e. it did not alter the amino 
acid sequence of PvdD. 
 
Figure 6-5. Domain architecture within the plasmid pDEC. Domains coloured blue and red were 
derived from the first and second modules of pvdD, respectively. Domains in green were absent in 
the base substitution plasmid and indicate where alternative domains would be added. X refers to 
a SpeI restriction site that was destroyed when ligating C domains into the plasmid via a 
compatible XbaI sticky end. S refers to a SalI restriction site that was destroyed when ligating 
C domains into the plasmid via a compatible XhoI sticky end. 
 
6.3.1.2 Creation of chimeric C domains 
To determine whether changing the third variable region of the C domain was sufficient 
to alter acceptor substrate specificity, three chimeric C domains were constructed (Figure 
6-6) and ligated into the pDEC vector, as described in Section 2.8.3.2. The three chimeric 
C domains were based on JCLys and had either one or two variable regions exchanged for 
the same region from DCThr. The first of these, J12-D3, contained the first and second 
variable regions from JCLys and the third variable region of DCThr. In naming J12-D3 and 
other chimeric C domains, the origin of each variable region of the C domain is indicated, 
e.g. for J12-D3, “J12” indicates the first and second regions are identical to those from 
JCLys and “D3” indicates the third variable region is identical to that from DCThr. The 
C domain J12-D3 contains the first two variable regions from a C domain specific at the 
acceptor site for Lys and the third variable region from a C domain specific at the 
acceptor site for Thr. As such, the ability of the J12-D3 chimeric C domain to function in 
the context of pvdD would show this C domain can receive a Thr monomer at the 
acceptor site, and support the hypothesis that the residues conferring acceptor site 
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specificity are mainly located within the third variable region. However, the second and 
third variable regions were in the same subdomain, and it was also possible that changing 
the entire third variable region may disrupt residues interacting between the second and 
third variable regions. To test whether or not the second variable region might be 
involved in modulating the function of variable region three, a second chimeric 
C domain, named J1-D23, containing the first variable region from JCLys and the second 
and third variable regions from DCThr was constructed that kept the entire subdomain 
intact. For the strain containing J1-D23 to be capable of pyoverdine synthesis would be 
consistent with the third variable region being involved in acceptor site specificity. 
However, if J12-D3 was non-functional, it might also suggest that the acceptor site 
specificity is mediated by the second variable region. To control for this, the chimera 
J1-D2-J3 was created containing the first and third variable regions of JCLys and the 
second variable region of DCThr. In addition, a control with the complete JCLys domain 
and a restriction site control containing the DCThr domain were constructed. The chimeric 
C domain constructs were all sequence verified and transformed into the P. aeruginosa 
PAO1 pvdD deletion strain.  
 
Figure 6-6. Domain architecture of pvdD and the chimeric C domains created to replace DCThr. 
(A) The domain architecture of pvdD with the three variable regions of DCThr indicated as 1-3. 
(B) The chimeric C domains created in this study. Green regions indicate origin from JCLys and 
red regions indicate origin from DCThr. 
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6.3.1.3 Analysis of the strains expressing chimeric C domain 
constructs on solid media and in liquid media 
Having created and transformed the chimeric C domain constructs, the levels of 
pyoverdine produced by the different strains were assessed both on solid media and in 
liquid media. The concentration of L-arabinose used in the assays was reduced to 0.1 % 
(v/v) because initial fluorescence tests in liquid media indicated that, at this concentration, 
the restriction site control was not impaired in pyoverdine production compared to the 
wild type strain and that the strain containing J12-D3 had maximum fluorescence at this 
concentration (Appendix E). When grown on solid media (Figure 6-7, panels A and B), 
the strain containing J1-D23 was the only chimeric C domain strain viable in the presence 
of EDDHA. This strain also had high levels of fluorescence, whereas the other strains 
were indistinguishable from the empty plasmid control. When grown in liquid media 
(Figure 6-7C), the strain containing J1-D23 produced high levels of pyoverdine as 
indicated by absorbance at levels of 67 % of the DCThr control strain. This result confirms 
that the first variable region was unlikely to be involved in acceptor site specificity. The 
other chimeric C domain strains had no increased pyoverdine synthesis as measured by 
absorbance, but exhibited slight increases in fluorescence with the greatest increase for 
the strain containing J12-D3. 
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Figure 6-7. Pyoverdine production by chimeric C domain strains measured on solid media and in 
liquid media. (A) Growth of the chimeric C domain strains on solid KB media. The restriction site 
control is labelled DC, the strains with chimeric C domain labelled according to the C domain, the 
JCLys substitution labelled JC and deletion strain labelled Del. Plates were incubated for 24 h, then 
photographs taken under UV light. (B) Growth on KB media supplemented with EDDHA. 
Conditions and labelling identical to (A). (C) Percentage of pyoverdine production from chimeric 
C domain strains grown in liquid media. Values are expressed as a percentage relative to the 
absorbance (400 nm) or fluorescence (ex. 400 nm/ em. 440 nm) of the restriction site control 
strain (DC), having first been zeroed against the absorbance/fluorescence of the pvdD deletion 
mutant. A pictorial representation of each chimeric C domain was added below the x-axis, in 
which green regions indicate origin from pvdJ and red from pvdD. Data are the mean of 6 
independent replicates, and error bars indicate 1 standard deviation. 
 
 
(B) DC J12-D3 J1-D23 
JC Del 
DC J12-D3 J1-D23 
JC Del 
(A) J1-D2-J3 J1-D2-J3 
(C) 
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6.3.1.4 MALDI-TOF detection of pyoverdine from chimeric 
C domain strains 
The chimeric C domain strains were next analysed by mass spectrometry (Figure 6-8). 
The strain producing high levels of pyoverdine and able to grow on EDDHA containing 
media, namely J1-D23, was confirmed to be synthesising wild type pyoverdine. The 
chimeric C domain strain containing J12-D3 had an abundant peak corresponding to 
truncated pyoverdine of 991.5 m/z and a very small peak corresponding to wild type 
pyoverdine at 1333.6 m/z. This was unusual in that for all other strains capable of 
synthesising wild type pyoverdine the mass peak corresponding to wild type pyoverdine 
was always the most abundant. This unusual observation could perhaps indicate that 
acceptor site specificity had been partially or completely altered, but that the C domain 
was severely impaired in activity as a consequence of the recombination. In contrast, only 
truncated pyoverdine was detected from the J1-D2-J3 strain and the JCLys control. This 
result was similar to that from non-functional C-A domain substitution strains (Section 
4.4.2), however, was unexpected because this C domain was shown to be able to receive 
the donor peptide from the first module of PvdD in the context of a C-A domain 
substitution. An alternative explanation for peptide synthesis stalling at the first T domain 
of PvdD, for this case, is that the Thr specifying A domain from the second module of 
PvdD may not be able to activate Lys (even at low “leaky” levels) due to the charge 
and/or increased size of Lys relative to Thr. This is consistent with extensive testing of 
substrate promiscuity of the Phe specifying A domain from TycA, which found that the 
A domain had reduced activity against larger substrates and no activity with charged 
amino acids (Villiers and Hollfelder, 2009).  
133 
 
 
 
 
Figure 6-8. Mass spectrometry of the supernatant from strains expressing pvdD variants that 
contain chimeric C domains. Arrows indicate abundant peaks corresponding to either 991.5 or 
1333.6 m/z and an additional minor peak corresponding to 1333.6 m/z for the strain containing 
the J12-D3 chimeric C domain. 
 
6.3.2 Altering the loop covering the active site of the C domain 
The above results suggested that the region responsible for acceptor site specificity was 
within the second and/or third variable regions of DCThr. From the structural modelling in 
Section 6.2.1, it was found that most non-identical residues between JCLys and DCThr, and 
close to the catalytic His residue, were located within the loop from variable region three 
that covered the active site. It was hypothesised that if these residues were involved in 
substrate specificity, then changing the loop of DCThr to the one from JCLys would inhibit 
activity. To test this, the loop from DCThr was replaced with the loop from JCLys as 
described in Section 2.8.3.3. Replacement of the C domain loop was confirmed by 
sequencing, and the resulting construct was then transformed into the pvdD deletion 
strain. 
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6.3.2.1 Testing pyoverdine production by the C domain loop 
substitution strain 
The function of the C domain loop substitution strain was tested in comparison to the 
pvdD deletion strain and the DCThr restriction site control strain. When grown on solid 
KB media (Figure 6-9, panels A & B), the loop substitution strain was fluorescent and 
grew in the presence of EDDHA at similar levels to the restriction site positive control. 
Testing the absorbance and fluorescence in liquid media found the levels of absorbance 
and fluorescence were identical to the positive restriction site control strain (Figure 6-9, 
panel C). The loop substitution strain was also confirmed to be synthesising wild type 
pyoverdine by mass spectrometry (Figure 6-9, panel D). These results indicated that the 
new loop did not impair the ability of the C domain to receive the Thr acceptor substrate, 
suggesting that it does not play a substantial role in substrate selectivity. 
 
 
Figure 6-9. Analysis of pyoverdine production by the loop substitution strain. (A) Growth of the 
chimeric C domain strains on solid KB media. The restriction site control is labelled DC, the 
strains with chimeric C domain labelled according to the C domain, the JCLys substitution labelled 
JC and deletion strain labelled Del. Plates were incubated for 24 h, then photographs taken under 
UV light. (B) Growth on KB media supplemented with EDDHA. Conditions and labelling 
identical to (A). (C) Percentage of pyoverdine production from the loop substitution strain grown 
in liquid media. Values are expressed as a percentage relative to the absorbance (400 nm) or 
fluorescence (ex. 400 nm/ em. 440 nm) of the restriction site control strain (DC), having first been 
zeroed against the absorbance/fluorescence of the pvdD deletion mutant. Data are the mean of 6 
independent replicates, and error bars indicate 1 standard deviation. (D) Mass spectrum obtained 
using the supernatant of the loop substitution strain. Arrow indicates peak consistent with 1333.6 
m/z. 
(B) 
(C) (D) 
DC Loop Del DC Loop Del (A) 
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6.3.3 Recombination of the third variable region of JCLys and DCThr  
The high levels of pyoverdine production from the strain containing the J1-D23 chimeric 
C domain suggested that residues within the second and third variable regions were 
sufficient for receiving a Thr monomer at the acceptor site. In contrast, the low levels of 
pyoverdine from strain J12-D3 indicated that either substituting the third variable alone 
disrupted protein structure, or the second variable region has a role in acceptor site 
specificity or in mediating activity of the third variable region. Moreover, the high level 
of pyoverdine production for the strain that had the third variable region loop from DCThr 
replaced with the loop from JCLys indicated that the predictions of residues involved in 
acceptor site specificity may be incorrect. This suggested the residues predicted to be 
close to the active site might not be the primary determinants of acceptor site specificity.  
In an attempt to identify residues of the third variable region of DCThr that were essential 
for activity in DCThr with a Thr acceptor substrate, it was decided to shuffle the third 
variable region of JCLys and DCThr, and then ligate the recombined region downstream to 
the first and second variable regions of DCThr. To ligate the recombined third variable 
region downstream to the first and second variable regions of DCThr, the first two variable 
regions from DCThr were PCR amplified and ligated into pDEC (the plasmid created for 
chimeric C domain substitutions in Section 6.3.1.1) to create the plasmid pTRN. Thus, 
pTRN contained pvdD lacking the third variable region of the C domain from the second 
module of pvdD. The plasmid pTRN contained SpeI/SacI restriction sites to ligate in the 
recombined third variable region. Both restriction sites were silent in terms of the PvdD 
amino acid sequence. The full details of construction for pTRN are described in Section 
2.8.3.4. 
As an initial test, the Staggered Elongation Process (StEP) (Section 2.6.3.4) was used to 
shuffle the third variable regions from JCLys and DCThr to determine whether this 
technique would provide diversity of C domains. StEP is a process whereby, during 
amplification of multiple templates by a DNA polymerase, a short elongation time at low 
temperature is used such that elongation is halted and, for homologous sequences, the 
truncated amplicon can bind either template in the next cycle (Zhao et al., 1998). This 
results in recombination of the domains in areas of homology. Here, StEP was used to 
recombine the third variable region from the C domains JCLys and DCThr using a forward 
primer that binds JCLys and the reverse primer that binds DCThr, and vice versa. The 
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recombined third variable regions were ligated into pTRN, and the ligated plasmids were 
transformed into the pvdD deletion strain. Active C domain variants were screened for in 
a 96-well plate assay using fluorescence according to methods in Section 2.9.4. In the 
fluorescence screening assays, using the JCLys forward and DCThr reverse primers 
generally resulted in strains that were highly efficient at synthesising pyoverdine (Figure 
6-10A), whereas using the JCLys forward and DCThr reverse primers resulted in strains 
with generally lower levels of activity (Figure 6-10B). 
 
Figure 6-10. Fluorescence based screening of StEP library. (A) The fluorescence of StEP library 
hits generated with the Lys-C forward primer and Thr-WT reverse primer. (B) The fluorescence 
of StEP library hits generated with the Thr-WT forward primer and Lys-C reverse primer. Data 
are from one replicate. 
 
To assess the levels of recombination, fifteen strains were selected to span a range of 
fluorescence and the plasmids from these strains were purified, sequenced and 
re-transformed into the pvdD deletion mutant. These strains were then reassessed for 
pyoverdine production by measuring fluorescence after growth in M9 medium (Figure 
6-11). The strains containing C domains amplified using the JCLys forward and DCThr 
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reverse primers are labelled J1-J7, whereas the strains with C domains amplified with the 
opposite primers are labelled D1-D9. From the sequenced strains there were three levels 
of activity, i.e. highly active strains, moderately active strains, and one strain (J1) that had 
only trace levels of fluorescence. The C domain from the J1 strain contained an internal 
stop codon, explaining why only trace levels of fluorescence were observed for this 
strain.  
 
 
Figure 6-11. Fluorescence of strains that were sequenced from the StEP library. Strains labelled 
D1-D8 were amplified using the primers DCThr forward and JCLys reverse. Strains labelled J1-J7 
were amplified using the primers JCLys forward and DCThr reverse. Data are the mean of 4 
independent replicates, and error bars indicate 1 standard deviation. 
 
The sequences for the shuffled third variable region from the sequenced strains from the 
StEP library, not including J1, were then aligned according to whether they were highly 
functional or moderately functional (Figure 6-12). The highly functional strains all had 
sequences highly similar to DCThr (Figure 6-12, top) whereas moderately active strains 
were more related to JCLys (Figure 6-12, bottom). In each case where the JCLys forward 
and DCThr reverse primers had been used, the JCLys forward primer was found to bind the 
C domain DCThr, resulting in amplification of the third variable region from DCThr. An 
exception to this was strain J5 that had one cross-over close to the 5′ terminus of the third 
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variable region. More frequent recombination caused by a single cross-over was observed 
when the DCThr forward and JCLys reverse primer set was used. For the highly active 
constructs generated using these primers (D3, D4 and D6), recombination occurred very 
close to the 3′ end of the third variable region, suggesting the sequence upstream to this 
point needed to be DCThr sequence for high levels of activity. In contrast, the moderately 
functional constructs were most similar to JCLys. In fact D1 and D2 had the identical 
amino acid sequence to the third variable region of JCLys. Interestingly, strain D5 (which 
exhibited similar fluorescence to the strains D1 and D2 containing the third variable 
region of JCLys) had a third variable region composed of the first half from DCThr and the 
second half from JCLys. This indicated that the residues of DCThr important for increased 
activity may be upstream to recombination point for strain D5 (Figure 6-12, highlighted 
in bold). Overall, the moderate levels of fluorescence observed for the strains containing 
the JCLys third variable region suggested the third variable region might have less 
influence on acceptor site specificity than predicted based on the distance from the 
catalytic His residue in Section 6.2.1.3. 
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Figure 6-12. Sequence alignments of the third variable region from strains that were highly or 
moderately active in pyoverdine synthesis identified by fluorescence screening of the StEP 
library. DC and JC are the sequences from DCThr and JCLys, respectively. Sequence alignments are 
continued over three lines, and for each line the sequences in the top rectangle are from highly 
active strains and the sequences in the bottom rectangle are from moderately active strains. 
Amino acid residues that are different from the sequence of DCThr are highlighted. The area of 
recombination for strain D5 is highlighted in bold. Alignments generated in Geneious version 
5.5.7 created by Biomatters. Available from http://www.geneious.com/.  
 
6.3.3.1 Evaluation of the J12-D3 chimeric C domain strain 
That the two StEP mutants containing the third variable region from JCLys (D1 and D2) 
were functional in the context of pvdD suggests that acceptor site specificity is not 
GIWASF 
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primarily defined by residues from this region. The strain D1 was analysed further in this 
section and is referred to as D12-J3. It should be highlighted that it contains the opposite 
variable regions to the previously tested J12-D3 strain (Section 6.3.1.3), which although 
unable to grow in the presence of EDDHA, was confirmed to have increased fluorescence 
in liquid media and to synthesise wild type pyoverdine by mass spectrometry, albeit the 
peak was unusual in its low abundance. The D12-J3 strain was tested alongside J12-D3 
for direct comparison of pyoverdine production. When grown on solid media (Figure 
6-13, panels A and B), D12-J3 had low levels of growth in the presence of EDDHA and 
low levels of fluorescence. In contrast (and consistent with previous results in Section 
6.3.1.3), J12-D3 was not viable in the presence of EDDHA and did not have increased 
fluorescence compared to the pvdD deletion strain. In liquid media, D12-J3 showed 
increased fluorescence and absorbance relative to J12-D3 (Figure 6-13, panel C) and was 
confirmed to be synthesising wild type pyoverdine by mass spectrometry (Figure 6-13, 
panel D). Overall, these results show that D12-J3 was more functional than J12-D3. This 
suggests that the second variable region may have a larger role in acceptor site specificity 
than the third variable region and that the previous hypothesis of the importance of the 
third variable region (Section 6.2.1.3) was incorrect. Although not helpful in pinpointing 
the substrate specificity residues, that both J12-D3 and D12-J3 were able to synthesise at 
least some wild type pyoverdine suggests that the C domains may have slightly relaxed 
acceptor site substrate specificity rather than altered specificity. Further work would be 
needed to confirm whether these results are indeed a useful step towards development of 
a relaxed acceptor site specificity C domain. 
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Figure 6-13. Analysis of pyoverdine synthesised by D12-J3 compared with J12-D3. (A) Growth 
of J12-D3 and D12-J3 strains on solid KB media. The restriction site control is labelled DC, the 
JCLys substitution strain is labelled JC and pvdD deletion strain is labelled Del. Plates were 
incubated for 24 h, then photographs taken under UV light. (B) Growth on KB media 
supplemented with EDDHA. Conditions and labelling identical to (A). (C) Percentage of 
pyoverdine production from J12-D3, D12-J3 and JCLys substitution strains grown in liquid 
media. Values are expressed as a percentage relative to the absorbance (400 nm) or fluorescence 
(ex. 400 nm/ em. 440 nm) of the restriction site control strain, having first been zeroed against the 
absorbance/fluorescence of the pvdD deletion mutant. A pictorial representation of each chimeric 
C domain was added below the x-axis, in which green regions indicate origin from pvdJ and red 
from pvdD. Data are the mean of 6 independent replicates, and error bars indicate 1 standard 
deviation. (D) Mass spectrum obtained using the supernatant of the J12-D3 substitution strain. 
Arrow indicates peak consistent with 1333.6 m/z. 
 
6.4 Discussion 
This chapter aimed to narrow down the residues involved in defining the acceptor site 
specificity of JCLys. A key hypothesis underpinning much of the research in this chapter 
was that residues close to the catalytic His would be most likely to be involved in 
substrate specificity. Based on homology modelling of DCThr, the non-identical residues 
between JCLys and DCThr that are close to and have access to the catalytic His were 
identified mainly within the third variable region. Therefore, it was hypothesised that 
chimeric C domains that contained the third variable region of DCThr would have the 
correct acceptor site specificity to function in the context of pvdD. The observations that 
(i) the J1-D23 strain was able to synthesise high levels of pyoverdine; and (ii) whereas the 
(B) 
(C) (D) 
DC J12-D3 D12-J3 JC 
Del 
DC J12-D3 D12-J3 JC 
Del 
(A) 
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J1-D2-J3 strain did not make any detectable levels of pyoverdine the J12-D3 strain did, 
albeit at only trace levels; together indicated that the third variable region might be more 
important than the first or second variable region in determining substrate selectivity. 
However, in conflict with this conclusion, the D12-J3 strain (i.e. with the opposite 
C domain variable regions to J12-D3), displayed increased activity relative to the J12-D3 
strain, indicating that the second variable region might in fact be more important than the 
third in terms of accommodating a Thr residue at the acceptor site. 
On the face of it, that both J12-D3 and D12-J3 were found to synthesise at least some 
wild type pyoverdine is a contradictory result. However, this may indicate a slight 
relaxation of acceptor site specificity for one or both of J12-D3 and D12-J3. Possible 
explanations for why substrate specificity may have been relaxed include that acceptor 
site specificity may be dependent on both the second and third variable regions such that 
acceptor site specificity was partially changed in each of J12-D3 and D12-J3, and/or that 
disrupting the subdomain caused structural changes that allowed greater access for 
alternative substrates to the acceptor site. Further testing would be required to definitively 
identify which regions are involved in specificity and whether the specificity of chimeric 
C domains was indeed relaxed. One way to test this would be by substituting the chimeric 
C domains into the second module of pvdD in partnership with the Lys specifying 
A
 
domain of pvdJ. Since the Lys specifying A domain substitution strain in Chapter 3 was 
shown to synthesise low levels of wild type pyoverdine, using this Lys specifying 
A domain may allow synthesis of pyoverdine containing either a terminal Lys or Thr 
residue and could therefore be advantageous in indicating whether any of the chimeric 
C domains had relaxed specificity and whether the second variable region is most 
important for Lys condensation. 
Although not yet definitive, the results in this chapter indicate that the second variable 
region of the C domain is the most important region for acceptor site substrate specificity. 
If this is true it follows that the predictions based on homology modelling were likely 
incorrect, because only one residue of the second variable region was within 15 Å of the 
catalytic His residue. Possible explanations for this incorrect prediction include that the 
15 Å cut off that was imposed was too small, the model had large errors, or that there are 
large structural rearrangements upon substrate binding that substantially alter the location 
of key residues. The structural model appeared to be of reasonable accuracy with 
predicted errors mostly below 1 Å, and the distance of residues within the 15 Å of the 
143 
 
 
 
catalytic His residue was selected to be conservative. As discussed earlier, it has been 
suggested that large conformational changes may occur during substrate binding and 
catalysis by C domains (Bloudoff et al., 2013). As such, determining the precise residues 
for substrate specificity may support that large conformational changes occur during 
catalysis. 
The shuffling of the third variable regions of JCLys and DCThr was an initial test to 
determine whether StEP would efficiently recombine the third variable regions. The 
primers used were not designed specifically for StEP PCR, and it was subsequently found 
that the forward primers could bind both sequences. This reduced level of recombination 
means new primers would be needed for StEP to result in higher levels of recombination. 
Nonetheless, the StEP recombination experiment showed that some activity was retained 
when the third variable region of pvdD was replaced with the equivalent sequence from 
JCLys. In addition, for strains with C domains created using the DCThr forward and JCLys 
reverse primers, high levels of activity were associated with recombination very close to 
the 3′ terminus of the third variable region. Since this recombination event was rare, few 
recombined C domains that were generated using these primers were subsequently found 
to have wild type levels of pyoverdine production (Figure 6-10B). When the cross-over 
location using these primers was in the middle of the gene (e.g. for strain D5), moderate 
levels of pyoverdine production were observed that were comparable to strains which 
contained the entire third variable region from JCLys. Since the D5 strain contains the 5′ 
half of the third variable region identical to DCThr, it suggests that the 3′ half of the third 
variable region of JCLys may cause reduced activity seen for the moderately active strains. 
To identify where the non-identical residues between JCLys and DCThr and within the 3′ 
half of the third variable region were located in the context of a C domain, the residues 
were mapped onto 2VSQ (the structural model of SrfA-C) based on sequence alignment 
(Figure 6-14). The 2VSQ structural model is shown here, rather than RaptorXmsa, 
because 2VSQ contained an entire module and the C domain substitutions in this chapter 
contained part of the A domain up until the A1 motif. In Figure 6-14, the non-identical 
residues from the 3′ half of the third variable region that were part of the C domain are 
indicated in orange, whereas all the residues from the A domain that were substituted 
with the C domain are shown in green. From the residues mapped onto 2VSQ, only one 
non-identical residue was close to the catalytic His residue, and all the remainder were at 
the C/A domain interface or part of the A domain. The location of these residues suggests 
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that the D5 strain may have lost activity by disrupting the C/A domain interface, and 
supports that the C/A interface is indeed important as previously suggested by Tanovic et 
al. (2008). Moreover, the reduced activity by disrupting the C/A domain interface may 
also explain the variation in levels of pyoverdine synthesis by Thr specifying A domain 
substitutions in Chapter 3, indicating that disrupting the C/A interface can reduce activity 
but often does not completely abolish activity. Additional screening of the StEP library 
may allow these residues to be further narrowed down. 
 
Figure 6-14. Location of residues potentially important for high levels of activity mapped onto 
2VSQ, the structure of SrfA-C, based on sequence alignment. The C domain backbone is 
coloured in blue. Residues substituted as part of the C domain substitution are shown in green if 
they were part of the A domain and in orange if they were part of the C domain and non-identical 
between JCLys and DCThr. The catalytic His residue is shown in cyan. 
 
The work in this chapter set out to narrow down the residues involved in substrate 
specificity of the C domain and to create a staging plasmid that might ultimately prove 
more suitable for directed evolution. For the first of these aims, it was attempted to 
narrow down residues based on predictions of residues close to the catalytic site. These 
predictions suggested most non-identical residues between JCLys and DCThr that were 
close to the catalytic His were located within the third variable region. Although not 
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entirely clear, the results suggest the initial hypothesis was incorrect and that the second 
variable region is most important for acceptor site specificity. More work is needed to 
understand acceptor site specificity and to test whether chimeric C domains created in this 
chapter are a step towards a C domain with relaxed acceptor site specificity. For the 
second aim of this chapter, a new plasmid was created and found to allow high levels of 
pyoverdine production. Moreover, in initial tests this plasmid was suitable for screening a 
small number of shuffled C domains. Overall, this chapter establishes a foundation for 
further work on C domain specificity and provides a plasmid suitable for directed 
evolution experiments. 
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Chapter 7: Key findings and future directions 
7.1 Research motivation 
Non-ribosomal peptides comprise a diverse set of peptides synthesised by NRPS 
enzymes. These peptides are of interest as many of them exhibit antibiotic, anticancer, 
anti-inflammatory, immunosuppressant or antiviral activities. In addition, the assembly 
line-like mode of synthesis and semi-autonomous nature of domains and modules 
indicates that they could potentially be manipulated as a means of creating new bioactive 
products. This would be advantageous because most new medically relevant 
non-ribosomal peptides are in fact synthetic or semi-synthetic derivatives of natural 
product scaffolds (Butler, 2005; Newman and Cragg, 2012; Walsh, 2003). The ability to 
functionally modify NRPS enzymes by domain substitution may provide a direct 
biosynthetic route to high yield generation of derivatives of current natural product 
scaffolds and potentially the de novo construction of entirely new NRPS pathways. 
However, historically domain substitution experiments have almost invariably caused a 
large loss in function, limiting product yield. Although a number of reasons have been 
suggested, the precise causes for the loss of function in domain substitution experiments 
remain unknown. The research in this thesis aimed to develop pyoverdine as a model for 
domain substitution and to identify constraints to domain substitutions. 
7.2 Key findings 
The research described in the third chapter of this thesis aimed to determine whether the 
function of A domain substitutions is mainly limited by the acceptor site substrate 
specificity of the partner C domain or by disruption of the C/A domain interface. It was 
found that Thr specifying A domain substitution strains all yielded relatively high levels 
of pyoverdine, whereas non-Thr specifying A domain substitution strains resulted in only 
trace levels of wild type pyoverdine. The high success of Thr (but not non-Thr) 
specifying A domain substitutions was consistent with previous A domain substitutions in 
module one of pvdD by Ackerley and Lamont (2004). Collectively, these results indicated 
that A domain substitutions in pvdD are mainly limited by the substrate specificity of the 
C domain rather than by disrupting the C/A domain interface. An implication of these 
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results is that if C domain acceptor site specificity can be overcome, then A domain 
substitution may be a viable approach for creating new products.  
As an alternative, C-A domains were substituted together to bypass acceptor site 
constraints. The results of this research confirmed that some C-A domain substitutions 
can produce modified full-length pyoverdines. However, in contrast to A domain 
substitutions, the success of C-A domain substitutions did not follow any obvious 
predictable rule. Moreover, a key difference from A domain substitutions was that 
C-A domain substitution strains exhibiting trace levels of fluorescence were found to be 
synthesising a truncated pyoverdine. This suggested that the peptide was being released 
prior to condensation by the introduced C domain. C domain donor site specificity – at 
least in terms of the incoming C-terminal residue – did not appear to be the primary 
limitation because the C-A domain substitutions that gave the highest yield of modified 
pyoverdine products contained C domains that normally receive L-hfOrn at the donor 
site, rather than the L-Thr they were receiving post-substitution into PvdD. Further 
evidence for relaxed donor site specificity was provided by the synthesis of pyoverdine 
from the strain CAhfOrn-J in Chapter 5, which also functioned in pvdD and contained a 
C domain that normally receives L-Lys at the donor site. 
Since donor site specificity was unlikely to be the main cause for C-A domain 
substitutions to be impaired in pyoverdine production, two alternative hypotheses were 
developed to explain why C-A domain substitutions are frequently non-functional. These 
were that T/C domain interactions may be impaired as a consequence of C-A domain 
substitutions or that the substituted C domains may not be capable of receiving the 
incoming peptide chain due to steric constraints at the donor site.  
Chapter 5 addressed the first hypothesis, by studying T domain interactions to investigate 
whether the function of C-A domain substitutions may be impaired due to disrupting 
T domain interactions with the surrounding domains. This work introduced a second 
NRPS model system, the single-module indigoidine synthetase BpsA, which was 
particularly well suited for T domain substitution. Previous directed evolution 
experiments by Dr Owen suggested that there are key residues (in particular at the +4 and 
+24 positions relative to the conserved Ser site of 4′-pp attachment) that can be 
functionally distinct in the otherwise closely related T domains found upstream of either 
C or TE domains. The pvdD system was used to show that residues at the +4 and +24 
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positions mutated to improve the ability of the first T domain of PvdD to interact with the 
TE domain of BpsA also improved its ability to interact with the TE domain of PvdD. 
However, despite the ability of specific mutations to dramatically improve the interaction 
of TC domains with TE domains, sequence and phylogenetic analyses found that TC and 
TTE domains were highly related to one another. Returning to the over-arching theme of 
identifying possible constraints to NRPS recombination studies, it was proposed that 
TC domains may similarly have optimised interactions with the downstream C domain 
and that C domains newly introduced by C-A domain substitution may therefore be 
unable to interact with the upstream T domain. If this issue were a major cause for 
decreased or inhibited function in C-A domain substitution studies, then it could 
potentially be bypassed by substituting T-C-A domains together to keep the T/C domain 
interactions intact. However, when three T-C-A domain substitutions were created and 
tested in comparison to the corresponding C-A domain substitutions, no major differences 
in pyoverdine production were observed between the T-C-A and C-A domain substitution 
strains. Since results from A domain substitutions had already indicated that A/T domain 
interactions are usually not substantially impaired in domain substitution experiments (at 
least, at the recombination sites used in this work), these results suggested that keeping 
the native T/C domain interactions intact had little effect. 
To disprove the hypothesis that impaired T/C domain interactions were the major cause 
for loss of function for C-A domain substitutions, it was decided to substitute T domains 
into the first module of pvdD. This shift from T-C-A domain substitutions was because 
the T domain substitution constructs were much easier to build due to the small size of the 
insert. In addition, substitution of TC domains into this position were conceptually similar 
to C-A domain substitutions in that they established a new A/T domain interaction, 
C-/T domain interaction and T/C domain interaction, and used equivalent fusion sites. 
This meant that they tested whether any T domain interactions might be disrupted by 
C-A domain substitutions, rather than solely focusing on the T/C interactions. In all, six 
Tc domain substitutions were constructed, and it was found that none of these were 
impaired in activity relative to the restriction site control. In contrast, twelve other types 
of T domain (four of each of TCt, TE and TTE domains) were also substituted and the 
resulting substitution strains found to have variable levels of pyoverdine synthesis. 
Nonetheless, the overall success rate was still high, with only three T domain substitution 
strains being completely inhibited in pyoverdine production. This indicates that there is 
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some specialisation of T domains and, consequently, that it would ideally be preferable 
(albeit not necessarily essential) to keep the type of domain downstream to a T domain 
constant in order to increase the chance of success for domain substitutions. Overall, 
these results suggest that T domains are relatively tolerant in interacting with new 
domains. The most important implication of this is that disrupted T/C domain interactions 
were unlikely to be the major cause of impaired NRPS function during the earlier 
C-A domain substitution experiments. 
The second hypothesis mentioned above for why C-A domains become non-functional 
when substituted was that steric constraints at donor site of the new C domain may block 
the peptide chain from accessing the catalytic site of the C domain. This would in turn 
suggest that C domains have potential to be limiting for domain substitutions because of 
constraints at both the donor and acceptor sites. The final research chapter aimed to create 
a plasmid suitable for directed evolution of C domains and to narrow down the region of 
the C domain responsible for acceptor site substrate specificity. It was decided to focus on 
acceptor site specificity instead of donor site specificity because it was thought that the 
former would be more defined. The residues within close proximity to the catalytic His 
residue were predicted based on homology modelling and hypothesised to be the residues 
most likely to be involved in determining acceptor site substrate specificity. Several 
chimeric C domains were created to test this. From these results, it appears that the 
residues predicted to be close to the catalytic His have only small effects on acceptor site 
substrate specificity and the second variable stretch of amino acids appeared to have the 
most involvement in substrate specificity. However, results were not definitive and 
further work will be needed to identify the key acceptor site residues. Although not 
successful in identifying substrate specificity conferring residues, the plasmid constructed 
was found to be highly efficient in terms of expressing pvdD in a manner that did not 
impair pyoverdine synthesis (in contrast with previous studies where higher copy number 
of pvdD was associated with decreased pyoverdine production (Ackerley and Lamont, 
2004)). In addition, initial tests using StEP to recombine the third variable regions of two 
C domains found that this plasmid was suitable for directed evolution experiments. Thus, 
the work described in this chapter provides a solid foundation for future work aiming to 
use directed evolution to interrogate, and perhaps overcome, C domain specificity 
constraints. 
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In light of the frequent loss of activity that has been observed for NRPS domain 
substitution studies (Baltz, 2012; Giessen and Marahiel, 2012), perhaps one of the more 
surprising results of this thesis was in fact how tolerant pvdD was for domain 
substitutions. This is shown by the success of Thr specifying A domain substitutions, the 
three functional C-A domain substitutions that led to modified full-length pyoverdine 
products, the similarity in activity recorded for equivalent T-C-A and C-A domain 
substitutions, and the tolerance of many modifications of the C domain reported in the 
final chapter. Factors that may have contributed to non-functional substitutions were 
predicted to be acceptor site specificity of the C domain, steric constraints at the donor 
site of the C domain, some specialised T domains not functioning with a downstream 
C domain or by making large changes within a subdomain of the C domain in Chapter 6. 
The final two factors can frequently be avoided when attempting to make new products 
using domain substitution, e.g. by ensuring the type of domain downstream to a T domain 
is not changed and making substitutions that keep domains intact. Consequently, a more 
global conclusion from this thesis is that domain substitutions that do not interfere with 
C domain constraints are likely to yield a functional pvdD enzyme. An implication of this 
is that if the limitations of the C domain could be overcome, then it may be that NRPS 
enzymes become relatively tolerant to domain substitution as a means of creating new 
products. 
7.3 Limitations of this research 
7.3.1 Limitations in the use of pyoverdine NRPS enzymes 
This project limited the substituted domains to those involved in pyoverdine synthesis 
from four Pseudomonas strains. The diversification of pyoverdine side-chains is proposed 
to be a mechanism to stop siderophore cheating, i.e. to inhibit other strains utilising the 
synthesised siderophore (Schalk and Guillon, 2013; Visca et al., 2007). A suggested 
evolutionary mechanism for the diversification of pyoverdines is that the pyoverdine 
uptake receptor is first modified, which in turn creates pressure for the rapid evolution of 
the peptide side-chain to enable interactions with the new receptor (Smith et al., 2005). It 
has been hypothesised that many different pyoverdine genes in nature have derived from 
recombination and horizontal gene transfer of NRPSs between pseudomonads (Smith et 
al., 2005), and pyoverdine pathways may therefore have become generally more 
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amenable to domain recombination experiments. As such, it is unclear how transferable 
these results may be to other systems or with distantly related domains. However, an 
important reason for focusing on related domains in this thesis was to maximise the 
likelihood of functional recombination events, and thereby highlight factors that might be 
inhibiting function when recombination resulted in impaired activity. Although additional 
factors may limit the ability to substitute more distantly related domains, understanding 
the factors inhibiting the function in one system provides a starting point for determining 
why other pathways might be non-functional. 
A second limitation of this study was that the modified derivatives of pyoverdine that 
were successfully generated have limited uses. Other products exist, such as antibiotics, 
where making derivatives could prove to be highly valuable (e.g. the daptomycin and 
related antibiotic derivatives generated by Baltz and coworkers; (Doekel et al., 2008; 
Nguyen et al., 2010)). However, pyoverdine has an advantage in that the wild type 
pyoverdine from P. aeruginosa PAO1 and the derivatives created in this study are easily 
detectable in chromogenic or fluorogenic assays, and, as a siderophore, allow growth in 
the presence of the iron chelator EDDHA. This makes pyoverdine a valuable model for 
testing domain substitutions and, as suggested above, the lessons learned in this system 
could aid in modifying other pathways. In addition, an advantage added by this research 
is that pvdD has now been characterised in-depth by domain substitution, i.e. in terms of 
both the number and variety of domain substitutions. 
7.3.2 Limitations in testing pyoverdine production 
In this study, the domain substitution strains were only tested by pyoverdine synthesis 
using in vivo assays. A consequence is that the level of stability and expression for 
individual recombinant proteins is unknown, and it may be that the activity of substituted 
domains was impaired in a manner that could have been more easily quantified in in vitro 
assays. However, the purification of NRPS enzymes is technically very challenging and 
can be variable, causing insolubility or inactivity. In particular, functional PvdD has only 
been successfully purified once before (Ackerley et al., 2003), and a large number of 
attempts to repeat this successful purification have all met with failure (DF Ackerley, 
personal communication). Moreover, in vitro assays commonly focus on reactions of 
individual domains and are not always predictive of in vivo activity. The focus of this 
research was on identifying robust ways in which domain substitutions can be performed 
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in the context of an NRPS pathway with the ultimate goal of creating new products in 
vivo. As such, the in vivo level of pyoverdine synthesis is substantially the most important 
metric for testing the success of domain substitution variants. 
Another limitation was that MALDI mass spectrometry does not provide a quantitative 
measurement of the different types of pyoverdine synthesised. Many factors can affect the 
peak intensity including different ionisation efficiencies of similar peptides, small 
changes in sample preparation and saturation of the ion detector (Albrethsen, 2011; Szájli 
et al., 2008). As a consequence, when truncated and full-length pyoverdines were 
detected in the supernatant, their relative yields remain unknown. However, the most 
important aspect of this study was detecting when domain substitution strains were able 
to create the full-length pyoverdine, and MALDI mass spectrometry was valuable in 
determining this. 
In the final chapter of this thesis, a total of 338 colonies were screened using fluorescence 
in a 96-well plate based assay. The screening method could be greatly scaled up, 
however, screening in 96-well plates is often limited to small libraries with a maximum 
limit of screening 10
5
 variants a day under ideal conditions, whereas selection or 
fluorescence-based screening can screen much larger libraries of up to 10
9
 variants 
(Dietrich et al., 2010; Leemhuis et al., 2009). As such, the screening method that was 
used here is highly limiting for the directed evolution techniques that could potentially be 
used on pvdD. Nonetheless, the modified pyoverdines in this study generated high levels 
of fluorescence and enabled growth in the presence of the iron chelator EDDHA. These 
characteristics provide the potential to create high-throughput screens focused on the 
siderophore or fluorescent properties of pyoverdine. 
7.4 Future directions 
7.4.1 Improve the activity of A domain substitutions 
The work presented in Chapter 3 suggested that the functionality of A domain 
substitutions is primarily limited by acceptor site specificity of the C domain. However, 
there was still variation in the level of activity observed for the different Thr specifying 
A domain substitution strains. It would be useful to find ways to improve the activity of 
A domain substitution strains because it would add value if the acceptor site specificity of 
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the C domain can be altered or relaxed. One of the main hypotheses for why A domain 
substitutions may be unsuccessful is that they disrupt an important C/A domain interface 
(Tanovic et al., 2008). Although this appeared not to have been a major factor in limiting 
pyoverdine synthesis in the A domain substitution experiments presented here, it may 
have been a contributing factor to the Thr specifying A domain substitutions having 
variable levels of activity. The C/A domain interface hypothesis is in fact supported by 
initial results in Chapter 6, where it appeared that residues at this interface were essential 
for high levels of activity. In particular, residues at the C/A domain interface and 
important for high levels of activity were found to be located in the 3′ half of the third 
variable region of the C domain. This indicates that using a new fusion site for A domain 
substitutions that is located partially into the C domain might avoid disrupting the C/A 
domain junction. Further screening of the two StEP libraries that recombined the third 
variable regions from JCLys and DCThr could be useful in confirming this and for 
indicating the best location for a fusion site. Another option would be to test the least 
functional Thr specifying A domain substitution with different fusion sites located further 
into the C domain. For a fusion site found to improve activity, the equivalent fusion site 
could be tested in other Thr specifying A domains to determine whether the new fusion 
site is generally able to improve activity. 
7.4.2 Perform T1 domain substitutions of TC domains from 
non-pyoverdine NRPS enzymes 
In Chapter 5, T domain substitutions into the first module of PvdD found that 6/6 
TC domain substitution strains were highly functional for pyoverdine production and 9/12 
domain substitution strains created using other types of T domain were able to synthesise 
pyoverdine at varying levels. These high success rates for pyoverdine production suggest 
that T domains are highly portable, and hence T domain function is unlikely to be 
substantially impaired by C-A domain substitution. This is important, as the ability of 
T domains to interact with new domains is essential for domain substitution experiments 
to be successful. However, because the T domains in this study were sourced exclusively 
from Pseudomonas pyoverdine NRPS enzymes, it is unknown how generally applicable 
these T domain substitution results may be. Thus, it would be of interest to repeat these 
T domain substitutions using a range of T domains from other NRPS enzymes to 
determine how portable other T domains are in interacting with new domains. The most 
155 
 
 
 
important T domains to substitute would be TC domains because substitution of 
TC domains mimics the most similar scenario to C-A domain substitutions in terms of the 
interactions altered. 
7.4.3 Identify residues involved in acceptor site specificity of the 
C domain 
The research in this thesis highlights the need to understand the substrate specificity of 
the C domain. The work in Chapter 6 attempted to narrow down the acceptor site 
substrate specificity of the C domain from the second module of pvdD because this may 
enable non-Thr A domain substitutions to be successful. To narrow down the acceptor 
site specificity it was attempted to identify which region of the C domain is involved. 
Based on homology modelling and prediction of the residues likely to be in close 
proximity to the catalytic His residue, it was hypothesised that residues within the third 
variable region of the C domain would most likely be involved in substrate specificity. 
However, the residues of the third variable region appeared to have only a small influence 
on substrate specificity, with greater influence instead from the second variable region. 
Moreover, it was found that strains containing diametrically opposed combinations of 
variable regions of the C domain could both synthesise at least trace levels of wild type 
pyoverdine. Further testing of each of the chimeric C domains will be needed to identify 
whether substrate specificity was altered or relaxed, and which region(s) play the most 
important role in determining substrate specificity. As such, it may be useful to substitute 
the Thr specifying A domain of the second PvdD module with the Lys specifying 
A domain of PvdJ for each of the chimeric C domain constructs. Results from Chapter 3 
suggest the PvdJ A domain is able to activate Thr with low efficiency in addition to Lys 
at high efficiency. Studying the pyoverdine production of strains containing these 
constructs may enable clearer results for identifying when specificity is altered versus 
relaxed. Following this, the substrate specificity could be further defined using the 
constructed pUCP22 based plasmid and directed evolution techniques. The choice of 
techniques for directed evolution would be highly dependent on the throughput of the 
screening method available and whether the acceptor site specificity of the C domain was 
narrowed down by testing the chimeric C domains with an alternative A domain. 
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7.4.4 Characterise the donor site constraints of the C domain 
An important corollary to identifying acceptor site constraints would be to define donor 
site constraints. An advantage for relaxing constraints that may exist at the donor site over 
focusing on acceptor site specificity is that changing acceptor site specificity may 
subsequently lead to problems with donor site constraints at the downstream C domain. 
However, altering donor site constraints has the limitation that – if based primarily on 
steric constraints – it may not be defined by consistent rules. Nonetheless, identifying the 
location of residues that block access to the catalytic site of the donor site of a C domain 
might prove useful in identifying potential problematic residues in other C domains or 
assist in identifying better recombination sites within the C domains. From the work in 
this thesis, the C domain that may be particularly useful for donor site specificity studies 
would be the C domain from the strain CAThr-E. The strain CAThr-E was found to 
synthesise the truncated pyoverdine product and was hypothesised to be limited by donor 
site steric constraints. As this C domain is not limited by acceptor site specificity (i.e. 
“expects” to receive Thr in the acceptor site) it would be an ideal choice for studying 
donor site specificity in the PvdD model. 
7.4.5 Development of large scale screens 
Future experiments could also focus on developing a high throughput screen or selection 
for pyoverdine synthesising strains. As mentioned in the limitations section above, the 
initial screen used in this study would limit throughput, and hence the range of directed 
evolution techniques that could be used on pvdD. However, the siderophore and 
fluorescent properties of pyoverdine give the potential to create powerful selections or 
screens for pyoverdine synthesis. The siderophore property is useful as it could be used to 
establish a conditional viability selection for directed evolution experiments. This would 
most likely require selection on solid media because secreted pyoverdine in liquid media 
could also be taken up by strains not synthesising pyoverdine themselves. The fluorescent 
property of pyoverdine is useful as it may enable the use of fluorescence activated cell 
sorting (FACS) to screen for pyoverdine producing strains. Similar to selection, a 
potential problem for FACS based screening is that pyoverdine is secreted and could be 
taken up by less functional strains. However, it has been shown that P. aeruginosa PAO1 
strains with mutations of the iron uptake receptor FpvA and efflux pump PvdRT-OpmQ 
are inhibited in pyoverdine uptake and have increased intracellular pyoverdine (Hannauer 
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et al., 2010). Both mutations would likely be needed in concert because there is still some 
secretion of pyoverdine when PvdRT-OpmQ alone is mutated (meaning that it is 
available for other strains to take up), yet deletion of FpvA alone does not lead to the 
same accumulation of pyoverdine (Hannauer et al., 2010). FACS would likely need to be 
combined with secondary screening because the fluorescence on a cell-to-cell basis in 
FACS based screening can differ greatly due to variation (Dietrich et al., 2010), which 
may cause overlap in the populations of the pyoverdine producing and pyoverdine 
deficient strains. For secondary screening a fluorescence based screen in 96-well plates 
would be valuable. 
7.5 Concluding remarks 
The potential to create new non-ribosomal peptides has created interest in NRPS domain 
substitution. However, it has time and time again proven difficult to alter non-ribosomal 
peptides using this method. This thesis has greatly extended previous work developing 
the enzyme PvdD as a model system to study the limitations to domain substitution. The 
enzyme PvdD was chosen for study because the pyoverdine product is fluorescent, 
required for growth in an iron limited environment, and there is a large amount of 
diversity in the naturally evolved peptide chains between Pseudomonas strains. The work 
in this thesis adds to this in that PvdD has now been extensively characterised by domain 
substitution and was shown to be highly amenable to certain forms of domain 
substitution. 
The main aim of this thesis was to identify barriers to effective domain recombination for 
the creation of novel non-ribosomal peptides. It was found that A domain substitutions 
are mainly impaired by C domain acceptor site specificity and hypothesised that 
C-A domain substitutions are inhibited by steric constraints at the C domain donor site. 
This provides more definition for why domain substitutions in pvdD lose activity and 
establishes a firm foundation for further work to identify how these constraints can be 
addressed, defined and overcome. In particular, this research may guide future 
development of relaxed specificity C domains, which could prove to be invaluable tools 
for targeted modification of biotechnologically relevant non-ribosomal peptide products. 
 
  
158 
 
  
159 
 
 
 
Appendix A. Accession numbers of NRPS genes used as 
templates for domain substitution, and the substrate 
specificity of key A domains. 
The accession numbers of genes used for domain substitution in this study are shown in 
Table A-1. Gene and protein sequences were obtained from the Pseudomonas Genome 
Database (Winsor et al., 2011), and were sourced from the genome sequences of 
P. aeruginosa PAO1 (Stover et al., 2000), Pseudomonas syringae pv. phaseolicola 1448A 
(Joardar et al., 2005), Pseudomonas putida KT2440 (Nelson et al., 2002) and 
Pseudomonas fluorescens SBW25 (Department of Energy Joint Genome Institute). 
Substrate specificity of modules was based on previous annotation by Ackerley and 
Lamont (2004) (P. aeruginosa PAO1); Owen & Ackerley (2011) (P. syringae 1448a); 
Moon et al. (2008) (P. fluorescens SBW25); and Ravel & Cornelis (2003) (P. putida 
KT2440). Binding pocket residues for substituted A domains are shown in Table A-2 and 
were predicted using the PKS/NRPS analysis tools available at 
http://nrps.igs.umaryland.edu/nrps/ (Bachmann and Ravel, 2009).  
 
Table A-1. Accession numbers of genes used for domain substitution 
Accession Number  Gene Name Organism* 
NP_251092   pvdI   P. aeruginosa PAO1 
NP_251090   pvdJ   P. aeruginosa PAO1 
NP_251089   pvdD   P. aeruginosa PAO1 
YP_274152.1   pspph1924  Pseudomonas syringae pv. phaseolicola 1448A 
YP_274153.1   pspph1925  Pseudomonas syringae pv. phaseolicola 1448A 
YP_274154.1   pspph1926  Pseudomonas syringae pv. phaseolicola 1448A 
NP_746337.1   pp4220  Pseudomonas putida KT2440 
NP_746336.1   pp4219  Pseudomonas putida KT2440 
YP_002872133.1  pvdI  Pseudomonas fluorescens SBW25 
YP_002872133.1  pvdJ  Pseudomonas fluorescens SBW25 
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Table A-2. Residues lining the A domain binding pockets and substrate specificity predictions 
Module  1 2 3 4 5 6 7 8 Prediction 
Thr-WT D  F  W  N  I  G M  V Thr 
Thr-A  D  F  W  N  I  G M  V Thr 
Thr-D  D  F  W  N  I  G  M  V Thr 
Thr-E  D  F  W  N  I  G  M  V Thr 
Ser-B  D  V  W  H  V  S  L  I Ser 
Ser-F  D  V  W  H  V  S  L  I Ser 
Ser-I   D  V  W  H  V  S  L  I Ser 
Lys-C  D  G  E  D  I  I  T  V Lys 
Asp-G  D  L  T  K  V  G  H  V Asp 
Gly-H  D  I  L  X
1
  I  G  L  I Gly 
Orn-J   D  G  E  V  C  G  G  V Orn 
1
 The Gly-H A domain had an insertion at this point so that this residue did not align to the subject 
A domain. 
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Appendix B. Optimisation of liquid media based assay for 
measuring pyoverdine levels  
To determine whether pyoverdine could be quantified through absorbance or 
fluorescence, strains were first grown in liquid media for 24 h and absorbance and 
fluorescence measured (Figure B-1). The background for fluorescence measurements was 
relatively low and differences in measurements between the culture and supernatant were 
small. In contrast, there was a high background in absorbance. As a result, measurements 
of the cell culture were increased and more variable than the supernatant. This increase 
was also observed for the pvdD deletion strain, indicating that it was due to the presence 
of cells rather than increased pyoverdine within cells. 
 
Figure B-1. Fluorescence (left) and absorbance (right) of the culture and supernatant of A domain 
substitution strains relative to the Thr-WT control strain. Values zeroed to a media control. Data 
are the mean of 3 independent replicates, and error bars indicate 1 standard deviation. 
 
To assess the quantification ability of fluorescence versus absorbance, a dilution series 
was made using the supernatant from the Thr-WT strain (Figure B-2). When dilution, 
absorbance followed a linear trend, whereas fluorescence became saturated. Thus, 
absorbance was more indicative of pyoverdine levels than fluorescence. However, 
fluorescence enabled detection of pyoverdine at much lower levels. As such, absorbance 
and fluorescence were both used in this research. 
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Figure B-2. Absorbance and fluorescence taken from a 2x serial dilution of the supernatant from 
strain Thr-WT. Line of best fit shown for absorbance measurements. Data are a mean of a 
triplicate dilution series and error bars represent 1 standard deviation. 
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Appendix C. Alignments of T domains from 
non-Pseudomonas strains 
Sequences of T domains for alignment were taken from the NRPS-PKS database (Ansari 
et al., 2004) and the enzyme accession numbers are shown in Table C-3. Criteria for 
choosing the T domains to include were that there should be only bacterial T domains 
(excluding Pseudomonas) and NRPS modules are colinear, or colinear and iterative with 
the product, i.e. type A or type B pathways. Boundaries for T domains were taken from 
the PKS/NRPS analysis website used to predict substrate specificity and domain 
arrangement of NRPS enzymes (Bachmann and Ravel, 2009). Sequences were aligned as 
per Section 2.10.2 and full alignments are shown in Figure C-3. 
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Table C-3: Accession numbers of enzymes from which T domain sequences were sourced. 
Accession Number Gene Name  Organism 
ADG27358.1  ACMSII  Streptomyces anulatus 
ADG27359.1  ACMSIII  Streptomyces anulatus 
AAD56240.1  DhbF   Bacillus subtilis  
O68006.1  BA1   Bacillus licheniformis 
O68007.1  BA2   Bacillus licheniformis  
O68008.1  BA3   Bacillus licheniformis  
NP_627443.1  CDA1   Streptomyces coelicolor A3(2)  
NP_627444.1  CDA2   Streptomyces coelicolor A3(2)  
CAD55498.1  CDA3   Streptomyces coelicolor A3(2)  
AAB80955.2  fenA   Bacillus subtilis  
AAB00093.1  fenB   Bacillus subtilis  
AAC36721  fenC   Bacillus subtilis  
CAA09819   fenD   Bacillus subtilis  
AAB80956  fenE   Bacillus subtilis  
BAA00406.1  GrsA   Brevibacillus brevis  
AAD04757.1  licA   Bacillus licheniformis  
AAD04758.1  licB   Bacillus licheniformis  
AAD04759.1  licC   Bacillus licheniformis  
CAA49816.1  srfA1   Bacillus subtilis  
CAA49817.1  srfA2   Bacillus subtilis  
CAA49818.1  srfA3   Bacillus subtilis  
AAC45928.1  TycA   Brevibacillus brevis  
AAC45929.1  TycB   Brevibacillus brevis  
AAC45930.1  TycC   Brevibacillus brevis  
Q54959  Pris2   Streptomyces pristinaespiralis  
O07944  Pris3   Streptomyces pristinaespiralis  
CAC01603.1  apdA   Anabaena sp. 90  
CAC01604.1  apdB   Anabaena sp. 90  
CAC01606.1  apdD   Anabaena sp. 90  
BAB69698.1  ItuA   Bacillus subtilis 
BAB69699.1  ItuB   Bacillus subtilis  
BAB69700.1  ItuC   Bacillus subtilis  
BAA83992.1  McyA   Microcystis aeruginosa  
BAA83993.1  McyB   Microcystis aeruginosa  
BAA83994.1  McyC   Microcystis aeruginosa 
AAF08795.1  Myc1    Bacillus subtilis subsp. spizizenii ATCC 6633 
AAF08796.1  Myc2   Bacillus subtilis subsp. spizizenii ATCC 6633 
AAF08797.1  Myc3   Bacillus subtilis subsp. spizizenii ATCC 6633 
AAO64403.1  NdaA   Nodularia spumigena  
AAO64402.1  NdaB   Nodularia spumigena 
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Figure C-3. ClustalW sequence alignments of T domains from non-Pseudomonas NRPS enzymes. 
Genes are labelled first by a letter representing the type of downstream domain, followed by the 
gene name according to Table C-3, and finally the module number from which the T domain was 
sourced. 
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Appendix D. Comparative modelling quality assessment 
The quality of 52 homology models of the second C domain of PvdD was assessed using 
QMEAN6 and QMEANclust. The models are ranked according to the QMEAN6 Z-score 
in Table D-4, in which a higher Z-score means the model is more similar to high quality 
crystal structures (Benkert et al., 2011). In Table D-5, the models are ranked according to 
the QMEANclust score. The model selected for use in this study was RaptorXsa, which 
was ranked third for QMEAN6 and ninth for QMEANclust. 
 
Table D-4. Ranking of comparative structural models of the Thr-WT C domain by QMEAN6. 
QMEAN6 
Model Z-score Rank 
Modeller_LoopRebuild.pdb -0.08 1 
Modeller_2JGP_1L5A_2XHG.pdb -0.21 2 
RaptorXmsa.pdb -0.24 3 
chunk-TASSER_2JGP.pdb -0.52 4 
Esypred_2jgpa.pdb -0.63 5 
muFold1_2JGP.pdb -0.66 6 
Modeller_2JGP_1L5A.pdb -0.66 7 
M4T_2JGP.pdb -0.71 8 
Modeller_2JGP.pdb -0.72 9 
SparkX_2jpa.pdb -0.75 10 
Modeller_2JGP_2XHG.pdb -0.83 11 
chunk-TASSER_1L5A.pdb -0.83 12 
chunk-TASSER_2XHG.pdb -0.84 13 
RaptorX_2JGP.pdb -0.86 14 
nFOLD_2JGP.pdb -0.93 15 
Modeller_2JGP_1Q9J_2XHG.pdb -1.01 16 
Multicom_msa.pdb -1.1 17 
Raptor2_2JGP.pdb -1.14 18 
TASSER_VMT_1L5A.pdb -1.18 19 
Phyre2_2vsqA.pdb -1.19 20 
SwissModel_2JGP.pdb -1.2 21 
muFold3_2VSQ.pdb -1.22 22 
chunk-TASSER_2VSQ.pdb -1.22 23 
muFold4_2VSQ.pdb -1.24 24 
TASSER_VMT_2XHG.pdb -1.29 25 
muFold2_2JGP.pdb -1.3 26 
popul4_2JGP.pdb -1.31 27 
popul3_2JGP.pdb -1.36 28 
TASSER_VMT_2JGP.pdb -1.37 29 
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popul5_2JGP.pdb -1.37 30 
pro_sp3_TASSER_msa5.pdb -1.43 31 
popul1_2JGP.pdb -1.45 32 
RaptorX_2vsqA.pdb -1.54 33 
I_TASSER_2JGP.pdb -1.6 34 
popul2_2JGP.pdb -1.6 35 
pro_sp3_TASSER_msa1.pdb -1.6 36 
muFold5_2XHG.pdb -1.66 37 
pro_sp3_TASSER_msa4.pdb -1.69 38 
pro_sp3_TASSER_msa3.pdb -1.71 39 
TASSER_VMT_2VSQ.pdb -1.75 40 
CPHmodel_2JGP.pdb -1.75 41 
3Djigsaw_2JGP.pdb -1.8 42 
SparkX_1l5a.pdb -1.81 43 
RaptorX_1l5a.pdb -1.83 44 
Phyre2_2jgpA.pdb -1.87 45 
pro_sp3_TASSER_msa2.pdb -2 46 
RaptorX_2xhgA.pdb -2.53 47 
Phyre2_2xhgA.pdb -2.84 48 
Modeller_2XHG.pdb -2.95 49 
Modeller_1L5A.pdb -3.17 50 
FUG_2jgpa.pdb -3.23 51 
FUG_1l5a.pdb -3.95 52 
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Table D-5. Ranking of comparative structural models of the Thr-WT C domain by QMEANclust. 
QMEANclust 
Model QMEANclust Rank 
muFold1_2JGP.pdb 0.871 1 
muFold2_2JGP.pdb 0.87 2 
muFold3_2VSQ.pdb 0.87 3 
Multicom_msa.pdb 0.867 4 
muFold4_2VSQ.pdb 0.866 5 
pro_sp3_TASSER_msa4.pdb 0.865 6 
M4T_2JGP.pdb 0.863 7 
nFOLD_2JGP.pdb 0.862 8 
RaptorXmsa.pdb 0.862 9 
I_TASSER_2JGP.pdb 0.862 10 
pro_sp3_TASSER_msa3.pdb 0.861 11 
TASSER_VMT_1L5A.pdb 0.861 12 
pro_sp3_TASSER_msa2.pdb 0.861 13 
pro_sp3_TASSER_msa1.pdb 0.861 14 
TASSER_VMT_2VSQ.pdb 0.859 15 
Esypred_2jgpa.pdb 0.859 16 
pro_sp3_TASSER_msa5.pdb 0.858 17 
chunk-TASSER_2VSQ.pdb 0.856 18 
Raptor2_2JGP.pdb 0.856 19 
FUG_2jgpa.pdb 0.855 20 
SparkX_2jpa.pdb 0.853 21 
muFold5_2XHG.pdb 0.853 22 
Modeller_2JGP.pdb 0.851 23 
chunk-TASSER_2XHG.pdb 0.851 24 
SwissModel_2JGP.pdb 0.851 25 
RaptorX_2JGP.pdb 0.851 26 
Modeller_2JGP_1L5A_2XHG.pdb 0.85 27 
Modeller_LoopRebuild.pdb 0.85 28 
Modeller_2JGP_1L5A.pdb 0.846 29 
chunk-TASSER_2JGP.pdb 0.846 30 
popul3_2JGP.pdb 0.839 31 
Modeller_2JGP_2XHG.pdb 0.837 32 
popul4_2JGP.pdb 0.834 33 
popul5_2JGP.pdb 0.834 34 
chunk-TASSER_1L5A.pdb 0.833 35 
Phyre2_2jgpA.pdb 0.831 36 
TASSER_VMT_2JGP.pdb 0.831 37 
TASSER_VMT_2XHG.pdb 0.829 38 
Modeller_2JGP_1Q9J_2XHG.pdb 0.824 39 
CPHmodel_2JGP.pdb 0.823 40 
RaptorX_2vsqA.pdb 0.668 41 
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popul2_2JGP.pdb 0.648 42 
Phyre2_2vsqA.pdb 0.648 43 
popul1_2JGP.pdb 0.645 44 
3Djigsaw_2JGP.pdb 0.607 45 
RaptorX_2xhgA.pdb 0.541 46 
Phyre2_2xhgA.pdb 0.534 47 
RaptorX_1l5a.pdb 0.512 48 
SparkX_1l5a.pdb 0.508 49 
Modeller_2XHG.pdb 0.5 50 
FUG_1l5a.pdb 0.489 51 
Modeller_1L5A.pdb 0.442 52 
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Appendix E. Pyoverdine production by strains containing the 
directed evolution construct 
The pUCP22 based plasmid created in Chapter 6 was tested to determine the 
concentration of L-arabinose to use for induction. This was first tested by measuring the 
fluorescence of the restriction site control strain containing the C domain ligated back 
into pDEC in comparison to the wild type and pvdD deletion strains (Figure E-4). This 
showed increased pyoverdine production compared to the wild type strain at low 
concentrations of L-arabinose, and similar levels at a concentration of 0.1 % (w/v) 
L-arabinose. When testing the fluorescence of other strains from Chapter 6 (Figure E-5), 
there was increased fluorescence for the strain J12-D3 that showed low levels of 
fluorescence. This increased fluorescence was greatest at 0.1 % (w/v) L-arabinose. 
Consequently, it was decided to use this concentration of L-arabinose for induction of 
pyoverdine when using this plasmid. 
 
 
Figure E-4. L-arabinose induction of pyoverdine synthesis for the pDEC restriction site control 
strain. Pyoverdine production measured using fluorescence. DC refers to the restriction site 
control strain, WT refers to the P. aeruginosa PAO1 strain, and Del to the pvdD deletion strain. 
Data are the mean of 6 independent replicates, and error bars indicate 1 standard deviation 
 
 
0 
50000 
100000 
150000 
200000 
250000 
300000 
350000 
400000 
0 0.05 0.1 0.15 0.2 0.25 
Fl
u
o
re
sc
e
n
ce
 (
R
FU
) 
% (w/v) of L-arabinose 
DC 
WT 
Del 
172 
 
 
Figure E-5. L-arabinose induction of pyoverdine synthesis for the chimeric C domain strains from 
Chapter 6. Pyoverdine production measured using fluorescence. Nomenclature for DCThr and Del 
is noted in Figure E-4 and nomenclature for remaining strains in Figure 6-6 . Data are the mean of 
3 independent replicates, and error bars indicate 1 standard deviation 
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